Cooperative Regulation of Translational Repression by FMRP and the miRNA Pathway by Kaul, Navneeta
University of Denver 
Digital Commons @ DU 
Electronic Theses and Dissertations Graduate Studies 
8-1-2018 
Cooperative Regulation of Translational Repression by FMRP and 
the miRNA Pathway 
Navneeta Kaul 
University of Denver 
Follow this and additional works at: https://digitalcommons.du.edu/etd 
 Part of the Molecular Biology Commons 
Recommended Citation 
Kaul, Navneeta, "Cooperative Regulation of Translational Repression by FMRP and the miRNA Pathway" 
(2018). Electronic Theses and Dissertations. 1501. 
https://digitalcommons.du.edu/etd/1501 
This Dissertation is brought to you for free and open access by the Graduate Studies at Digital Commons @ DU. It 
has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital 
Commons @ DU. For more information, please contact jennifer.cox@du.edu,dig-commons@du.edu. 
 




A Dissertation  
Presented to 
the Faculty of Natural Sciences and Mathematics 




In Partial Fulfillment 
of the Requirements for the Degree 





Navneeta Kaul  
August 2018 
Advisor: Dr. Scott A. Barbee 
  ii 
Author: Navneeta Kaul  
Title: Cooperative Regulation of Translational Repression by FMRP and the miRNA 
Pathway  
Advisor: Dr. Scott A. Barbee  
Degree Date: August 2018  
ABSTRACT 
 
Fragile X syndrome (FXS) is the most common inherited monogenic cause of 
intellectual disability. FXS patients exhibit social and language deficits, hyperactivity, 
seizures, growth abnormalities, macroorchidism, anxiety, and epilepsy. FXS is caused by 
the transcriptional silencing of the fragile X mental retardation gene 1 (Fmr1), resulting in 
the loss of the fragile X mental retardation protein (FMRP). FMRP is a selective mRNA 
binding protein that plays a role in translation repression. Studies suggest that FMRP 
utilizes the miRNA pathway to repress translation of its target mRNAs through an 
unknown mechanism. The aim of my thesis is to investigate the mechanism by which 
FMRP regulates the translation of specific mRNA targets via the miRNA pathway 
using Drosophila melanogaster as a model system. Here, we demonstrate that FMRP 
requires the core miRNA-induced silencing complex (miRISC) components, AGO1 and 
GW182, to mediate translation repression. Moreover, we show that FMRP itself is 
necessary for miRNAs to repress translation of a reporter mRNA, which suggests an inter-
dependent role of FMRP and miRNA in regulating gene silencing. Finally, our findings 
elucidate a novel role for GW182 in the maintenance of proper synaptic structure and 
morphology at the glutamatergic larval neuromuscular junction (NMJ) in an FMRP-
dependent manner. We propose that FMRP binds to the 3'UTRs of target mRNAs and 
controls translation of target mRNAs in a GW182-dependent manner. Our data improve 
current understanding of the normal FMRP function in neurons. We postulate that this 
  iii 
could assist in the discovery of novel therapeutic targets to treat FXS and related autism 
spectrum disorders. 
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CHAPTER ONE: INTRODUCTION 
1.1 Overview of Fragile X Syndrome (FXS). 
 Fragile X Syndrome (FXS) is one of the most frequent forms of inherited mental 
disability in humans and a widely studied monogenic cause of autism (Ascano et al. 2012; 
Khayachi et al. 2018). FXS is an X-linked disorder that affects about 1:4000 males and 
1:8000 females worldwide (Crawford et al., 2001; Kashima et al., 2017; Khayachi et al., 
2018; Penagarikano et al., 2007). Patients with FXS exhibit severe intellectual disability, 
delayed development, hyperactivity, abnormal facial traits, macrocephaly, attention deficit, 
social behavioral problems and male macroorchidism (Boyle and Kaufmann, 2010; Drozd 
et al., 2018).  
Genetic mapping of disease-causing mutations revealed that FXS results from an 
abnormal expansion of trinucleotide ‘CGG’ repeats within the 5' untranslated region (UTR) 
of the FMR1 gene (Figure 1; Coffee et al., 1999, 2002; Sutcliffe et al., 1992). These CGG 
expansions fall into two classes: premutation and full mutation (Bassell and Warren, 2008; 
Hagerman and Hagerman, 2002; Schaeffer et al., 2001). Individuals with relatively modest 
expansions (55-200) are considered to have a premutation (Jin et al., 2004a; Todd et al., 
2013). Premutation alleles can cause the increased transcription of FMR1 gene and confer 
the risk to develop fragile X-associated tremor/ataxia syndrome (FXTAS) in males and 
fragile X-related primary ovarian insufficiency (FXPOI) in females (Chen and Joseph, 
2015). In contrast, full mutations are characterized by large expansions (ranging between 
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200- >1000 repeats) (Fu et al., 1991; Li et al., 2008; Schaeffer et al., 2003). This expansion 
results in hypermethylation of the promoter region of the FMR1 gene, causing 
transcriptional silencing and a loss of the encoded Fragile-X mental retardation protein, 
FMRP (Eberhart et al., 1996; Loomis et al., 2013; Pieretti et al., 1991). Subsequent studies 
have shown that loss of FMRP alters synaptic structure and function, which contributes to 
the profound effects observed on learning, memory and cognitive function (Banerjee et al., 
2018; Bassell and Warren, 2008; Gibson et al., 2008; Grossman et al., 2006; Richter et al., 
2015). Therefore, FMRP deficiency has been well- characterized to directly affect 
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Figure 1: A schematic representation of the FMR1 gene and its various allelic forms. 
The 5'UTR of the FMR1 gene has a promoter region, polymorphic CGG repeats (pink box), 
and the coding region. Based on the number of CGG repeats, the FMR1 gene has three 
main classes of alleles. A) Normal alleles: characterized by less than 55 repeats, proper 
transcription of FMR1 and translation of FMRP. B) Premutation alleles: Characterized by 
55-200 repeats cause increased transcription of FMR1 gene that leads to FXTAS and 
FXPOI in individuals. Interesting, this results in increased transcription of a “toxic” mRNA 
that accumulates in the nucleus. Thus, overall levels of FMRP are lower than in healthy 
individuals. C) Full mutation alleles: Characterized by more than 200 repeats cause an 
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 FMRP is a selective mRNA binding protein that is highly expressed in the central 
nervous system and testis in mammals (Ashley et al., 1993a; Devys et al., 1993; Hinds et 
al., 1993). Neurons in FXS patients are characterized by long, thin immature dendritic 
spines (Bagni and Greenough, 2005; Irwin et al., 2001). These structural defects result from 
an abnormal synaptic maturation or a failure in the synaptic elimination process (Khayachi 
et al., 2018). FMRP plays an important role in the translational regulation of specific 
neuronal transcripts, many of which encode proteins essential for synaptic structure and 
function (Bassell and Warren, 2008; Bhakar et al., 2012; Edbauer et al., 2010). Previous 
studies on the regulation of synaptic translation have shown that mutations in translational 
regulators including Smaug, Nanos, and Pumilio also lead to a similar dendritic phenotype 
as observed in FXS patients (Gabriela et al., 2013). Taken together, this suggests that the 
tight regulation of translation is key to normal synaptic function. Further, this suggests that 
loss of translation regulation by FMRP deficiency could lead to these phenotypes in FXS 
patients (Bagni and Greenough, 2005) . 
 Some FXS patients have a normal number of CGG repeats but have missense 
mutations in the coding region of FMR1 (Kenny and Ceman, 2016). Two identified 
missense mutations are isoleucine to asparagine (I304N) in the RNA binding 
ribonucleoprotein K homology domain (KH2), and arginine to glutamine mutation 
(R138Q) in a KH-like domain (KH0) (Figure 2; Collins et al., 2010; Feng et al., 1997a; 
Kenny and Ceman, 2016; Myrick et al., 2015a). These mutations are linked to defects in 
the association of FMRP with polysomes, target mRNAs and interacting proteins (Feng et 
al., 1997; Hu et al., 2015; Myrick et al., 2015b; Siomi et al., 1994). Together, these findings 
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support an important relationship between FMRP-mediated translational control and 
synaptic dysfunction in FXS (Bassell and Warren, 2008; Ronesi and Huber, 2008).  
 Currently, there are no effective FDA-approved treatment options in the United 
States for FXS patients (Banerjee et al., 2018; Berry-Kravis et al., 2017; Penagarikano et 
al., 2007). This is partly due to a significant gap in our understanding of which specific 
aspect of neurophysiology is most affected by FMRP deficiency. This suggests that a 
deeper understanding of the underlying mechanisms by which FMRP can regulate mRNA 
translation is necessary to better understand the pathogenesis in FXS patients and in order 
to identify novel therapeutic targets (Banerjee et al., 2018; Belmonte and Bourgeron, 2006; 














Figure 2: Domain organization of human FMRP. 
The human FMRP protein has three putative mRNA binding domains: KH0 (yellow box), 
KH1(pink) KH2 (green), and the RGG box (orange. KH0 contains a nuclear localization 
signal (NLS) required for nuclear localization of FMRP. There is also a C-terminal nuclear 
export signal (NES) required for its role as a nucleocytoplasmic shuttling protein. Also 
shown are the R138Q, G266E, and 1304N point mutations linked to the severe form of 
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1.2 Structure and function of FMRP. 
Multiple isoforms of FMRP exist in humans due to alternative splicing but much 
remains to be learned about the precise role and functional significance for each of these 
variants (Ashley et al., 1993b; Sittler et al., 1996; Verkerk et al., 1993). In mammals, FMRP 
belongs to a family of RNA binding proteins that include its autosomal paralogs, the Fragile 
X-Related proteins FXR1 and FXR2 (Ceman et al., 1999; Khandjian, 1999; Kirkpatrick et 
al., 2001; Siomi et al., 1995; Zhang et al., 1995). FMRP contains three well-defined RNA 
binding domains: two KH domains (KH1 and KH2) and an arginine-glycine-glycine 
(RGG) box motif (Ashley et al., 1993a; Siomi et al., 1993). FMRP is enriched in the 
cytoplasm and binds selectively to about 4% of target mRNAs in the mammalian brain 
(Ashley et al., 1993a; Brown et al., 2001; Santos et al., 2014).  
Drosophila melanogaster has been widely used as a genetic model system to study 
FXS pathology, in part due to the ease of working with fruit flies and conducting genetic 
studies in drosophila neurons (Drozd et al., 2018; Weisz et al., 2015). Drosophila expresses 
only a single ortholog of FMRP which is called dFMRP (Wan et al., 2000). Sequence 
comparison shows that dFMRP has 56% overall amino acid similarity to mammalian 
FMRP (Figure 3; Bagni and Oostra, 2013). However, the RNA binding domains are about 
75% identical between dFMRP and human FMRP (Chen et al., 2014; Wan et al., 2000) . 
Moreover, dFMRP has similar biochemical and neuronal functions compared to 
mammalian FMRP (Dockendorff et al., 2002; Inoue et al., 2002; Ishizuka et al., 2002; 
Morales et al., 2002; Siomi and Dreyfuss, 1997; Wan et al., 2000; Zhang et al., 2001). 
These characteristics make Drosophila a viable system to study FMRP function. 
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In both mammalian and fly neurons, FMRP with its multiple conserved domains 
interacts with specific mRNAs to form membrane-less RNA-protein granules (Aschrafi et 
al., 2005; Barbee et al., 2006; Bassell, 2011; Mazroui, 2002). In neurons, FMRP is involved 
in the transport, targeting and translational regulation of synaptically localized mRNAs in 
response to synaptic stimulation (Antar et al., 2004, 2005, 2006; Bassell and Warren, 2008; 
Dictenberg et al., 2008; Kiebler and Bassell, 2006; Otero et al., 2002) .  Additional details 

















Figure 3: Domain organization of dFMRP. 
The dFMRP protein is 56% similar overall to human FMRP with conserved mRNA binding 
domains: Shown are the conserved KH0 (yellow), KH1 (pink), KH2 (green), and RGG box 
(orange). Also depicted are NES domains (blue) with amino acids on the top. As with 
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1.2.1 Role of FMRP in regulating neurodevelopment. 
 Proteins encoded by synaptically localized mRNAs modulate the structure and 
strength of synapses, memory formation, and cognitive functions (Bramham and Wells, 
2007; Costa-Mattioli et al., 2009; Lin and Holt, 2008; Martin and Zukin, 2006; Steward 
and Schuman, 2003; Zukin, 2009). Dysregulation of local protein synthesis and mRNA 
transport is closely linked with improper neurodevelopment and synapse maturation 
(Bassell, 2011; Gabriela et al., 2013; Xing and Bassell, 2013). FMRP is thought to be 
involved in maintaining proper synaptic plasticity by binding to several key neuronal 
transcripts and maintaining them in a translationally inactive state in mRNA-containing 
ribonucleoprotein (mRNP) granules (Bagni and Greenough, 2005; Ferrari et al., 2007; 
Miyashiro et al., 2003; Muddashetty et al., 2007; Todd et al., 2003; Zalfa et al., 2003; 
Zukin, 2009).  
FMRP is involved in the transport, stability and translation of several neuronal 
transcripts (Bagni and Oostra, 2013; Fernández et al., 2013). FMRP transports several 
mRNAs, including the Fmr1 mRNA itself, from the cell body towards synapses in an 
activity-dependent manner through an association with motor proteins including kinesin 
(Fernández et al., 2013; Ferrari et al., 2007). For example, the loss of FMRP impairs the 
localization of several important mRNA targets such as MAP1B and the PSD-95-
associated protein 4 (Sapap4) mRNA to synapses (Dictenberg et al., 2008; Kao et al., 
2010). Furthermore, FMRP can modulate the stability of some mRNAs by preventing or 
promoting mRNA decay (Fernández et al., 2013; Zalfa et al., 2010; Zhang et al., 2007). 
For example, previous studies have shown that the association of hippocampal FMRP can 
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protect PSD-95 transcript from decay (Zalfa et al., 2010). In contrast, it can promote the 
decay of nuclear RNA export factor 1 (NXF1) transcript in mouse neuroblastoma (N2a) 
cells (Zhang et al., 2007). Together, this suggests that FMRP’s interaction with specific 
transcripts regulates their stability and localization in a transcript-dependent manner. 
FMRP plays an important role in repressing the translation of a subset of mRNAs. 
Studies in cells derived from FXS patients as well as mice and flies lacking FMRP show 
an increased rate of translation for mRNAs targeted by FMRP (Bolduc et al., 2008; Brown 
et al., 2001; Dolen et al., 2007). These data support a role for FMRP as a translation 
repressor. Based in part on these data, it is hypothesized that translation dysregulation of 
FMRP associated mRNAs is the major contributor to FXS pathology (Bagni and Oostra, 
2013; Fernández et al., 2013; Richter et al., 2015). In the absence of FMRP, key target 
mRNAs are excessively translated in dendritic spines leading to defects in synaptic 
morphology (Bagni and Greenough, 2005; Cruz-Martín et al., 2012; Darnell and Klann, 
2013; Grossman et al., 2006; Mientjes et al., 2006; Nimchinsky et al., 2001; The Fragile X 
Consortium, 1994; Zhang et al., 2001).  
In mammalian neurons, FMRP activity is regulated by metabotropic glutamate 
receptor (mGluR) stimulation (Antar et al., 2004; Bear et al., 2004; Dictenberg et al., 2008; 
Weiler et al., 1997). Activation of mGluR induces the rapid dephosphorylation of FMRP 
followed by ubiquitination and subsequent proteasome-mediated degradation (Hou et al., 
2006; Nalavadi et al., 2012). As a result, specific FMRP-bound mRNAs are released from 
RNP granules and translated to make proteins (Aschrafi et al., 2005; Bear et al., 2004; 
Muddashetty et al., 2011). Conversely, phosphorylation of FMRP inhibits the translation 
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of its associated mRNA (Narayanan et al., 2007; Niere et al., 2012). Interestingly, recent 
studies suggest that the activation of mGLuR can also lead to the reversible sumoylation 
of FMRP, suggesting that mGLuR activation can regulate FMRP’s function through 
different mechanisms (Khayachi et al., 2018).  
 Many studies have focused on identifying the mRNAs whose translation is 
regulated by FMRP in order to understand the neuropathology of FXS (Banerjee et al., 
2018; Darnell and Klann, 2013; Richter et al., 2015). Several approaches have been used 
to identify FMRP associated mRNAs in neuronal mRNA granules (Brown et al., 2001; 
Darnell et al., 2011; El Fatimy et al., 2016). Isolation and purification of FMRP-containing 
neuronal granules from mouse brain homogenates has led to the identification of several 
associated transcripts (El Fatimy et al., 2016). Additionally, crosslinking-
immunoprecipitation combined with high-throughput sequencing (HITS-CLIP) has  been 
used to identify FMRP-associated target mRNAs (Darnell et al., 2011).  Finally, 
photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-
CLIP) approach was utilized to isolate FMRP bound target mRNAs and to identify binding 
sites (Ascano et al., 2012). Collectively, these studies have demonstrated that FMRP-
associated target mRNAs that encode for key proteins involved in the control of synaptic 
structure and function. Some notable examples of these mRNAs include the microtubule-
associated protein 1b (MAP1B), Down syndrome cell adhesion molecule (DSCAM), 
Postsynaptic density protein 95 (PSD-95), FMRP, Ataxin, Human antigen R (HuR), 
Calcium/Calmodulin-dependent protein kinase II (CaMKII), Amyloid precursor protein 
(APP), the Activity-regulated cytoskeleton-associated protein (ARC), Zinc-finger 
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CysCysCysHis [CCCH]-type 14 (ZC3H14), Ras-related C3 botulinum toxin substrate 1 
(Rac1) and Staufen2 (Bienkowski et al., 2017; Brown et al., 2001; Darnell et al., 2011; 
Davis and Broadie, 2017; Elvira et al., 2006; El Fatimy et al., 2016; Kanai et al., 2004; 
Muddashetty et al., 2007; Sudhakaran et al., 2014; Suhl et al., 2015; Zalfa et al., 2003; 
Zhang et al., 2015). FMRP granules are also enriched in mRNAs which encode for 
molecular motor proteins (Dync1h1, Myo18a, Myh10, Myo5a) and several members of the 
spectrin and ankyrin families, which are essential for synaptic stability and maintenance 
(Darnell et al., 2011; El Fatimy et al., 2016; Lindsay and Mccaffrey, 2014). Targets of 
dFMRP have also been identified in Drosophila neurons, including Futsch (the fly 
orthologue of MAP1B), Dscam (the fly orthologue of DSCAM), chickadee (the fly 
orthologue of Profilin), Rac1 (the fly ortholog of Rho GTPase RAC1) and pickpocket1 (the 
fly ortholog of PPK1) (Lee, 2003; Reeve et al., 2005; Sterne et al., 2015; Xu et al., 2004; 
Zhang et al., 2001). These studies provide an extensive list of mRNAs whose activity is 
regulated by FMRP, and mis-regulation of which may contribute to aberrant dendritic spine 
development in Fragile X patients (El Fatimy et al., 2016). 
1.2.2 Function of RNA binding domains of FMRP.  
FMRP has multiple conserved RNA binding domains that allow it to bind to and 
regulate the translation of several mRNAs (Ashley et al., 1993a; Gareau et al., 2013a; 
Siomi et al., 1996). Previous studies have demonstrated that essential functions of FMRP 
rely on functional KH domains, as missense mutations within these domains can cause a 
severe form of FXS. These mutations (G266E within KH1), I304N in KH2 and R138Q in 
KH0) disrupt the association of FMRP with target mRNA and polyribosomes (Figure 2; 
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De Boulle et al., 1993; Feng et al., 1997a; Hu et al., 2015; Myrick et al., 2014, 2015b, 
2015a). However, the precise role of these KH domains in mediating the interaction of 
FMRP with target mRNAs is not clear. Darnell et al demonstrated that KH2 domain binds 
to a double stem-loop structure in RNAs known as “kissing complex” or “loop-loop 
pseudo-knot” (Darnell et al., 2005; Kenny and Ceman, 2016). The authors showed that 
RNAs with this structure could compete FMRP off polyribosomes, suggesting that FMRP 
strongly binds to RNAs containing this secondary structure (Darnell et al., 2005). 
However, no structure of this type has been reported in any known endogenous target 
mRNAs (Santoro et al., 2012). The identity of specific structures in mRNA targets bound 
by KH1 and KH0 domains is not known (Kenny and Ceman, 2016). Thus, the precise role 
and function of KH domains in binding target mRNAs needs to be studied in detail.  
 FMRP also possesses a well-characterized RGG box motif, which selectively binds 
to G-rich secondary structures known as G-quadruplexes (GQs) (Blackwell et al., 2010; 
Darnell et al., 2001, 2004; Dolzhanskaya, 2006; Menon and Mihailescu, 2007; Phan et al., 
2011; RAMOS, 2003; Schaeffer et al., 2001). G-quadraplexes are formed by guanine 
tetrads held together by Hoogsteen base-pairing and stabilized by monocations (Blice-
Baum and Mihailescu, 2014; Joachimi et al., 2009; Santoro et al.; Schaeffer et al., 2001; 
Williamson et al., 1989). Studies show FMRP binds to several target mRNAs including 
MAP1B which are capable of folding into distinct G-quadruplex structures (Darnell et al., 
2001; Schaeffer et al., 2001). This suggests that FMRP can regulate the activity of specific 
mRNAs that can fold into G-quadruplex substructures. 
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Recent studies also have indicated that low complexity domains (LCDs) within the 
conserved RGG motif can modulate the flexible interactions of FMRP with several mRNA 
ligands and proteins (Kenny and Ceman, 2016; Ozdilek et al., 2017). These domains are 
unstructured and disordered in solution, become structured when bound to a target mRNA, 
and are proposed to drive RNP granule formation (Coletta et al., 2010; Kenny and Ceman, 
2016). However, it is not clear whether these domains co-operate with other domains of 
FMRP to mediate its activity (Davis and Broadie, 2017).  
1.2.3   FMRP binds to distinct mRNA sequence and structural elements. 
  The RNA binding domains of FMRP recognize a variety of specific sequence and 
structural motifs in target mRNAs (Ashley et al., 1993a; O’Donnell and Warren, 2002; 
Siomi et al., 1993). Recent studies using PAR-CLIP indicate that the KH2 and KH1 
domains of FMRP preferentially bind to ACUK, WGGA and GAC sequences in target 
mRNAs (in which K=G or U and W= A or U) (Ascano et al., 2012; Ray et al., 2013; Suhl 
et al., 2014b, 2014a). However, the frequency of these sequences to be present in all human 
mRNAs is very high (1 in 128 nucleotides) (Chen et al., 2014). Therefore, it is unknown 
how these sequences can provide FMRP the specificity required to bind to its target 
mRNAs (Chen et al., 2014). G-quadruplex structures are found in several (but not all) 
FMRP-associated targets including the Fmr1, MAP1b, and Sema3F mRNAs (Didiot et al., 
2008; Menon and Mihailescu, 2007; Menon et al., 2008; Santoro et al.,2012; Schaeffer et 
al., 2001). However, an analysis of FMRP associated neuronal mRNAs in mice by HITS-
CLIP did not show an enrichment for G-rich quadruplexes or pseudoknot forming 
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sequences (Darnell et al., 2011; Kenny and Ceman, 2016). Therefore, specific RNA 
elements that recruit FMRP to target mRNAs are not well understood. 
FMRP has been shown to bind to other structural motifs in specific target mRNAs. 
For example, FMRP binds to a unique structural motif composed of three independent 
stem-loops in the superoxide Dismutase 1 (Sod1) mRNA through the RGG box domain 
(Anderson et al., 2016). This motif termed as ‘Sod1 mRNA Stem Loops Interacting with 
FMRP’ (SoSLIP) competes with the GQs for binding to the RGG box (Bechara et al., 2009; 
Santoro et al., 2012). Surprisingly, these motifs are structurally modified upon interaction 
with FMRP and promote the translation of Sod1, in contrast to FMRP’s canonical role as 
a translation repressor (Bechara et al., 2009).  Other RNA secondary motifs have also been 
identified in FMRP targets, including U-rich sequences with 5-23 bases of U-rich pentamer 
repeats in some FMRP target mRNAs (Chen et al., 2003; Dolzhanskaya et al., 2003; 
Fähling et al., 2009). The U-rich motifs need further characterization as not much is known 
about the role of these motifs or the specific domains in FMRP that mediate this interaction 
(Santoro et al., 2012). 
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1.3 FMRP acts as a translation repressor through different mechanisms. 
 FMRP is characterized as a protein that regulates the translation of several mRNAs 
in mammalian cells. An early study identified FMRP to be associated with the 60S 
ribosomal subunit (Siomi et al., 1996). However, the functional consequences of that 
association were not known.  Laggerbauer et al. provided the first evidence for a function 
of FMRP in translation regulation (Laggerbauer et al., 2001). The authors incubated 
recombinant FMRP with in vitro transcribed mRNAs encoding for the survival of motor 
neuron (SMN) protein, FMRP or the luciferase protein in rabbit reticulocyte lysate assays. 
In this system, FMRP strongly inhibited the translation of all these mRNAs in a sequence-
independent manner. Moreover, Xenopus oocytes injected with the FMRP-mRNA 
complexes showed identical results (Laggerbauer et al., 2001). Immortal cells from Fmr1 
KO mice provided the first in vivo evidence for FMRP function as a translation repressor 
(Mazroui, 2002). Fmr1 KO cells were co-transfected with human FMRP and reporter genes 
encoding for FXR1P and the sine oculis homeobox homolog transcription factor (SIX3)  
(Mazroui, 2002). The transfection of human FMRP led to a reduction in the translation of 
reporter genes, suggesting FMRP to be a negative regulator of translation.  
 Consistent with the role of FMRP as a translation repressor, in vivo assays in Fmr1 
KO mice exhibited an increase in the expression of FMRP-target proteins including 
MAP1B, Arc and CamKII (Santoro et al.; Zalfa et al., 2003). dFmr1 null flies also showed 
an increase in the expression of the MAP1B ortholog, futsch (Zhang et al., 2001). 
Moreover, subcellular fractionation of synaptoneurosomes from Fmr1 KO mice show 
elevated expression levels for other FMRP target proteins (Zalfa et al., 2003). Together, 
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these results highlight the ability of FMRP to repress the translation of several mRNAs in 
both mammalian cells and in Drosophila neurons. 
 Several in vitro studies suggested that direct interaction of FMRP with its target 
mRNA is critical for translation repression (Li et al., 2001). The authors removed the 
3'UTR from the myelin basic protein mRNA (MBP), a known target of FMRP regulation 
in mammalian oligodendrocytes, and observed an inability of FMRP to repress its 
translation (Li et al., 2001; Wang et al., 2004; Zalfa et al., 2010). In contrast, FMRP 
repressed the translation of the full length MBP transcript (Li et al., 2001). This suggests 
that the association of FMRP with its target regulates its ability to repress translation. 
 In addition to interacting with polyribosomes, FMRP also localizes to RNP 
granules knows as P-bodies and stress granules, which are high-order complexes that 
contain repressed mRNAs (Barbee et al., 2006; Mazroui, 2002; Santoro et al., 2012). 
FMRP is hypothesized to control the translation of mRNAs in part by promoting their 
movement between these “storage” granules and polysomes (Aschrafi et al., 2005; Bassell 
and Warren, 2008). However, the mechanism behind this process remains unknown.  
 FMRP is suggested to be an effector of translational repression through several 
different mechanisms (Ascano et al., 2012; Brown et al., 2001; Chen et al., 2014; Darnell 
et al., 2001, 2005; Jin et al., 2004b; Kenny and Ceman, 2016; Stefani, 2004; Zalfa et al., 
2003). However, these mechanisms by which FMRP regulates translation of neuron targets 
remain poorly understood (Bagni, 2008; Chen et al., 2014; Costa-Mattioli et al., 2009; 
Iacoangeli et al., 2008a; Kenny and Ceman, 2016). FMRP can repress the translation of 
target mRNAs at both initiation and elongation stages (Bhakar et al., 2012; Ceman et al., 
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2003; Santoro et al., 2012). FMRP also regulates mRNA translation via the miRNA 
pathway in P-bodies (Barbee et al., 2006; Eulalio et al., 2007a; Parker and Sheth, 2007). It 
is important to note that these mechanisms are not mutually exclusive. It is likely that the 
repression of FMRP targets by FMRP binding is mRNA specific.  
1.3.1 Evidence that FMRP stalls translation at the elongation stage.  
 Previous studies suggest that FMRP causes ribosomes to stall during the elongation 
stage of translation (Figure 4). In-vivo CLIP studies of FMRP demonstrate that it can 
directly bind to the coding regions of some target mRNAs (Stefani, 2004). Subsequent 
studies by Darnell and colleagues demonstrated that FMRP co-sediments with 
polyribosomes and confers resistance to puromycin, which releases elongating ribosomes 
(Darnell et al., 2011; Harigaya and Parker, 2014). These results indicate that by binding to 
coding regions of mRNA, FMRP could either block puromycin action or could impede 
ribosome movement to slow translation elongation. Interestingly, after puromycin 
treatment, target mRNAs of FMRP were deeper in the polysome gradient compared to non-
targets (Darnell et al., 2011; Harigaya and Parker, 2014). These results suggest FMRP 
causes increased retention of ribosomes on target mRNA. The authors further characterized 
FMRP-stalled complex with electron microscopy and demonstrate target mRNAs to be 
complexed with multiple ribosomes (Darnell et al., 2011). Ribosomal run-off assays on 
these transcripts also demonstrate that FMRP is associated with stalled ribosomes on these 
transcripts (Ceman et al., 2003). Phosphorylation of FMRP at serine residues correlates 
with its association with stalled polyribosomes, and dephosphorylated FMRP associates 
with actively translating polyribosomes (Ceman et al., 2003). These results suggest that the 
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molecular mechanism controlling FMRP phosphorylation may thereby regulate translation 
elongation of FMRP targeted mRNAs. 
 Recent cryo-electron microscopic studies in Drosophila suggest that FMRP stalls 
ribosome movement on mRNAs to repress their translation (Chen et al., 2014; Harigaya 
and Parker, 2014). The authors showed that FMRP directly binds to the L5 protein of 80S 
subunit of the ribosome, blocking the access of tRNAs and essential translation elongation 
factors to inhibit translation (Chen et al., 2014). According to Chen et al., FMRP binds to 
specific structural elements in target mRNA, which leads to the KH2 domain of FMRP 
interacting with the 80S subunit of the ribosome (Chen et al., 2014; Harigaya and Parker, 
2014). This interaction causes a steric conflicts with the tRNA at the P-site, leading to 
ribosomal stalling (Chen et al., 2014). These results also explain why FMRP-bound 
mRNAs are resistant to puromycin treatment, since FMRP’s interaction with the 80S 
subunit will block access of puromycin to the ribosome. 
 Recent studies directly compared the movement of ribosomes along mRNAs in 
brain lysates from wild-type and Fmr1 KO mice (Richter et al., 2015; Udagawa et al., 
2013). These lysates were supplemented with hippuristanol, a drug that blocks new 
translation initiation, allowing ribosomes already associated with transcripts to runoff the 
transcript after completing translation (Bordeleau et al., 2006; Richter et al., 2015; 
Udagawa et al., 2013).  The authors found that the rate of radioactive amino acid 
incorporation was higher in Fmr1 KO lysates compared to wild-type lysates. Given that 
new translation initiation was blocked in these experiments, these results strongly suggest 
that FMRP stalls ribosomes on target mRNAs and blocks translation elongation. 
 








Figure 4: FMRP regulates mRNA translation at the elongation stage.  
FMRP can stall the progression of ribosomes along the target mRNA. Electron microscopy 
shows FMRP to be in a complex with polyribosomes. Recent cryo-EM studies demonstrate 
that dFMRP can directly bind to the 80S ribosome through KH2 domains and interfere 
with the binding of essential elongation factors to the ribosome. Post-transcriptional 
modification of FMRP such as phosphorylation at serine residues and methylation on 
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1.3.2 Evidence that FMRP stalls translation at the initiation stage.  
 While a significant amount of research points to a role of FMRP in regulating 
translation at elongation stage, some data suggests that FMRP blocks the translation of 
specific mRNAs at the initiation stage. Specifically, it was shown that FMRP can block 
translation initiation by modulating the interaction between the cytoplasmic FMRP-
interaction protein (CYFIP1) and eukaryotic initiation factor eIF4E which binds to the 
m7G cap and initiates translation (Figure 5; Napoli et al., 2008; Richter et al., 2015; 
Schenck et al., 2001). Bulk cap-dependent translation requires the formation of the eIF4A-
eIF4G-eIF4E (eIF4F) complex in association with the 5’ m7G cap structure (Richter and 
Sonenberg, 2005).  eIF4E-binding proteins (4E-BPs) regulate the formation of eIF4E 
complex by interfering with eIF4E-eIF4G interaction (Banko et al., 2007; Klann and 
Richter, 2007; Marcotrigiano et al., 1999; Richter and Sonenberg, 2005), and 
phosphorylation of 4E-BPs results in their dissociation from eIF4E and initiation of 
translation (Gingras et al., 2001). FMRP interacts biochemically with CYFIP1, a protein 
which has a non-canonical eIF4E-binding protein (4E-BP) domain (Marcotrigiano et al., 
1999). Another binding partner of FMRP, the noncoding brain cytoplasmic RNA 1 (BC1), 
helps to facilitate the interaction between FMRP and the CYFIP-eIF4E complex in the 
mammalian brain (Napoli et al., 2008; Zalfa et al., 2003, 2005).  
 FMRP-CYFIP1-eIF4E is transported as a translationally inactive complex in 
dendrites stabilized by target mRNAs and responds to synaptic stimulation induced by 
either brain-derived neurotrophic factor (BDNF) or group 1 mGluR signaling (DeRubeis 
et al., 2013; Napoli et al., 2008). Evidence suggests that local synaptic stimulation results 
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in the release of FMRP-CYFIP1 from eIF4E to rapidly alleviate translation repression 
(DeRubeis et al., 2013; Napoli et al., 2008; Richter et al., 2015). Consistent with these 
results, genetic loss of CYFIP1 in the brain results in an increase in the expression of known 
FMRP targets including MAP1B, APP, CaMKII (Bagni and Greenough, 2005; Hou et al., 
2006; Napoli et al., 2008; Westmark and Malter, 2007).  
 The in vivo significance of the FMRP-BC1-CYFIP interactions, however, has been 
challenged (Iacoangeli et al., 2008a, 2008b; Stefani, 2004; Wang et al., 2005). In one 
specific study, the authors were unable to detect specific interactions between FMRP and 
BC1 mRNA in vitro (Iacoangeli et al., 2008b). Moreover, competitor tRNA abolished the 
association between FMRP and BC1 mRNA in mobility shift assays, suggesting that the 
binding of FMRP to BC1 may be non-specific (Iacoangeli et al., 2008b; Wang et al., 2005). 
Therefore, the model of FMRP-mediated interaction between CYFIP1 and eIF4E and its 
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Figure 5: FMRP regulates mRNA translation at the initiation stage.                                              
FMRP has been shown by some to recruit CYFIP1 (orange) and sequester the general 
translation initiation factor eIF4E (green) from binding to eIF4G (light green). The 
inability to form the pre-initiation complex leads to translation repression. BC1 mRNA 
increases the affinity of FMRP-CYFIP1 interaction in vitro. Studies propose that in 
response to mGLuR activation, the CYFIP1-FMRP complex gets released from eIF4E for 
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1.4 miRNA biogenesis and miRISC assembly.  
 FMRP can also regulate the translation of target mRNAs through its interaction 
with specific miRNAs and conserved components of the RNA-induced silencing complex 
(RISC) (Figure 6; Fabian and Sonenberg, 2012). Recent studies suggest that FMRP 
cooperates with miRNAs to modulate synaptic structure and function (Loffreda et al., 
2015). Before addressing the details of how FMRP interacts with miRNAs and miRISC, 
an overview of the regulation of miRNA biogenesis and function is summarized below.  
 miRNAs are small ~22 nucleotide non-coding mRNAs with an important role in 
regulating gene expression by binding to complementary mRNAs and regulating 
translation (Baek et al., 2008; Bartel, 2009; Eulalio et al., 2008a; Fabian et al., 2010; Ha 
and Kim, 2014; Krol et al., 2010; Lim et al., 2005; Selbach et al., 2008). Published evidence 
indicates a role for miRNAs in nearly every biological process ranging from development 
to the regulation of the cell cycle and synaptic plasticity (Ambros, 2011; Bushati and 
Cohen, 2007; Eulalio et al., 2008a; Kim et al., 2009; McNeill and Van Vactor, 2012; Nesler 
et al., 2013; Shenoy and Blelloch, 2014). miRNA biogenesis and function are tightly 
regulated, and dysregulation of their expression or function is linked to human diseases 
ranging from cancer to neurodevelopment disorders (Chang and Mendell, 2007; Garzon et 
al., 2009; McNeill and Van Vactor, 2012; Saugstad, 2010). 
 miRNA genes are transcribed by RNA polymerase II (Pol II) to form the long 
primary miRNA (pri-miRNA) (Figure 7; Filipowicz et al., 2008a; Ha and Kim, 2014; Kim, 
2005; Lee et al., 2004a). Following transcription, the pri-miRNA undergoes several steps 
of processing (Denli et al., 2004; Ha and Kim, 2014). The pri-miRNA folds into a dsRNA 
 
  26 
hairpin structure with the embedded miRNA sequences and undergoes cleavage by the 
microprocessor complex to form precursor miRNAs (pre-miRNA) (Kim et al., 2009; Lee 
et al., 2002). The microprocessor complex is composed of dsRNA binding proteins with 
endonucleolytic activity:  DROSHA and DGCR8 (Pasha in flies)(Du, 2005; Gregory et al., 
2004; Han et al., 2004, 2006; Kim et al., 2009; Landthaler et al., 2004). The pre-miRNA is 
exported from into the cytoplasm by Exportin 5 (XPO5) in a RAN-GTP dependent manner 
(Bohnsack et al., 2004; Kim, 2004; Lund et al., 2004). Upon export, the pre-miRNA is 
further cleaved by Dicer to produce a miRNA duplex of approximately 22 nucleotides 
(Bernstein et al., 2001; Grishok et al., 2001; Hutvágner et al., 2001; Ketting et al., 2001; 
Knight and Bass, 2001). Like DROSHA, Dicer also belongs to an RNAase endonuclease 
family and cleaves dsRNAs (Ma et al., 2004; Song et al., 2003; Zhang et al., 2004). Dicer 
acts as a molecular ruler and cuts miRNAs at specific cleavage sites with a fixed distance 
of about 22-25 nucleotides from either 3' or 5' end (Coffee et al., 2002; Macrae et al., 2006; 
MacRae et al., 2007; Vermeulen et al., 2005; Zhang et al., 2002, 2004). Although mammals 
have a single Dicer gene, Drosophila expresses two Dicer paralogs (Ha and Kim, 2014; 
Kim et al., 2009). Dicer 1 is required for miRNA biogenesis whereas Dicer 2 is involved 
in short interfering (siRNA) processing (Lee et al., 2004b). Several RNA binding proteins 
(RBPs) modulate the activity of Dicer for efficient processing of most miRNAs 
(Chendrimada et al., 2005; Förstemann et al., 2005; Fukunaga et al., 2012; Lee and 
Doudna, 2012; Lee et al., 2013; Saito et al., 2005; Trabucchi et al., 2009). In Drosophila, 
Dicer1 associates with Loquacious (Loqs) for efficient pre-miRNA processing (Kim et al., 
2009), whereas in humans, Dicer interacts with TAR RNA binding protein (TRBP) and 
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Protein activator of the interferon-induced protein kinase (PACT) protein for formation of 
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Figure 6: FMRP regulates mRNA translation through the interaction with the 
miRISC components. 
Genetic and biochemical studies show that FMRP associates directly with miRNAs, Dicer, 
and AGO1. AGO1 is a core component of the miRNA-containing RISC complex 
(miRISC). FMRP can recruit the miRISC complex to facilitate the recognition of target 
mRNAs and regulate the translation of a target mRNA using miRNAs. The FMRP-miRISC 
complex can repress translation at either the initiation or at the elongation stage. The 
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Figure 7: A schematic of miRNA biogenesis and their assembly into miRISC 
complex. 
miRNA genes are transcribed by RNA polymerase II to generate the pri-miRNA. The 
nuclear endonuclease DROSHA and DGCR8 process the pri-miRNA to form the pre-
miRNA hairpin structure. Then, XPO5 recognizes the pre-miRNA and exports it to the 
cytoplasm for further processing by Dicer. Dicer catalyzes the formation of the pre-miRNA 
to generate miRNA duplex. One strand of the duplex, known as the guide strand, is 
preferentially loaded onto the AGO proteins to form the miRISC complex. The miRISC 
complex binds to miRNA binding sites, primarily in the 3'UTR of the target mRNA to 
mediate translation repression or decay. The nucleotides at the 5'end of the miRNA known 
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1.4.1 miRNA loading and RNA induced silencing complex formation.   
 Once the mature miRNA duplex is generated following several processing steps, 
the duplexed RNA is loaded onto the Argonaute (AGO) protein (Figure 7; Elkayam et al., 
2012; Gregory et al., 2005; MacRae et al., 2008; Maniataki and Mourelatos, 2005; 
Nakanishi et al., 2012; Schirle and MacRae, 2012). Loading of the miRNA duplex is 
followed by a subsequent unwinding of the strands. The non-associated strand, called the 
“passenger strand”, is released and degraded, whereas the active strand, called the “guide 
strand” is retained to complete the formation of the miRNA-containing RISC (Diederichs 
and Haber, 2007; Ha and Kim, 2014; Kawamata and Tomari, 2010). The guide strand is 
selected on the basis of the relative thermodynamic stability of the 5' and 3' end of the small 
RNA duplex (Khvorova et al., 2003; Schwarz et al., 2003).  
 Mammals express four AGO paralogs (AGO1-4) which are capable of inducing 
translation repression or decay of target mRNAs to varying degrees utilizing either the 
miRNA or the siRNA pathways (Ha and Kim, 2014; Huntzinger and Izaurralde, 2011; 
Ipsaro and Joshua-Tor, 2015; Yoda et al., 2010). In contrast, Drosophila expresses two 
paralogs of the AGO proteins (dAGO1 and dAGO2) (Förstemann et al., 2007; Okamura et 
al., 2004; Tomari et al., 2007). dAGO1 is utilized by the miRNA pathway and dAGO2 is 
utilized by the siRNA pathway (Czech et al., 2009; Kawamata et al., 2009).  
 Thermodynamic stability of base-pairing between the miRNA and complementary 
sequences generally located in the 3'UTR of target mRNA determines the ability of miRNA 
to repress translation of target mRNA (Clarke et al., 2012). The nucleotides at positions 2-
8 at the 5' end of the miRNA, known as seed region, are crucial for miRNA target 
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recognition (Ameres and Zamore, 2013; Bartel, 2009; Brennecke et al., 2005; Doench and 
Sharp, 2004; Grimson et al., 2007; Pasquinelli, 2012). Following miRNA binding, the 
regulation of target mRNAs is facilitated by another core protein component of the 
miRISC, the trinucleotide repeat containing protein (TNRC; also known as GW182; 
Eulalio et al., 2008b, 2009; Fabian and Sonenberg, 2012; Huntzinger and Izaurralde, 2011; 
Pfaff and Meister, 2013). The primary function of GW182 is to acts as a scaffold for other 
accessory proteins that mediate either translation repression or mRNA degradation (Braun 
et al., 2011, 2013; Chekulaeva et al., 2011; Fabian and Sonenberg, 2012; Fabian et al., 
2012; Huntzinger et al., 2010, 2013; Zekri et al., 2009). How the bound miRNA regulates 
translation of the target mRNA is described in detail below. 
1.4.2 Mechanisms of miRNA-mediated gene silencing.  
 miRNAs have been shown to target mRNAs for translational repression via four 
distinct mechanisms: translation initiation, translation elongation, premature termination  
(ribosome drop off) and co-translational protein degradation (Chendrimada et al., 2007; 
Eulalio et al., 2008a; Hu et al., 2010; Humphreys et al., 2005; Kiriakidou et al., 2007; 
Maroney et al., 2006; Nottrott et al., 2006; Petersen et al., 2006; Pillai et al., 2005; 
Seggerson et al., 2002; Tat et al., 2016). miRNAs can also directly target mRNAs for 
degradation (Figure 8; Bagga et al., 2005; Braun et al., 2011; Chekulaeva et al., 2011; 
Eulalio et al., 2007b; Fabian et al., 2012; Rehwinkel et al., 2005; Wu et al., 2006). mRNA 
degradation is initiated by a gradual shortening of the poly (A) tail by components of the 
deadenylase complexes, CCR4-NOT1 and PAN2-PAN3 (Antic et al., 2015; Decker and 
Parker, 2012; Houseley and Tollervey, 2009; Parker and Song, 2004). In eukaryotes, the 
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poly (A) tail is initially shortened by the PAN2-PAN2 complex, followed by rapid 
deadenylation by the CCR4-NOT complex (Wahle and Winkler, 2013; Yamashita et al., 
2005). Following deadenylation, mRNAs can either be degraded by the exosome in a 3'-5' 
manner or undergo decapping by the DCP1-DCP2 complex followed by 5'-3' decay by the 
XRN1 exonuclease (Decker and Parker, 2012; Meyer et al., 2004). 
 There is a lack of clear understanding of what factors determine whether a specific 
mRNA-regulated mRNA will undergo translation repression or degradation (Eulalio et al., 
2008a). Thus, whether or not miRNAs elicit mRNA degradation is likely to be strongly 
dependent upon specific features of the miRNA-binding site, miRISC factors, specific 
accessory proteins associated with the miRISC, target mRNA and various additional 
interacting RBPs (Eulalio et al., 2007b, 2008a; Grimson et al., 2007).  The evidence 
supporting known mechanisms of miRNA-mediated translation repression at both the 




















Figure 8: Mechanisms of miRNA mediated target gene silencing.  
miRNAs (red) can either inhibit translation of target mRNAs or facilitate their 
deadenylation followed by subsequent decapping, and decay. These mechanisms require 
core components of the miRISC complex, AGO1 (orange), and GW182 proteins (green). 
miRNAs can repress the translation of target mRNAs by blocking translation initiation, 
elongation or by premature termination of ribosomes. Alternatively, GW182 can recruit 
the components of the deadenylase complex (CAF1, CCR4 and the NOT proteins) to 
facilitate deadenylation of the poly (A) tail. Following deadenylation, the Dcp1-Dcp2 
complex removes the m7G cap to facilitate 5’ to 3’ exonucleolytic decay. Repressed 
mRNAs can move to P-bodies for either storage or degradation. Deadenylation as well as 
the displacement of poly(A)-binding protein (PABP) through GW182 and CCR4–NOT 
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1.4.2.1 Translation repression by miRNAs at the initiation stage.  
Several studies suggest that miRNAs inhibit translation of target mRNAs at the 
initiation stage ( Figure 9; Eulalio et al., 2008a). Pillai et al demonstrated that miRNAs and 
target mRNAs do not co-sediment with the polysomal fractions in sucrose gradients, but 
rather with the free mRNP pool in mammalian cells (Humphreys et al., 2005; Pillai et al., 
2005). These results are indicative of a defect in translational initiation due to an impaired 
ribosome recruitment (Ding and Großhans, 2009; Fabian and Sonenberg, 2012). This work, 
coupled with several other studies, showed that mRNAs lacking the m7G cap can bypass 
miRNA mediated repression. This indicates that miRNAs can target the m7G cap-
dependent translation and inhibit translation at the initiation stage (Filipowicz et al., 2008; 
Pillai et al., 2005; Wu and Belasco, 2008). Moreover, studies in cell free assays provide 
support for a role of miRNAs in inhibiting translation initiation (Mathonnet et al., 2007; 
Wakiyama et al., 2007). In cell lysates, miRNAs repressed translation of m7G-capped 
mRNAs but not mRNAs with an artificial unmethylated cap analog (ApppN) (Huntzinger 
and Izaurralde, 2011). Further, miRNAs also did not repress the translation of mRNAs 
containing an internal ribosome entry site (IRES) (Filipowicz et al., 2008; Mathonnet et 
al., 2007; Wakiyama et al., 2007). The importance of m7G cap was further supported by 
experiments with bi-cistronic reporters. The translational activity of the first cap-dependent 
cistron was repressed by the endogenous let-7 miRNA. On the other hand, the second 
cistron was unaffected by let-7 miRNA (Filipowicz et al., 2008; Pillai et al., 2005). Taken 
together, these results suggest that cap-dependent translational initiation is repressed via 
the miRNA-mRNA interaction. 
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 In agreement with a role for miRNAs inhibiting translation initiation, several 
studies suggest that translation initiation factors play a critical role in miRNA mediated 
repression (Iwakawa and Tomari, 2015; Kiriakidou et al., 2007; Mathonnet et al., 2007). 
Supplementation or depletion of translation initiation factors in HEK293 cells, S2 cells and 
in vitro cell-free translation system results in an attenuation of miRNA-mediated 
translation repression (Fukao et al., 2014; Fukaya et al., 2014; Meijer et al., 2013). The 
eIF4F complex is composed of three proteins: the cytoplasmic cap-binding protein eIF4E, 
the scaffolding protein eIF4G and the RNA helicase eIF4A (Huntzinger and Izaurralde, 
2011). Interestingly, Kiriakidou et al., (2007) demonstrated that central domains of AGO 
proteins exhibit sequence similarity to the cap binding region of eIF4E (Kiriakidou et al., 
2007). The authors found that mutations of two crucial phenylalanines in this region 
severely compromised the ability of tethered AGO proteins to repress reporter mRNAs. 
These data suggest that AGO proteins might compete with eIF4E for m7G binding, block 
the eIF4E-eIF4G interaction, abolish mRNA circularization and thus prevent the 
translation of capped mRNAs (Hurschler et al., 2010; Kiriakidou et al., 2007).  
More recently, studies using in vitro UV crosslinking indicate that miRNAs 
dissociate the eIF4A protein from target mRNAs (Fukaya et al., 2014). eIF4A is an RNA 
helicase normally involved in unwinding the secondary structures within target mRNA to 
allow the 43S pre-initiation complex to scan the 5'UTR for translation (Jackson et al., 
2010). The authors showed that crosslinking of eIF4A to reporter mRNA was abolished in 
the presence of miRNAs, whereas crosslinking of eIF4E showed no change. These results 
indicate that miRISC targets eIF4A and not eIF4E for repression. The interaction between 
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eIF4A proteins and miRISC components is proposed to block 43S scanning, resulting in 
translation repression (Fukaya et al., 2014; Meijer et al., 2013; Ricci et al., 2013). Fukao et 
al. used multiple approaches in HEK293 cells to show the significance of the dissociation 
of eIF4A for miRNA-mediated translational repression. The authors used in vitro 
translation assays to assess the effect of eIF4A proteins on target mRNA repression. In this 
system, miRNAs failed to repress the translation of a Hepatitis C virus (HCV) IRES-
containing reporter mRNA, which is known to be translated independently of eIF4A 
(Fukao et al., 2014). Furthermore, HuD and silvestrol, which facilitate the retention of 
eIF4As on mRNAs attenuated miRNA-mediated dissociation of eIF4As and translational 
repression in vitro (Fukao et al., 2014). Future studies are needed to determine the 
mechanism by which miRNAs dissociate eIF4A from target mRNAs. Taken together, these 
results suggest that miRNAs can repress the translation of target mRNAs by inhibiting 
formation of the pre-initiation complex. mRNAs that can undergo cap-independent 














Figure 9: miRNA mediated translation repression at the initiation stage. 
The miRISC can inhibit translation initiation by interfering with the m7G cap recognition. 
The miRISC proteins can either compete with the eIF4E for binding to the m7G cap or 
impede the association of the 40S and the 60S subunit to form the 80S ribosomal subunit. 
The interaction between the GW182 protein and the PABP protein can interfere with the 
closed-loop mRNA configuration thus contributing to the translation repression at the 
initiation stage. Alternatively, miRNAs can inhibit the association or activity of eIF4A (not 
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1.4.2.2 miRNA-mediated translation repression at the elongation stage.  
 While extensive studies have suggested that miRNA can block translation at the 
initiation stage, other data suggests that some mRNAs can also repress translation at 
elongation stage. For example, some miRNA-bound mRNAs remain associated with 
polysomes (Maroney et al., 2006; Nottrott et al., 2006; Olsen and Ambros, 1999; Petersen 
et al., 2006; Seggerson et al., 2002; Wu and Belasco, 2008). Additional studies using IRES-
containing reporters support miRNA repression after translation initiation. Lytle et al. and 
Peterson et al. demonstrated that specific miRNAs can mediate repression of IRES-
containing reporters (Lytle et al., 2007; Petersen et al., 2006). Because IRES elements 
initiate translation independently of the m7G cap, these results indicate that miRNAs 
repress translation at a step after cap recognition (Filipowicz et al., 2008). The 
interpretation of polysome profiles of miRNAs and their associated target mRNAs have 
led to several possible mechanisms by which miRNAs might regulate mRNA repression. 
Some specific miRNAs are proposed to repress translation at the elongation step through 
mechanisms including co-translational protein degradation, premature translational 
termination, or ribosome stalling (Eulalio et al., 2008a; Filipowicz et al., 2008).  
 In support of the co-translational protein degradation model, sucrose sedimentation 
assays demonstrated that some miRNAs co-sediment with target mRNAs and polysomes 
but have no detectable protein product (Olsen and Ambros, 1999; Seggerson et al., 2002). 
Based on these results, Nottrott et al. proposed that the nascent polypeptide chain might be 
degraded co-translationally when miRNAs are bound to mRNAs (Figure 11; Nottrott et al., 
2006). However, the identity of the protease remains unknown and treatment with 
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proteosome inhibitors did not restore protein expression of these reporters (Eulalio et al., 
2008a; Nottrott et al., 2006). Therefore, additional experiments are needed to validate this 
mechanism. Petersen et al. proposed that some miRNAs cause premature termination of 
ribosomes (known as “ribosome drop off”) (Petersen et al., 2006). To test this hypothesis, 
the authors used a reporter with target sites for miRNAs. They performed a sedimentation 
assay on the repressed reporter and an unrepressed mRNA followed by treatment with the 
translation inhibitor hippuristanol. They found that ribosomes on repressed miRNA 
reporter were released rapidly compared to the ribosomes on non-repressed mRNAs. These 
correlative results suggest that miRNAs can lead ribosomes to fall off during translation 
(Petersen et al., 2006).  
 An alternative mechanism for miRNA mediated repression at the post-initiation 
stage was proposed by Chendrimeda et al. (Chendrimada et al., 2007). The authors 
identified that eIF6 is involved in miRNA-mediated translation repression. Previous 
studies have demonstrated that eIF6 plays a crucial role in the assembly of the 60S 
ribosomal subunit. eIF6 inhibits the premature assembly of the 60S ribosomal subunits 
with the 40S ribosomal subunit (Russell and Spremulli, 1978). The authors showed that 
AGO proteins can repress translation by recruiting eIF6, which prevents the association of 
the 60S and 40S ribosomal subunits (Chendrimada et al., 2007). However, the mechanism 
by which AGO proteins recruit eIF6 to target mRNAs is not exactly clear. Moreover, the 
involvement of eIF6 in this process has been challenged (Ding et al., 2008; Hurschler et 
al., 2010). Knocking down eIF6 in Drosophila S2 cells did not affect miRNA mediated 
repression (Fabian et al., 2010). eIF6 knockdown in C. elegans enhanced miRNA mediated 
 
  41 
translation repression (Ding et al., 2008). Other studies have suggested that eIF6 may 
instead affect either miRNA maturation or miRNA loading onto the miRISC complex 
(Hurschler et al., 2010). 
 Taken together, these data provide evidence that for some mRNAs, miRNAs can 
repress translation by releasing elongating ribosomes, as well as through co-translational 
protein degradation. However, this data is contradictory to previous studies that suggested 
that miRNAs primarily affected translation initiation. Different experimental conditions, 
cell lines and reporters can explain some of these contradictions. However, it is also 
possible that specific miRNAs can utilize both pre-initiation and post-initiation translation 
inhibition mechanisms to regulate translation of a wider variety of mRNAs. This versatility 
could especially be useful in physiological conditions where cap-dependent translation is 
limited or when certain mRNAs utilize both cap-dependent and IRES-dependent 





















Figure 10: miRNA mediated translation repression at the elongation stage. 
The miRISC proteins have been suggested to either slow the movement of ribosomes along 
the target mRNA or to induce ribosomal drop-off. The premature dissociation of ribosomes 
is proposed to cause the ribosomes to drop off the target mRNA. The precise mechanisms 
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Figure 11: miRNA mediated co-translational protein degradation.  
Nascent polypeptides are proposed to be degraded co-translationally via the association of 
specific miRNAs with target mRNAs. However, the identity of the putative protease 























  44 
1.4.2.3 Role of GW182 in mediating translation repression. 
 The GW182 family of proteins is important for miRNA-mediated gene silencing 
(Braun et al., 2013; Eulalio et al., 2008b). GW182 designates target mRNAs for translation 
repression or degradation through multiple protein-protein interactions (Braun et al., 2013; 
Fabian and Sonenberg, 2012). Besides interacting with the AGO proteins, GW182 interacts 
with Poly-A binding protein (PABP) and the CCR4-NOT deadenylase complexes to 
contribute to miRNA-induced translation repression (Eulalio et al., 2008a; Fabian and 
Sonenberg, 2012; Fabian et al., 2009, 2010).  
 Several studies suggest that the PABP–GW182 interaction is important for miRNA 
mediated gene silencing (Fabian et al., 2009; Huntzinger et al., 2010; Jinek et al., 2010; 
Zekri et al., 2009). One model posits that GW182 competes with eIF4G for PABP binding, 
thereby interfering with the PABP-eIF4G association, mRNA circularization, and cap-
dependent translational initiation (Fabian et al., 2009; Zekri et al., 2009). A second model 
proposes that GW182–PABP interaction may reduce the association between PABP and 
the poly-A tail, leading to translation repression (Huntzinger et al., 2010). In contrast to 
these observations, several other studies have demonstrated that GW182-PABP interaction 
does not affect miRNA-mediated repression. Notably, in S2 cell lysates and zebrafish 
embryos, depletion of PABP or addition of PABP-binding protein 2 (PAIP2), which inhibit 
both the eIF4G–PABP and the PABP–poly (A) interactions, did not affect miRNA-
mediated translational repression (Fukaya and Tomari, 2011; Iwakawa and Tomari, 2015; 
Mishima et al., 2012). These results suggest that although PABP’s interaction with GW182 
is important for miRNA-mediated repression, inhibition of GW182-PABP interaction is 
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likely not the only mechanism for miRNAs to mediate translation repression (Iwakawa and 
Tomari, 2015).  
 Previous studies in S2 cells and human cells demonstrate that the GW182 proteins 
act as docking platforms to recruit CCR4-NOT1 and PAN2-PAN3 deadenylase 
components to regulate deadenylation of polyadenylated mRNAs (Braun et al., 2011; 
Chekulaeva et al., 2011; Fabian et al., 2012). Interestingly, knockdown of the deadenylase 
components severely impairs GW182-meditated repression of non-adenylated mRNAs 
(Braun et al., 2011; Chekulaeva et al., 2011). These results led to the model that 
deadenylase complexes facilitate a deadenylation-independent mode of translation 
repression (Braun et al., 2013; Fabian and Sonenberg, 2012). However, mechanistic details 
on how GW182 might either recruit deadenylase components to mediate deadenylation or 
how GW182 mediates translation repression independent of deadenylation remain elusive 
(Fabian et al., 2010). Recent structural and biochemical studies demonstrated that the 
deadenylase NOT1 interacted directly with the DEAD-box RNA helicase DDX6. DDX6 
is believed to function primarily as a translation repressor in mammalian cells (Chen et al., 
2014b; Mathys et al., 2014; Rouya et al., 2014). Therefore, the GW182 proteins might 
recruit DDX6 to target mRNAs through an interaction with the CCR4-NOT1 complex 
(Iwakawa and Tomari, 2015). Recent studies also indicate that CCR4-NOT1 recruits the 
eIF4E-binding protein 4E-T through interaction with DDX6 (Nishimura et al., 2015; 
Waghray et al., 2015), and 4E-T represses translation by binding to eIF4E proteins and 
inhibit cap-dependent translation initiation. However, further studies are needed to identify 
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the specific step of translation blocked by the interaction between GW182 and DDX6 
(Wilczynska and Bushell, 2014).  
1.4.2.4 Compartmentalization of miRNA-mediated repression in P bodies.  
 mRNAs subject to translational repression are localized to cytoplasmic RNP 
granules knows as P bodies along with miRNAs and the miRNA machinery in eukaryotic 
cells (Eulalio et al., 2007a; Liu et al., 2005; Parker and Sheth, 2007). Cellular components 
that are involved in miRNA function, including AGO1, GW182, the CCR4-NOT1 
deadenylase complex, the decapping enzyme DCP2, decapping enhancers (DCP1, EDC3) 
and the RNA helicase DDX6/RCK/ME31B, also localize to P bodies (Anderson and 
Kedersha, 2006; Eulalio et al., 2007a; Parker and Sheth, 2007). P bodies are devoid of 
ribosomal subunits and translation initiation factors (Filipowicz et al., 2008; Liu et al., 
2005; Mitchell and Parker, 2014; Teixeira et al., 2005). Previous studies have indicated a 
correlation between miRNA-mediated translational repression and the accumulation of 
target mRNAs in P bodies (Bhattacharyya et al., 2006; Filipowicz et al., 2008; Liu et al., 
2005; Pillai, 2012). Specifically, miRNAs, AGO1 and GW182 interact with other P body 
components, and the knockdown of ME31B or other decapping enhancers weakens 
miRNA-mediated translation repression (Chu and Rana, 2006; Fabian et al., 2010). 
Importantly, a functional miRNA pathway is important for P body formation (Eulalio et 
al., 2007c; Filipowicz et al., 2008), and inhibition of miRNA biogenesis or depletion of 
GW182 or AGO1 protein results in a dispersal of P bodies in mammalian and S2 cells 
(Filipowicz et al., 2008). However, knockdown of some P-body components (for example 
LSM1, LSM3) result in the dispersal of P-bodies but have no effect on miRNA function 
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(Filipowicz et al., 2008). Therefore, P bodies are likely not required for miRNA function, 
and their formation is a consequence rather than the cause of translational silencing (Chu 
and Rana, 2006; Eulalio et al., 2007c).   
1.5 Role of FMRP in miRNA-mediated repression.  
 Previous studies have demonstrated that FMRP interacts with some miRNAs and 
core miRISC components to regulate translation. This association provides selective, 
bidirectional, spatial and temporal control for regulating mRNA translation (Liu-
Yesucevitz et al., 2011; Muddashetty et al., 2011). FMRP is genetically and biochemically 
linked to the miRNA pathway (Edbauer et al., 2010; Li and Jin, 2009). dFMRP and 
mammalian FMRP interact directly with Dicer1, AGO1, and the miRISC-associated RNA 
helicase MOV10 (Cheever and Ceman, 2009; Jin et al., 2004b; Kenny et al., 2014; Li and 
Jin, 2009; Loffreda et al., 2015; Plante et al., 2006).  Moreover, translationally repressed 
mRNAs along with FMRP, miRNAs, core miRISC components (AGO1, GW182) and 
other RNA binding proteins are localized in motile neuronal mRNA granules in axons and 
dendrites (Barbee et al., 2006; Muddashetty et al., 2011).  
 In vitro studies have indicated that FMRP can also act as an acceptor of miRNAs derived 
from Dicer processing of pre-miRNAs through its KH2 domain (Plante et al., 2006). 
Moreover, phosphorylation of FMRP inhibits its association with Dicer (Cheever and 
Ceman, 2009). These results suggest that cooperation between Dicer and FMRP is 
important for miRNA function and mRNA regulation. KH domains of FMRP have been 
demonstrated to be crucial for the association of FMRP and miRISC components. A 
specific mutation in the KH2 domain of FMRP (I304N) causes a severe form of FXS. This 
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mutation causes defects in association with ribosomes and target mRNA (Caudy et al., 
2002). The analogous mutation (I307N) in Drosophila has been shown to disrupt the 
association between FMRP and AGO proteins (Caudy et al., 2002; Loffreda et al., 2015). 
These results suggest the importance of a direct interaction between FMRP and miRISC 
components in the function of FMRP- and miRNA-mediated repression in cells. 
 Recent studies have proposed that modification of the secondary structure of 
mRNA can facilitate the interaction between FMRP and miRISC components. The 3’UTRs 
of mRNAs contain secondary structures and have embedded seed regions for miRNAs. 
FMRP was shown to interact with an RNA helicase, MOV10, which is a component of the 
miRISC (Kenny and Ceman, 2016; Kenny et al., 2014). FMRP recruits MOV10 to target 
mRNA for unwinding the secondary structure for subsequent access of miRISC complex 
to repress target mRNA (Kenny and Ceman, 2016; Kenny et al., 2014). Taken together, 
these results support a model in which the binding of FMRP to target mRNAs contributes 
to the ability of miRISC to repress target mRNAs (Banerjee et al., 2018; Edbauer et al., 
2010; Kenny et al., 2014; Li et al., 2014; Muddashetty et al., 2011).  
Other studies have demonstrated that a functional relationship between FMRP and specific 
miRNAs is essential to repress target mRNAs (Li and Jin, 2009). It is unclear if this 
interaction involves the RISC but it is important for proper synaptic structure and function 
(Edbauer et al., 2010; Kenny and Ceman, 2016; Loffreda et al., 2015). Edbauer et al. 
demonstrated that FMRP associates with miR-125b and miR-132 to control dendritic spine 
morphology in mice (Kenny and Ceman, 2016). The authors showed that overexpression 
of miR-125b and miR-132 resulted in dendritic spine defects in hippocampal neurons. 
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Importantly, a knockdown of FMRP rescued these phenotypes in mice, suggesting that 
FMRP interacts with specific miRNAs to control dendritic spine development (Banerjee et 
al., 2018; Edbauer et al., 2010; Richter et al., 2015). 
 Additional studies have demonstrated the existence of a cooperative mechanism 
between FMRP and miRISC components to reversibly and selectively regulate synaptic 
mRNAs in response to mGLuR signaling (Loffreda et al., 2015; Muddashetty et al., 2011). 
FMRP recruits the miR-125a-AGO2 complex to the 3'UTR of the PSD-95 mRNA to 
repress translation of the postsynaptic density protein 95 (PSD-95) at the synapse in 
response to mGLuR stimulation. Phosphorylation of FMRP at a specific serine residue 
(Ser499) results in the formation of the miR-125a-AGO2 inhibitory complex on PSD-95. 
Dephosphorylation of FMRP, on the other hand, relieves PSD-95 from repression (Kenny 
and Ceman, 2016; Muddashetty et al., 2011). Similarly, dephosphorylation of FMRP by 
the specific phosphatase 2A (PP2A) plays an important role in the bidirectional regulation 
of mRNA translation in neurons (Loffreda et al., 2015).   
 Although previous studies demonstrated that interactions between FMRP and 
miRNA pathway are critical to regulating translation of target mRNAs, the mechanism of 
FMRP’s interaction with various miRNA components is not well understood. Studying this 
interaction will shed light on an important function of FMRP in cells. Because FMRP 
deficiency and loss of function is implicated in FXS, understanding of the function of 
FMRP in miRNA-mediated translation repression (or vice versa) has the potential to 
identify underlying mechanisms that contribute to the pathology of FXS in patients.  
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1.6 Summary 
Previous studies indicate that FMRP interacts biochemically and genetically with 
Dicer1 and miRISC proteins such as AGO1 and MOV10 (Caudy et al., 2002; Jin et al., 
2004b; Kenny et al., 2014). FMRP is also known to associate with specific miRNAs to 
regulate translation repression (Edbauer et al., 2010; Muddashetty et al., 2011). These 
interactions are required to control normal synaptic development in mammals and flies. A 
growing amount of evidence points towards a cooperative mechanism of FMRP-mediated 
translation repression of target mRNAs via miRNAs. However, the details of this 
mechanism remain elusive. The underlying objective of this thesis is to explore the 
mechanism of FMRP-mediated translation repression via the miRNA pathway. To 
address this, we used Drosophila as our model as it offers multiple advantages compared 
to the other model organisms. Drosophila are easier to maintain, less expensive, have a 
shorter lifespan and generation time with a completely sequenced genome (Drozd et al., 
2018). Moreover, dFMRP, the only Drosophila ortholog of human FMRP, is highly 
conserved with a similar amino acid sequence, RNA-binding properties and biochemical 
function in vivo (Bhogal and Jongens, 2010). dFmr1-null flies recapitulate many of the 
FXS phenotypes, such as defects in memory, social behavior, circadian rhythmicity and 
sleep (Weisz et al., 2015). Further, dFmr1 nulls display defects in synaptic growth 
mimicking dendritic spine overgrowth in FXS patients (Weisz et al., 2015).  
In this study, we have used an in vitro system to study FMRP mediated translation 
control by using a translational reporter system in Drosophila S2 cells. Our results suggest 
that FMRP requires AGO1 and GW182 to mediate translation repression when FMRP is 
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tethered to a luciferase reporter mRNA. We have also examined the role of the RNA 
binding domains (RBDs) of tethered FMRP in translation repression and found that KH1 
and 2 domains contribute to its ability to repress translation. Further, we show that 
untethered FMRP can repress translation of the reporter by recognizing and binding to a 
small stem-loop structure within its 3’UTR. These results point towards the importance of 
structural elements in target mRNAs for FMRP mediated translation regulation. 
Remarkably, our analysis suggest role for FMRP in the recruitment of miRNAs to a target 
mRNA for translation repression, suggesting a role for FMRP in miRNA-mediated 
repression.  
FMRP associates with mRNAs as part of a large mRNP complex in distinct 
cytoplasmic foci (Kedersha and Anderson, 2007; Kenny and Ceman, 2016). Therefore, we 
also examined the intracellular localization of FMRP with miRISC components within S2 
cells and the larval CNS. Our results demonstrate that FMRP is present in same cells as 
core miRISC components. We performed co-immunoprecipitation to test the direct 
association of FMRP with core miRISC components. Our results indicate a strong 
association of FMRP with AGO1 and a weak association of FMRP with GW182 under low 
salt conditions. Under high salt conditions, we found a dissociation of FMRP with GW182 
with not much effect on the association of FMRP-AGO1. Therefore, the association 
between FMRP and AGO1 appears to be stronger than GW182. Next, we used the larval 
neuromuscular junction (NMJ) to study genetic interactions between FMRP and AGO1 or 
GW182. We demonstrate that genetic interactions of FMRP with AGO1 and GW182 are 
crucial to regulate synaptic structure at the larval NMJ.   
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FMRP-associated mRNAs that are targeted for translation repression are found to 
localize in cytoplasmic foci such as P-bodies and stress granules. Previous studies also 
indicate that miRISC regulates repression by targeting mRNAs for repression via 
deadenylation followed by translation repression in P bodies (Braun et al., 2013; Eulalio et 
al., 2007c; Fabian and Sonenberg, 2012). Therefore, we screened for a genetic interaction 
between the key proteins involved in deadenylation and repression: CCR4, NOT1, and 
PABP, in order to identify the downstream mechanism for FMRP-miRISC mode of 
repression. We demonstrate that FMRP is present in the same cells as the components of 
deadenylase enzyme (CAF1, CCR4, and NOT1) within larval CNS. However, FMRP does 
not interact genetically with CCR4, NOT1 or PABP to control synaptic morphology. These 
results suggest that FMRP does not interact with CCR4, NOT1 or PABP within the same 
pathway. Therefore, FMRP-GW182 utilizes an alternative mechanism to control synaptic 
structure and morphology in Drosophila. 
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CHAPTER TWO: METHODS 
2.1 Key resources table  
2.1.1Reagents and Chemicals  
Shields and Sang media  Sigma Adrich  S-8398  
Effectene transfection reagent  Qiagen  301425 
Dual-luciferase reporter assay system  Promega  E2940 
Corning Flat bottom, non-treated, white 
polystyrene well plate  
Fisher Scientific  3912  
MEGAscript T7TM Transcription kit  Fisher Scientific AM1333 
Q5 polymerase hot start high-fidelity 
DNA polymerase  
New England Biolabs  M0493S 
RNeasy mini kit  Qiagen  74104 
Ambion DNAase I (RNase free)  Fisher Scientific  AM1906 
Betamercaptoethanol  Bio-Rad 161-0710 
2x Laemmli sample buffer  Bio-Rad  161-0737 
SouthernBiotech Dapi-Fluoromount-G 
clear mounting media  
Fisher Scientific  OB010020  
Pierce protease inhibitor tablets- EDTA 
free  
Fisher Scientific A32955 
iQ SYBR green supermix  Bio-Rad 170-8880 
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RNA to cDNA eco-dry premix (double 
primed)  
Clonetech  639549 
RNAeasy mini kit   Qiagen  74104  
Super signal west dura substrate Fisher Scientific 34076 
GFP trap beads  Chromotek  Gtmak-20 
RNase inhibitor tablets  Fisher Scientific AM2694  
NP-40 Surfact-Amps Detergent solution  Fisher Scientific 28324 
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2.1.2 Experimental models: Cell lines 
Cell line                   Source     Identifier  




2.1.3 Experimental models: Fly strains  
Fly strains                   Source   Identifier  
w1118 Bloomington Drosophila Stock Center  3605 
dfmr1∆113 Bloomington Drosophila Stock Center  6929 
Ago1I(2)k00208 Bloomington Drosophila Stock Center 10470  
gw1 (Schneider et al., 2006) N/A  
TwinGS12209 Kyoto Stock Center (DGGR)  203904 
Not1M107631 Bloomington Drosophila Stock Center 44201 
pAbpk10109 Bloomington Drosophila Stock Center 10970 
Dcp1442p (Lin et al., 2006) N/A 
elav-Gal4  Bloomington Drosophila Stock Center 8765 
w1118;ActGFP,unc13[In(
4)ciD,ci[D]pan[ciD] 
Bloomington Drosophila Stock Center 9549 
UAS-Dcr1RNAi Bloomington Drosophila Stock Center 34826 
UAS-AGO1 RNAi Bloomington Drosophila Stock Center 33727 
UAS-gawky RNAi Bloomington Drosophila Stock Center 34796 
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2.1.4 DNA constructs  
DNA constructs           Source       Identifier  
pAc5.1C- FLuc-Stop-5BoxB         Addgene  21301 
pAc5.1C-RLuc-Stop-V5His6           Addgene 21182 
pAc5.1B-lambdaN-HA         Addgene  21302 
pAc5.1B-lambdaN-HA 
FMRP  
        This study   N/A 
pAFW-Ago1       (Kawamata et al., 2009) N/A 
pAFW-Ago2         (Iwasaki et al., 2010) N/A 
pAFW-GW182          This study    N/A 
pAFW-Dicer1         This study     N/A 
pAc5.1B-EGFP          Addgene 21181 
pAc5.1B-EGFP-DmAGO1          Addgene 22768 
pAc5.1B-EGFP-DmGW182          Addgene 22419 
pAc 5.1(dV5-HisA)  Fisher Scientific  V411020  
pAc 5.1 miR-958           This study   N/A 
pAc 5.1 miR-13b          This study   N/A 
pAc 5.1 miR-33          This study   N/A 
pAc 5.1 miR-2b          This study   N/A 
pAc 5.1 miR-2a          This study   N/A 
pAc 5.1 miR-279           This study   N/A 
pAc 5.1-FLuc-ppk 3’UTR           This study   N/A 
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pAc 5.1-FLuc-chic 3’UTR          This study   N/A 
pAc 5.1-FLuc-arc 3’UTR          This study   N/A 
pAc 5.1-FLuc- rac1 3’UTR          This study   N/A 
pAc 5.1-FLuc- tral 3’UTR          This study   N/A 
pAc5.1B-lambdaN-HA-
∆RGG FMRP 
         This study   N/A 
pAc5.1B-lambdaN-HA-
∆KH0 FMRP 
         This study   N/A 
pAc5.1B-lambdaN-HA-
∆KH1/2 FMRP  
        This study   N/A 
pAc5.1B-EGFP-∆RGG 
FMRP 
         This study   N/A 
pAc5.1B-EGFP-∆KH0 
FMRP 
         This study   N/A 
pAc5.1B-EGFP-∆KH1/2 
FMRP 
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2.1.5 Oligonucleotides  
Oligonucleotide name  Sequence (5’to 3’)  
Forward primer to amplify the 
Tral3’UTR 
CACCTGCCGCCCGGCCAGTGGAA 








Reverse primer to amplify the ppk 
3’UTR 
GCGAACACATTTTTTATTGTCGTG 




Reverse primer to amplify the chic 
3’UTR 
TGACTTTGGGAACCGCGATA 




Reverse primer to amplify the rac1 
3’UTR 
CCTTTTATTATGCTTTATTGATTTCC 
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Reverse primer to amplify the arc 
3’UTR 
GTCCCATCCACCCCATAAA 





Reverse primer for RNAi against Dicer1   TAATACGACTCACTATAGGG 
CGCAACACGGTGACAATATC 
 
Forward primer for RNAi against AGO1 TAATACGACTCACTATAGGG 
ATTTGATTTCTATCT ATGCAGCCA 
 
Reverse primer for RNAi against AGO1 TAATACGACTCACTATAGGGGCCCT
G GCCATGGCACCTGGCGTA 
 
Forward primer for RNAi against 




Reverse primer for RNAi against 
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Forward primer for RNAi against EGFP TAATACGACTCACTATAGGGAA 
GAAATCCTCGCCCATTAC 
Reverse primer for RNAi against EGFP TAATACGACTCACTATAGGG 
TGCTCAGGTAGTGGTTGTCG 
Forward primer for RNAi against AGO2 TAATACGACTCACTATAGGG 
AGGATGGAGCAACTCAGGT 
Reverse primer for RNAi against AGO2 TAATACGACTCACTATAGGG 
ATTCTAAACTGAGGAATAATCACA 
Forward primer for qRT-PCR of the 
FLuc reporter  
AAACGCTTCCACCTACCAGG 
 Reverse primer for qRT-PCR of the 
FLuc reporter 
TGATCAGAATGGCGCTGGTT 
Forward primer for qRT-PCR of the 
RLuc  
TTTACATGGTAACGCGGCCT 
Reverse primer for qRT-PCR of the 
RLuc 
TAATACACCGCGCTACTGGC 
Forward primer for amplifying miR-33a  CACC GCTGTGCTGCGAGCTAAGAT 
Reverse primer for amplifying miR-33a ACACAAGCTCAGGTTACGGA 
Forward primer for amplifying miR-13b CACC CCGTCATAAATCGGTTTGG 
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Reverse primer for amplifying miR-13b ATAGCAAAATGTGACCCGTG 
Forward primer for amplifying miR-279 CACC 
CGTACGCCTATGTGTATGTGTG 
Reverse primer for amplifying miR-279 ATCGCTCTTCCTTTTGGGC 
Forward primer for amplifying miR-2a CACC 
TAAGTCTGAGGTGCCAGTCCAC 
Forward primer for amplifying miR-2b CACC 
CAGAAAGGGGAGTGATGTTC 
Reverse primer for amplifying miR-2b GTTGATTTCTTGCGCCTATG 
Forward primer for EGFP-Dicer1  GGTGGTGCGGCCGC 
ATGGCGTTCCACTGGTGCGAC 
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2.1.6 Antibodies  
          Antibody             Source         Identifier  
  Mouse anti-FMRP (6A15)              Abcam  AB-10299  
  Rabbit anti-Dicer1             Abcam AB-4735 
  Rabbit anti-AGO1             Abcam AB-5070 
  Rabbit anti-AGO2               Abcam AB-5072 
  Guinea-pig anti-GW182      (Schneider et al., 2006) N/A  
  Mouse anti-Armitage      (Saito et al., 2010) N/A  
  Rabbit anti- CCR4      (Temme et al., 2004) N/A 
  Rabbit anti- NOT1      (Temme et al., 2010)  EG 314 
  Rabbit anti-CAF1      (Temme et al., 2004)  N/A 
  Mouse anti- HA (6E2)   Cell Signaling Technology  2367  
  Rat anti-EGFP (3H9)            Chromotek  ABIN- 398304 
  Rabbit anti-GFP            Torey Pines  TP401 
  Mouse anti-FLAG (M2)           Sigma-Aldrich   F3165  
  Mouse anti-Actin               Abcam AB-8224 
  Anti-discs large (4F3)  Developmental Studies 
Hybridoma Bank  
AB-528203 
Horse anti mouse IgG HRP-
linked antibody  
Cell Signaling Technology  7076 
 Goat anti-rabbit IgG HRP-
linked antibody 
Cell Signaling Technology  7074 
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 Donkey anti-guinea pig IgG Jackson Immunoresearch 
Laboratories  
706-035-148  
 Alexa Flour 488 goat anti-
mouse IgG 
Invitrogen  A-2534069 
 Alexa Fluor 568 goat anti 
rabbit IgG 
Invitrogen A-3534072 
 Alexa Fluor 594 goat anti 
guinea pig IgG 
Invitrogen  A-11076 
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2.1.7 Media and buffer composition 
                            Media         Composition  
M3 media (10 L)  393.6 g Shields and Sang powdered 
medium, 5g KHCO3, 10g yeast 
extract,25g bactopeptone (pH 6.6)  
 
Buffers for western blot  Composition  
S2 lysis buffer 50mM Tris-HCl (pH 7.4), 150mM 
NaCl, 1mM EDTA, 0.1% Triton, 0.5% 
NP40, supplemented with EDTA free 
protease inhibitor tablets 
Sample buffer 2X Lamelli buffer and ß-
mercaptoethanol 
10 X TGS (Tris Glycine SDS) Running 
buffer 
250 mM Tris, 1.92M Glycine and 1% w/v 
SDS 
1X Transfer buffer (2 L)  6.0 g Tris, 28.8 g Glycine, 200ml 
Methanol, 1.6ml water   
1X Tris-buffered saline (1X TBS)  150mM NaCl, 50mM Tris-Cl (pH 7.5)  
TBST (Tris-buffered saline, 0.1% 
Tween 20) -(1L) 
100 mL of TBS 10X – 900 mL of distilled 
water – 1 mL Tween 20 
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Blocking buffer  1X TBST with 5% w/v dry milk  
Gentle stripping buffer (1L)  15 g glycine, 1 g SDS, 10 ml Tween20 
(pH 2.2)  
Harsh stripping buffer (0.5 L)  20 ml 10% SDS, 12.5 ml Tris HCl (pH 
6.8), 67.5 ml water, 0.8ml of ß-
mercaptoethanol 
 
Buffers for co-immunoprecipitation   Composition  
1X PBS (Phosphate buffered saline)  
(pH 7.4)  
0.137M NaCl, 0.0027M KCl, 0.01M 
Na2HPO4, 0.0018M KH2PO4 
S2 lysis buffer 150mM NaCl, 0.5% NP40, 20mM 
HEPES (pH 7), 2mM MgCl2, 1mM 
DTT supplemented with EDTA free 
protease inhibitor tablets and RNAase 
inhibitor 
Low-salt wash buffer  150 NaCl, 0.5% NP40, 20mM HEPES 
(pH 7), 2mM MgCl2, 1mM DTT  
High- salt wash buffer 300mM NaCl, 0.5% NP40, 20mM 
HEPES(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 2mM 
MgCl2, 1mM DTT (pH 7), 
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2X SDS elution buffer  4% SDS, 20% glycerol, 0.004% 
bromophenol blue, 0.125M Tris-Cl 
(pH6.8), 10% ß-mercaptoethanol  
 
 
Buffers for CNS dissections     Composition  
1X PBS (Phosphate buffered saline) (pH 
7.4)  
0.137M NaCl, 0.0027M KCl, 0.01M 
Na2HPO4, 0.0018M KH2PO4 
Permeabilization buffer (PBS-T)  1X PBS with 0.3% Triton X-100 
Blocking buffer       1X PBS-T with 5% Normal Goat 
Serum and 2% Bovine Serum 
Albumin (BSA)  
 
Buffers for NMJ dissections     Composition  
Calcium-free HL-3 buffer (1L) (pH 7.2)  70mM NaCl, 5mM KCl, 20mM 
MgCl2.6H2O,10mMNaHCO3, 
115mM Sucrose, 5mM Trehalose, 
5mM HEPES  
Permeabilization buffer (PBS-T)  1X PBS with 0.1% Triton X-100 
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Software  URL  
Flybase  http://flybase.org/ 
RNAfold  http://rna.tbi.univie.ac.at/cgibin/RNAWebSuite/RNAfold.cgi 
SnapDragon  http://www.flyrnai.org/cgi-bin/RNAi_find_primers.pl 
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METHOD DETAILS  
2.2 DNA Constructs  
 For tethering assays, we obtained pAc5.1C- FLuc-Stop-5BoxB, pAc5.1C- RLuc-
Stop-V5His6 and pAc5.1B-lambdaN-HA vectors from Prof. Elisa Izzauralde via Addgene 
as listed in Table 2.1 (Behm-Ansmant et al., 2006; Rehwinkel et al., 2005). To generate 
the pAc5.1B-λN-HA FMRP, the full sequence of FMRP was amplified by PCR and cloned 
into the pAc5.1 backbone vector in frame with the λN-HA tag. The pAc5.1C-FLuc-Stop-
3XBoxB, pAc5.1C-FLuc-Stop-1XBoxB and pAc5.1C-FLuc-Stop were generated by 
removing the 5BoxB sequence from the pAc 5.1C-FLuc-Stop-5XBoxB and cloning oligos 
containing the indicated number of BoxB repeat sequences.  
 Snapdragon was used to design optimal RNAi primers with no off-target effects 
against Dicer1, AGO1, AGO2, Armitage and GW182 in S2 cells. Templates for dsRNA 
synthesis were either cDNA isolated from Drosophila S2 cells or cDNA clones obtained 
from DGRC. cDNAs were PCR amplified using primers listed in Table 2.1.5. The 
amplified products were extended to have convergent T7 promoters. Following cDNA 
clones were obtained from DGRC: AGO1 (CG6671) and GW182 (CG31992). Dicer1, 
AGO2, and Armitage were amplified using primers listed in Table from cDNA of 
Drosophila S2 cells. The EGFP sequence was amplified via PCR from the pAC5.1-EGFP 
plasmid. Predicted dsRNAs were 300-566 nucleotide long and corresponded to the coding 
sequences for control EGFP dsRNA, GW182, AGO1, AGO2, Armitage, and Dicer1. PCR 
products were isolated, purified and transcribed into dsRNA using MEGAscript T7TM 
Transcription Kit. Transcription reactions were treated with DNAase and purified using 
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phenol-chloroform extraction. dsRNAs were ethanol precipitated and resuspended in 
nuclease-free water. Agarose gel and UV absorbance values were used to assess the yield 
and the quality of dsRNAs. 
 The 3'UTR sequences of known FMRP target mRNAs including Trailer-hitch, 
pickpocket, Rac, Chicadee, Arc1 were amplified by PCR and cloned into pENTR and 
subsequently into pAc5.1-FLuc2 [dPolyA] destination vector using the Gateway system. 
These constructs were used for transfection in S2 cells for analysis of repression by FMRP. 
For primer sequences, refer to Table 2.1.4. 
 For miRNA expression in S2 cells, PCR primers were designed to amplify a 
sequence 200 nucleotide sequence upstream and downstream of each miRNA hairpin from 
genomic DNA to allow proper processing. The PCR products of miR-958, Bantam, miR-
13b, miR-33, miR-2b, miR2a were cloned into pENTR and then into the pAC5.1 (dV5-
HisA) expression vector for transfections in S2 cells as we have previously described 
(Nesler et al., 2013). The primers are described in Table 2.1.4.  
 For the pAFW-GW182 construct, cDNA clone obtained from DGRC was used to 
amplify GW182 using primers described in table 2.1.4. The product was cloned into the 
pENTR vector as an entry vector for LR recombination into the pAFW expression vector 
(Drosophila Gateway Vector Collection, Carnegie Institution). Using primers listed in table 
2.1.4, Dicer1 was amplified from the cDNA of S2 cells and inserted into the sites between 
Not1 and SacII sites in the pAc5.1-EGFP plasmid to generate pAc5.1-EGFP Dicer1.These 
plasmids were used for S2 cell transfection.  
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 The pAc5.1B plasmids containing EGFP-FMRP and deletions for EGFP FMRP 
(∆RGG), FMRP(∆KH1/2), FMRP(∆KH0) were cloned as described (Gareau et al., 2013b). 
The first PCR product was amplified from pAc5.1 λN-HAFMRP using oligos with BamHI 
and HindIII sites, and the second PCR fragment was amplified using oligos with BamHI 
and EcoR1 sites. The amplified products were digested and ligated into pAc5.1 EGFP 
FMRP construct, previously digested with HindIII and EcoRI, to generate pAc5.1 EGFP 
FMRP(∆KH1/2) and FMRP(∆KH0) constructs respectively. To generate the pAc5.1 EGFP 
FMRP(∆RGG), the first PCR product was amplified from pAc5.1 λN-HAFMRP using 
oligos with HindIII and EcoR1 sites at the end and the second product was amplified using 
primers with BamHI and HindIII sites. These PCR products were digested with restriction 
enzymes for ligation into the pAc5.1 EGFP FMRP previously digested with EcoRI and 
HindIII for directional cloning.  
2.3 S2 Cell Culture and Transfection 
 Drosophila S2 cells were maintained in vented 75cm2 cell culture-treated flasks 
and cultured in M3 media, supplemented with 10% FBS, 1% Penicillin-Streptomycin and 
Fungizone. Cells were incubated at room temperature in an incubator and passaged every 
72 hours at a ratio of 4 ml cells to 12 ml cell culture media. The day before transfection, 
cells were split into 250 ml suspension flasks in M3 media without Fungizone at 1:1 
dilution. 
 On the day of transfection, cells were vigorously suspended and detached from 
tissue culture flasks with a pipette. Hemocytometer was used to determine the number of 
viable cells in the original cell suspension. The volume of cell suspension corresponding 
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to a density of 1 x 106 cells/ml was determined. Cells were centrifuged at 2,500 rpm for 3 
minutes and resuspended in 1X PBS for 15 minutes followed by resuspension in an 
appropriate volume of cell culture media (0.8ml/well). All transfections were performed in 
three biological replicates in 12 well plates using Effectene transfection reagent. 
Manufacturer's instructions were followed to prepare transfection mixtures, as described 
below. 
 Briefly, the transfection mixture contained reporter plasmid, plasmid encoding 
gene of interest, control plasmids, DNA condensation buffer (Buffer EC), Enhancer 
solution and Effectene solution. After incubation for 10 minutes, 1.5 ml of media was 
added directly to the tubes and mixed with a pipette. The cells were dispensed drop-wise 
(500ul) into individual wells while gently swirling the plate. Post-transfection, the cells 
were incubated for 72 hours until harvested, and were processed for gene expression or 
biochemical analysis as described below.  
2.3.1 Tethering Assays  
 In tethering experiments, cells were co-transfected with 0.05µg of the FLuc-BoxB 
reporter plasmid, 0.2µg of RLuc plasmid, 0.25µg of plasmid-expressing the λN-HA protein 
per well of a 12-well plate. The plasmid expressing the λN-HA-tagged FMRP was added 
in increasing amounts from 0.125µg to 0.5µg per well. The modified FLuc reporter with 3 
(FLuc-3xBoxB), 1(FLuc-1xBoxB) or no BoxB sites (FLuc-0xBoxB) was transfected using 
similar procedure and concentration as described above. At least three independent 
transfection experiments were performed, each with three technical replicates. 
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2.3.2 Assays with untethered FMRP  
 Transfection assays with untethered FMRP (FMRP lacking λN-HA tag) followed 
a similar transfection procedure as described above. In assays with miR-958, transfection 
mix contained FLuc-Box B reporters mainly 0.05µg of FLuc-1XBoxB or FLuc-0XBoxB 
reporter, 0.2µg of RLuc plasmid, 0.25µg of empty vector (no miRNA control) and 0.5µg 
of untethered FMRP.  
 The entire SV40-3'UTR sequence of the FLuc-BoxB reporter was replaced by the 
3'UTR of ppk, chic, tral, rac, and arc as described previously. These reporters were co-
transfected with increased concentration of untethered FMRP (0.125-0.5 µg), 0.2 µg of 
RLuc, and 0.25 µg of λN-HA control. 
2.4 Luciferase Assays  
 The FLuc and RLuc luciferase activities were measured sequentially with the Dual-
Luciferase Reporter Assay System. The ratio of the FLuc/RLuc was measured for each 
well in three technical replicates on an infinite M1000 plate reader.  
 For the measurement of FLuc activity, 75µl of cell suspension was dispensed into 
the wells of a 96-well plate, followed by the addition of an equal volume of Dual-Glo® 
Reagent.  FLuc values were quenched with Stop & Glo® reagent, followed by the 
measurement of the RLuc activity in the same wells. The FLuc/RLuc ratio for each sample 
was normalized to the ratio of the well with transfected λN-HA. Cells were frozen at -800C 
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2.5 RNAi Against miRISC Constructs in S2 Cells  
 1x106 S2 cells were seeded in 12 well plates and transfected with 2µg of the 
appropriate dsRNA per well along with 0.05µg of the FLuc-BoxB reporter plasmid, 0.2µg 
of RLuc plasmid, and 0.25µg of plasmid-expressing the λN-HA protein. All transfections 
were performed using the Effectene transfection reagent. Post-transfection, the cells were 
incubated for 72 hours in an incubator at 25°C to be used for luciferase assays and western 
blotting. Primers for dsRNA synthesis have been listed in Table 2.1.4.  
2.6 Western blotting  
 S2 cells were scraped in 1 ml of ice-cold 1X PBS buffer and centrifuged at 1000xg 
for 10 min at 4°C. Cell pellets were resuspended in ice-cold lysis buffer and mixed 
intermittently on ice for 15 minutes to ensure proper lysis. The samples were mixed in 
loading buffer, boiled for 3 min at 100°C and loaded in an 8% SDS-polyacrylamide gel. 
For detailed composition of the buffers and refer to table 2.1.6. The resolved proteins were 
then transferred onto a PVDF membrane. A stack consisting of filter papers and sponges 
soaked in transfer buffer was assembled to ensure the transfer of proteins onto PVDF 
membrane. The PVDF membrane, soaked in methanol and equilibrated in transfer buffer 
was placed in this stack with the resolved polyacrylamide gel. This stack was placed in the 
blotting apparatus for overnight transfer at 22V.  
 Before incubation with antibodies, the membrane was blocked for an hour in 5% 
non-fat milk in 1X TBST. The lysates were immunoblotted with primary antibodies against 
FMRP (1:1000) or HA tag (1:500) for 2 hours to examine the expression of FMRP. We 
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used antibodies against Β-actin for loading control. Antibodies have been listed in table 
2.1.5.  
 To confirm the efficiency of RNAi in S2 cells, blots were probed with primary 
antibodies against Dicer1 (1:1000), AGO1 (1:2000), Armitage (1:1000), AGO2 (1:1000) 
and GW182 (generously gifted to us by Dr. Andrew Simmonds) (1: 2000) (Schneider et 
al., 2006). The PVDF membrane was washed with 1xTBST thrice for 5 min followed by 
incubation HRP-conjugated secondary antibodies. We used super signal solution to detect 
the proteins on the PVDF membrane and developed the blot on an X-ray film.  
2.7 Co-Immunoprecipitation 
 For FMRP immunoprecipitation, we seeded 4x 106   S2 cells in 25 cm2 flasks and 
transfected with plasmids expressing 1 µg of EGFP-FMRP, FLAG-AGO 1, FLAG-AGO2, 
and FLAG-GW182 respectively. Three days after transfection, S2 cells were harvested, 
washed with ice-cold 1X PBS, centrifuged at 1000 x g for 10 min at 4°C followed by 
washing with ice-cold 1X PBS buffer. Cells were re-suspended in 200µl lysis buffer, 
incubated on ice for 30 minutes and centrifuged at 16000xg for 20 minutes at 40C. We 
added 300 µl of the lysis buffer to the lysate and discarded the cell pellet. 50µl of the ‘Input 
fraction’ was saved from the lysate for western blotting and 250 µl of the lysate was used 
for FMRP-immunoprecipitation (‘IP fraction’).   
 The GFP-trap bead slurry (25 µl) was equilibrated as per manufacturer's 
instructions and incubated with the IP fraction for about 2 hours at 40C. The beads were 
washed five times with 500 µl of low and high salt wash buffer (150 mM or 300 mM NaCl) 
and magnetically separated from the supernatant.  The proteins bound to beads were eluted 
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directly off beads with 100 µl of the 2X SDS buffer, resolved by 8% polyacrylamide gel 
electrophoresis (PAGE) and probed with anti-FLAG (1:1000) and anti-EGFP antibody 
(1:1000). The buffers for co-immunoprecipitation experiments have been listed in table 
2.1.6.  
2.8 Real-Time PCR  
2.8.1 RNA Isolation and Purification  
 Total RNA was isolated from S2 cells transfected with 0.05µg of FLuc, 0.2µg of 
RLuc, 0.25µg of λN-HA and 0.125- 0.50µg of λN-HAFMRP or untethered FMRP using 
500µl of TRIzol. The RNAeasy mini kit was used to isolate and purify mRNA from cell 
lysates. Briefly, the total isolated mRNA was incubated with RNase-free DNase I using 
the DNA-free kit and dissolved in 50 µl of nuclease-free water. 1µg of DNA-free RNA was 
used as a template for cDNA synthesis with RNA to cDNA EcoDry Premix as per 
manufacturer’s instructions. 
2.8.2 qRT-PCR  
 We used iQ SYBR Green Supermix and designed gene-specific primers for FLuc 
and RLuc as described in Table 2.1.4. Melt curve analysis indicated that the primers 
generated a single PCR product. Quantitative RT–PCR was performed on an iCycler 
thermocycler as per the manufacturer’s instructions. For relative quantification of the 
transcripts, we averaged the results from three technical replicates to generate Ct values for 
each biological replicate. The Ct results were analyzed for differential fold change as 
described by Livak (ΔΔCt) method (Livak and Schmittgen, 2001).  
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2.9 miRNA Target-Site Prediction   
 Potential miRNAs targeting the SV40 3’UTR of the FLuc-BoxB reporter were 
identified using the PITA algorithm. PITA scans miRNA-mRNA interactions based on the 
seed sequence of the miRNA, secondary structure of the target mRNA and free energy 
(Kertesz et al., 2007). For URL to the website refer to Table 2.17.  
2.10 RNA Secondary Structure prediction  
 RNAfold web server was used to predict secondary structures of 3'UTR sequences 
of known FMRP targets. The 3'UTR sequences of known FMRP target mRNAs including 
Trailer-hitch, pickpocket, dRac, Chicadee, Arc1 were shown to have stem-loops very 
similar in structure to the BoxB stem-loop.  Predicted secondary structures are represented 
in Figure 18A-B. 
2.11 S2 Cell Immunofluorescence and Microscopy  
2.11.1 FMRP Granules in S2 Cells: 
 S2 cells transfected with plasmids expressing pAc5.1B EGFP-FMRP, and deletions 
for EGFP FMRP (∆RGG), FMRP(∆KH1/2), FMRP(∆KH0) were used to characterize the 
phenotype of FMRP granules. Cells were transfected with 0.25µg of plasmid DNA as 
described above and incubated for about 72 hours. Images were acquired using a 100x 
objective (N.A.= 1.40) on an FV1000 Laser Scanning Confocal Microscope. 
2.11.2   Immunofluorescence in S2 cells 
 S2 cells were examined for endogenous expression of FMRP and with AGO1, 
GW182, or DCR1 respectively.  S2 cells were allowed to adhere to a poly-d-lysine coated 
dish and fixed using 4% paraformaldehyde. Cells were treated with 1 ml of 
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permeabilization buffer and after incubation with blocking buffer cells were 
immunostained with primary antibodies against FMRP, AGO1 and GW182 as described 
previously. Images were acquired using a 100x objective (N.A. = 1.40) on a FV1000 Laser 
Scanning Confocal microscope. Buffers for S2 cell immunofluorescence have been 
described in Table 2.1.6.  
2.11.3 S2 cell colocalization analysis  
The raw images were resized using Adobe Photoshop and resolution was adjusted 
to 300 pixels/inch.  The images were split using the split channels feature on Fiji into green, 
red and blue channels.  The green channel was for FMRP, the red channel was for the 
proteins of interest, and the blue channel was for DAPI.  For colocalization analysis, six 
independent S2 cells were measured for colocalization of FMRP with the miRISC proteins. 
The images were thresholded manually before Mander's coefficient calculation using the 
‘Just another colocalization plug-in’ (JaCOP) from ImageJ/Fiji (Bolte and Cordelieres, 
2006). Mander's coefficient varies from 0 to 1 corresponding to overlapping images, and 1 
represents 100% colocalization.  The Mander's coefficient of green channel (FMRP) 
colocalizing with red channel (the miRISC proteins), M2 value, was imported into Prism 
for statistical analysis. 
2.12 Generation, and characterization of Drosophila stocks 
All stocks used in the study were raised at 250C on standard Bloomington media. 
The fly stocks are listed in table 2.1.2. The Drosophila isogenized strain w1118 (or Iso31) 
was used as a wild-type control. dFmr1 heterozygotes were generated by crossing flies 
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from dFmr1Δ113M with flies from the w1118 genetic background.  The Not1M107631, pAbpk10109 
lines were balanced over CyoGFP balancer to allow for larval NMJ analysis.  
Trans-heterozygotes were generated by crossing dFmr1Δ113M to all the indicated 
lines and selecting against markers on the balancer chromosome. Transgenic lines with the 
gawky (gw182) mutation were a kind gift from Prof. A. Simmonds (Schneider et al., 2006). 
The gawky gene is located on the fourth chromosome which significantly complicates 
genetic analysis. To obtain trans-heterozygous gawky mutant lines for larval NMJ analysis, 
flies from w1118; pan2/P{ActGFP}unc-13GJ were crossed with flies from Tm3Sb/Ly; 
gw1/ciD.  F1 progeny from the cross were selected against Lyra and for GFP, Tm3Sb to 
generate gw1/ActGFP.   
Transgenic short-hairpin (UAS -RNAi) targeting  Dcr1, Ago1, and gawky were 
expressed in larvae using a specific pan-neuronal driver elav-Gal4 for larval CNS staining. 
2.13 NMJ Dissections and Immunostaining 
All indicated genotypes were crossed with w1118 or dFmr1Δ113M to generate 
heterozygotes or trans-heterozygotes for larval NMJ analysis respectively. Wandering third 
instar larvae were collected and pinned in Sylgard dishes. Larval fillets were dissected in a 
calcium-free HL-3 buffer and fixed in 4% Paraformaldehyde for 15 minutes.  
 Fixed larvae were then rinsed in 1X PBS, permeabilized in 1XPBS-T and blocked 
in the blocking solution for 1 hour. Larval filets were incubated with primary antibody 
against discs large (1: 100) at 4°C overnight. Post-incubation, larvae were washed with 1X 
PBS thrice for 5 minutes followed by incubation with anti-mouse Alexa Fluor 488 (1:500) 
and goat Anti-HRP-Dylight-647 (1:500) for 2 hours at room temperature. Antibody against 
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HRP was used to label presynaptic neuronal membranes. Post-incubation, larvae were 
washed with 1X PBS thrice for 5 minutes followed by incubation with anti-mouse Alexa 
Fluor 488 (1:500) and goat Anti-HRP-Dylight-647 (1:500) for 2 hours at room temperature. 
Following the antibody incubation, the samples were washed extensively with 1XPBS, 
mounted on a charged slide in DAPI Fluoromount G (Southern Biotech) and stored at -
200C for analysis as described below. The buffer compositions for NMJ dissections and 
immunostaining have been described in Table 2.1.6.  
2.13.1 Image Acquisition and Quantification of NMJ  
 The images of NMJs were acquired at muscle 6/7 in larval abdominal segment 
3(A3) using an FV1000 Laser Scanning Confocal microscope using 20X (N. A=0.85) and 
60X (N. A=1.35) objectives.  Max-intensity projections were obtained using the FV1000 
software. All images were randomized and scored blindly to avoid potential bias in 
quantification. Using cell counting plugin for ImageJ/Fiji, NMJs were manually counted 
for a total number of boutons, 1b boutons, 1s boutons, branch points and tips. Based on the 
size and intensity of Dlg staining, type 1b and type 1s boutons were classified. Synaptic 
boutons were normalized to muscle surface area (MSA) calculated using the 20X objective. 
2.14 Larval CNS Immunostaining  
For immunohistochemistry, larval brains from w1118 were dissected in ice-cold 1X 
PBS under 20 minutes and fixed in 4% Paraformaldehyde for 20 minutes at room 
temperature.  Fixed CNSes were permeabilized with 1XPBST for 20 minutes at room 
temperature followed by blocking for an hour at room temperature. After blocking, the 
samples were incubated with primary antibodies against FMRP (1:1000), Dicer1(1:1000), 
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AGO1 (1:1000), and GW182 (1:2000) overnight at 40C. Post-incubation, larval CNSs were 
washed with PBST thrice for 20 minutes and incubated in PBT with secondary antibodies 
conjugated to anti mouse Alexa Fluor 488 (1:500) and anti-rabbit Alexa Fluor 568(1:500) 
for two hours. Larval CNSes were then washed with PBST thrice for 10 min and mounted 
on a slide using DAPI Fluoromount G (Southern Biotech). Buffer compositions for the 
larval CNS immunostaining have been listed in Table 2.1.6.  
Immunostained brains were imaged using a FV1000 Laser Scanning Confocal 
microscope using 40X (N. A=0.90) and 100X (N. A=1.40) objectives.  Maximum intensity 
Z projections were assembled from 0.4 um sections using Olympus Fluoview software.  
2.14.1 Larval CNS colocalization analysis  
We used three independent CNSs for the analysis of protein colocalization. The 
images were split into green, red and blue channels using Fiji. FMRP was imaged in green 
channel, the protein of interest was imaged in the red channel and the nuclei were imaged 
in the blue channel. The images were thresholded manually before the calculation of 
Mander's coefficient (M1 and M2 values) using the JaCoP plugin. The M2 values for green 
channel (FMRP) colocalization with red channel (miRISC/deadenylase proteins) were 
imported into Prism for statistical analysis. 
2.15 Larval crawling assay  
Larval crawling behavior was analyzed for w1118, heterozygotes and trans-
heterozygotes of the indicated genotypes as described previously  (Kashima et al., 2017). 
Average velocity and relative distance were computed from 3 independent experiments for 
each genotype. Ten individual wandering third-instar larvae were rinsed briefly in 1XPBS 
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and transferred from vials onto a 90 mm petri dish containing 2% agarose. The crawling 
behavior was digitally recorded using iPhone 7 for 1 min in QuickTime movie (MOV) 
format with time-lapse settings using the constraints described by Kashima et al. The 
videos were analyzed computationally for relative crawling distance and velocity using the 
LavaTrack algorithm. The URL of the website is listed in Table 2.1.7. Briefly, the position 
of each larva was recorded on most frames, and the cumulative distance was computed for 
four 15-second intervals. The velocity was calculated by determining the average speed 
from 30 to 45 seconds as larvae were slow in first 10 seconds and some of them reached 
the edge of the petri dish in last 10 seconds.  
2.16 Statistical analyses 
All statistical analyses including graphing was performed using ANOVA Turkey’s 
one-way posthoc test or Kruskal-Wallis; Dunn’s posthoc test for the NMJ boutons. Data 
are normalized to the controls and errors are presented as ± SEM with p values calculated 
using GraphPad software. For larval crawling, a two-way ANOVA test was used to analyze 
the data for distance and one-way ANOVA test was used to analyze average velocity. 













CHAPTER THREE: RESULTS 
 
3.1 Tethered FMRP represses translation of a FLuc reporter in a dosage-dependent 
manner. 
 To understand the role of FMRP in translation repression, we developed an in vitro 
translational reporter-based assay. The experiments were based on an existing tethering 
assay in Drosophila S2 cells (Pillai et al., 2004; Rehwinkel et al., 2005). We fused FMRP 
with λN-HA tag that can to bind to five tandem BoxB sites cloned within the 3’UTR of the 
firefly luciferase (FLuc) reporter. The λN tag is derived from the N protein of the 
bacteriophage λ to enable tethering to a FLuc reporter via the BoxB structural element in 
its 3’UTR (Keryer-Bibens et al., 2008) and an HA (hemagglutinin) tag for detection of the 
expressed protein by Western blot. The UTR in the FLuc reporter is derived from the 
Simian virus 40 (SV40) small T antigen (Figure 12A).  
 We transfected S2 cells with a plasmid expressing firefly luciferase (FLuc) and 
Renilla luciferase (RLuc), co-transfected with and increasing concentration of plasmid 
expressing λN-HA-FMRP. As a negative control, we co-transfected with a plasmid 
expressing λN-HA alone. We used RLuc as a transfection control since it did not have 
BoxB sites within the 3'UTR (Figure 12B). We hypothesized that tethered FMRP might 
repress the translation of FLuc-BoxB reporter in a dosage-dependent manner. 
 We observed that λN-HA-tagged FMRP repressed the translation of FLuc reporter, 
relative to λN-HA alone (Figure 12C) (p < 0.0001). At 0.125µg, 0.25µg and 0.5µg of λN-
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HA tagged FMRP repressed the translation of FLuc-5xBoxB reporter was repressed by 
60%, 70%, and 80% compared to controls (Figure 12C) (p < 0.0001). These results suggest 
that FMRP can repress translation when tethered to the reporter mRNA in a concentration-
dependent manner. We confirmed a concentration dependent increase in the levels of λN-
HA-tagged FMRP by Western blotting (Figure 12D).  
 We proposed that it was possible that FLuc protein levels in our reporter assays 
could be reduced either due to a mechanism involving translational repression or mRNA 
decay. To investigate whether FLuc mRNA levels decreased upon binding to FMRP, we 
measured FLuc mRNA levels using qRT-PCR. We observed that FLuc mRNA levels 
remained constant irrespective of the concentration of FMRP transfected in S2 cells (Figure 
12E). This observation suggests that FMRP-dependent decrease in the expression of the 
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Figure 12: Tethered FMRP represses the translation of FLuc reporter in a dosage-
dependent manner.   
A) A schematic of λN-HA-tagged FMRP tethered to the FLuc-5xBoxB reporter in S2 cells. 
λN-HA-tagged FMRP binds with high affinity to 5 tandem BoxB sites inserted into the 
SV40 3’UTR of the FLuc-5xBoxB reporter. B) A schematic of the RLuc construct 
(transfection control) with no BoxB sites. C) Results of S2 cells transfected with a mixture 
of the FLuc-5xBoxB reporter, RLuc control, and λN-HA (empty vector) or increasing 
concentrations of λN-HA-tagged FMRP (0.125µg, 0.25µg and 0.50µg). FLuc expression 
was normalized to the RLuc transfection control. D) S2 cell lysates were immunoblotted 
with antibodies against the HA tag and endogenous dFMRP. An antibody against Actin 
served as a loading control. Arrow represents endogenous FMRP and star represents an 
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isoform of approximately same size as λN-HA-FMRP. E) qPCR and luciferase activity to 
quantify the expression levels of FLuc-5xBoxB reporter show consistent mRNA levels 
with reduced protein expression in response to higher concentration of tagged FMRP 
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3.2 The KH domains of tethered FMRP are required for translation repression of 
the FLuc-BoxB reporter. 
 We investigated whether domains within FMRP are required for translation 
repression by tethered FMRP. We designed a series of λN-HA and EGFP tagged FMRP 
deletion constructs that excluded these conserved domains: ∆RGG (470-507), ∆KH0 (116–
212) and ∆KH1/2 (226–335) (Figure 13A). Surprisingly, our results suggest that deleting 
the KH1 and 2 domains significantly rescued the translation repression (p<0.0001) by 
tethered FMRP (Figure 13C). We observed a 20% repression of the FLuc reporter with the 
0.50µg of ∆KH1/2 FMRP plasmid (Figure 13C). Similar, albeit weaker results were 
observed when the KH0 domain was deleted (Figure 13C B, 70% p<0.0001) and observed 
a 50% repression of the FLuc reporter with 0.50µg of ∆KH0 FMRP plasmid (Figure 13C). 
These results suggest that the KH domains of FMRP are required for mediating repression 
of its target mRNAs. Since, FMRP is already tethered to the reporter via the high-affinity 
λN/BoxB interaction, the requirement for these domains in translational repression appears 
to be independent of their RNA binding activity. 
 FMRP has previously been shown to localize to cytoplasmic foci in cells that 
contain mRNA (Barbee et al., 2006; Gareau et al., 2013b). Formation of these structures is 
facilitated, at least in part, through the activity of FMRP’s functional domains (Gareau et 
al., 2013b). We, therefore, next investigated whether deletion of the FMRP domains 
required for translation repression are involved the formation of FMRP granules in the 
cytoplasm. Our results suggest that deletion of the KH1 and 2 domains results in distinct 
cytoplasmic puncta (Figure 13B). These structures appear to be very large and roughly 
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spherical. Deletion of the RGG domains did not result in significant changes on the 
morphology of FMRP granules (Figure 13B). On the other hand, deletion of KH0 domains 
result in diffused localization of FMRP (Figure 13B). Since KH1 and 2 domain deletions 
also rescues translation repression by FMRP, these results suggest there might be a 
correlation between the size of the granules and de-repression. Taken together, we 
conclude that FMRP requires the KH domains for translation repression of its target 
mRNAs. This function may be associated with the morphology and dynamics of FMRP 
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Figure 13: The KH domains of tethered FMRP are required for translation 
repression of the FLuc-BoxB reporter and FMRP-containing granule formation. 
A) A schematic representation of dFMRP showing the positions of the mRNA binding 
domains in dFMRP. Deletion versions of dFMRP were cloned into EGFP and λN-HA 
backbone vectors. The KH0 domains are boxed in yellow, KH1 in pink, KH2 in green, 
RGG in orange, and NES in blue. B) Live S2 cells expressing EGFP, EGFP-dFMRP, 
EGFP-tagged dFMRP deletion variants were imaged by confocal microscopy to detect 
EGFP. All images were taken using a 100X objective. Scale bar: 20µm C) Luciferase 
reporter assay for the FLuc-5xBoxB reporter with λN-HA-dFMRP and indicated λN-HA-
tagged deletion versions of dFMRP. S2 cells transfected with λN-HA-dFMRP (∆KH1/2) 
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3.3 Tethered FMRP requires miRISC components to mediate repression of the 
FLuc-BoxB reporter. 
 Previous results suggest that FMRP interact with miRNAs to regulate the 
repression of target mRNAs (Edbauer et al., 2010; Jin et al., 2004b; Muddashetty et al., 
2011) . Therefore, we hypothesized that if miRNAs are involved in FMRP mediated 
repression, then depleting components of the miRNA pathway should attenuate the 
repression of the FLuc-BoxB reporter. Taking advantage of our translational reporter, we 
sequentially knocked down Dicer-1, core miRISC components (AGO1 and GW182), by 
RNAi in S2 cells and examined translation repression by tethered FMRP.  
 Knocking down Dicer1 (p<0.05), AGO1 (p<0.01) and GW182 (p<0.01) by 
transient transfection with the FLuc and RLuc plasmids rescued FMRP-mediated 
translation of the FLuc-BoxB reporter (Figure 14A). As a control, the introduction of 
dsRNA targeting EGFP had no significant impact on reporter expression (Figure 14A). We 
confirmed the knockdown efficiency of RNAi constructs targeting Dicer1, AGO1, and 
GW182 in transfected cells using antibodies and detected expression of these proteins by 
Western blotting (Figure 14B-D). Taken together, our data suggest that tethered FMRP 
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Figure 14: Tethered FMRP requires miRISC components to mediate repression of 
the FLuc-BoxB reporter. 
A) S2 cells were transfected with the FLuc-5xBoxB reporter, RLuc, vectors expressing 
λN-HA or λN-HA-tagged FMRP and co-transfected with dsRNA targeting Dicer1, AGO1, 
or GW182. We used RNAi against EGFP as our negative control, which did not affect the 
expression levels of FLuc reporter. RNAi against Dicer1 and candidate miRISC 
components (AGO1, GW182) significantly attenuated FMRP mediated repression. Data is 
shown from three independent experiments (*; p<0.05, **; p<0.01). The error bars are + 
SEM.  B-D) We used Western blotting to visualize the efficiency of Dicer1, AGO1, and 
GW182 RNAi knockdown using antibodies specific to the indicated proteins. Actin was 
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3.4 FMRP interacts biochemically with AGO1 and GW182 in S2 cells.   
 
Our results suggest that FMRP requires AGO1, GW182, and Dicer1 to repress 
translation of the reporter. Next, we investigated the nature of this interaction using co-
immunoprecipitation assays in S2 cell lysates. We co-transfected S2 cells with FLAG-
tagged AGO1 or GW182 and EGFP-tagged FMRP and isolated binding partners of FMRP 
using GFP-Trap (Figure 15A). We found that FMRP pulled down both AGO1 and GW182 
under low salt conditions (150mM NaCl) (Figure 15B). The pull-down of GW182 was not 
nearly as efficient as that of AGO1. We propose that this could be due to an indirect 
interaction between FMRP and GW182, which is directly mediated by AGO1. To test this 
possibility, we co-transfected with an additional construct expressing HA-tagged AGO1 in 
order to alter the stoichiometry of the FMRP: AGO1 complex. Surprisingly, this had no 
impact on the amount of GW182 that was pulled down with FMRP (Figure 15B). It is 
possible that this is due to the abundance of target mRNAs for the miRISC components or 
the kinetics of the interaction of FMRP with AGO1. 
In contrast, immunoprecipitation under high salt conditions (300mM NaCl) 
completely abolished the interaction between FMRP and GW182 (Figure 15C). However, 
interactions between FMRP and AGO1 were unperturbed. In these experiments, AGO2 
was used as a positive control, as previous studies have shown a strong biochemical 
interaction between FMRP and both AGO1 and AGO2 (Caudy et al., 2002) (Figure 15C). 
Together, our data support the conclusion that FMRP interacts in a complex with the 
miRISC components, AGO1 and GW182. Moreover, these results also suggest an indirect 
relationship between FMRP and GW182 mediated either by AGO1 or some other protein. 
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Figure 15: FMRP co-immunoprecipitates with AGO1 and GW182 in S2 cells.  
A) GFP-trap beads were used to pull-down EGFP-tagged FMRP and EGFP protein from 
S2 cell extracts. The proteins were resolved by SDS-PAGE and probed with antibodies 
against GFP and FMRP. Endogenous FMRP was detected in both non-transfected cells and 
cells transfected with EGFP-FMRP.  EGFP-FMRP was detected in the IP fraction of 
transfected cells.  B) Lysates from S2 cells transfected with plasmids expressing FLAG-
tagged AGO1, GW182 were co-immunoprecipitated using GFP-trap under low salt 
conditions (150mM NaCl) C) Lysates from S2 cells transfected with plasmids expressing 
FLAG-tagged AGO1, GW182 were co-immunoprecipitated using GFP-trap under high salt 
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3.5 Untethered FMRP can repress the translation of the FLuc-BoxB reporter.  
 
Previous studies suggest that FMRP is capable of recognizing and binding to small 
stable stem loops that are similar in structure to BoxB motifs and regulate the translation 
of specific target mRNAs (Bechara et al., 2009; Zalfa et al., 2003). Thus, we next asked 
whether transfected FMRP lacking the λN-HA tag was also able to repress the translation 
of the FLuc-5xBoxB reporter in a dosage-dependent manner.  
To test this hypothesis, we modified the FLuc-BoxB reporter and reduced the 
number of BoxB motifs or remove them altogether (Figure 16A). We generated a series of 
FLuc-BoxB reporter with 3x, 1x, and 0x copies (essentially the “wild-type” SV40 3’UTR) 
of the BoxB sequence. Surprisingly, we found that FMRP was capable of repressing the 
translation of the FLuc reporter containing only a single BoxB stem-loop just as well as 
the reporter containing five BoxB stem-loops (Figure 16C; p<0.0001) and as well as 
tethered FMRP. In contrast, translation of a reporter containing no copies of the BoxB 
sequence was unaffected by untagged FMRP (Figure 16C). These results suggest that 
mRNAs with small stem-loops could be targets for FMRP, expanding the toolbox for the 






  95 
 
Figure 16:  Untethered FMRP can repress the translation of FLuc-BoxB reporter.               
A) A schematic representation of FLuc-1xBoxB reporter showing a single BoxB site and 
a binding site for miR-958. B) A schematic representation of FLuc-0xBoxB reporter with 
no stem loops for FMRP to bind. C) Results for luciferase reporter assay for FLuc-5xBoxB, 
FLuc-3xBoxB, FLuc-1xBoxB and FLuc-0xBoxB reporter with 0.125µg, 0.25µg, and 0.50 
µg of FMRP. (**; p<0.01, ****; p<0.0001). The error bars are + SEM. 
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3.6 miRNA-958 requires FMRP to mediate translation repression of the FLuc-BoxB 
reporter.  
Our data provide evidence for a requirement of the miRISC complex for FMRP-
mediated translation repression. However, it was unclear whether this process required 
miRNA binding to the target mRNA in order to repress its translation. In order to identify 
miRNAs that bind to the FLuc reporter, we ran the SV40 3’UTR (with the BoxB sequence) 
through a miRNA prediction algorithm, PITA, which scans for miRNA-mRNA base pair 
interactions and predicts a score for the interaction (Kertesz et al., 2007; Peterson et al., 
2014). The prediction is based on the seed sequence of the miRNA, secondary structure of 
the target mRNA, and free energy of the interaction. miR-958 was predicted to have the 
highest score for FLuc mRNA interaction (Figure 17B). Moreover, the putative binding 
site for miR-958 is only 80 nucleotides from the BoxB stem-loop sequence, which is just 
outside the “footprint” of the RISC complex when it interacts with a target mRNA. 
Therefore, we transfected S2 cells with a plasmid expressing miR-958 to determine if it 
can repress translation of the minimal FLuc-1xBoxB reporter.  
We found that transfected miR-958 represses translation of the FLuc mRNA by 
34% compared to control (Figure 17A p<0.01). To elucidate the nature of the interaction 
between FMRP and miR-958, we used RNAi to knock down endogenous FMRP 
expression and asked if it disrupted miR-958-mediated repression of the FLuc-1xBoxB 
reporter. We found that miR-958 was unable to repress the translation of the FLuc reporter 
in the absence of FMRP in S2 cells (Figure 17A). This suggests that FMRP and the miR-
958 are both required for effective translation repression of target FLuc mRNA.  
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To further validate the requirement of FMRP, we used the FLuc-0xBoxB reporter 
lacking the BoxB stem-loop sequences (Figure 16B). This reporter is not repressed by 
untagged FMRP (Figure 16C). We found that miR-958 did not repress the translation of 
the FLuc-0xBoxB reporter even in the presence of endogenous FMRP (Figure 17A). This 
suggests that miR-958 mediated translation repression requires FMRP’s interaction with 
the target mRNA via the BoxB sequence. These results suggest that FMRP binding is 
required for miR-958 to mediate translation repression. Moreover, these findings suggest 
that FMRP and miRNAs can function cooperatively in the repression of a shared target 
mRNA. However, miR-958 is expressed in S2 cells at extremely low abundance (Figure 
17B). Therefore, we rule out endogenous miR-958 in repressing the translation of the 
FLuc-1xBoxB reporter in the tethered FMRP experiments described above.  
Next, we sought to determine the identity of actual miRNA that might work in 
concert with FMRP to repress translation of the FLuc-BoxB reporter. We used PITA to 
identify other endogenous, abundant miRNAs in S2 cells that a predicted to bind to the 
3'UTR of the FLuc-BoxB reporter. In our analysis, bantam, miR-33, miR-13, miR-2a, and 
miR-2b were predicted to bind to the FLuc-BoxB 3’UTR (Figure 17B). We have cloned 
the indicated miRNAs in the miRNA-expression plasmid for future analysis. 
To validate an interaction between FMRP and the identified miRNAs, we pulled 
down FMRP-containing RNPs from S2 cells expressing EGFP-tagged FMRP using a GFP 
trap system. The isolated mRNA and miRNA levels from FMRP-IP fraction were analyzed 
by quantitative real-time PCR (qRT-PCR). Compared to non-transfected control cells, we 
observed an enrichment of bantam, miR-2b, miR-13b and miR-33 in cells expressing 
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tagged FMRP (Figure 17C). We also observed non-specific binding using the IgG 
antibody. Future experiments are needed to optimize the RNA-IP experiment to explore 
the coordinated nature of FMRP and miRNA in target mRNA repression.  
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Figure 17: miRNA-958 requires FMRP to mediate translation repression of the FLuc-
Box reporter.  
A) Cells were co-transfected with the FLuc-1xBoxB reporter, RLuc and a plasmid 
expressing miR-958. Interestingly, miR-958 was unable to repress the reporter when 
FMRP was depleted by RNAi. Furthermore, in the absence of BoxB motifs, miR-958 could 
not repress the FLuc reporter. These results suggest a requirement of FMRP (or FMRP 
binding) for miR-958 to mediate the repression of FLuc-BoxB reporter. Values in columns 
represent the % of the control activity (*; p<0.05, **; p<0.01). The error bars are + SEM. 
B) List of miRNAs predicted by PITA algorithm for binding to SV40 3’UTR in the FLuc 
reporter based on the position relative to the first nucleotide in the 3’UTR sequence, seed 
region, free energy of binding and reads per million C) FMRP containing mRNPs were 
pulled down and the isolated mRNAs were analyzed by the quantitative real-time PCR 
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(qRT-PCR) using probes against miRNAs. Bantam, miR-2b, miR-13b and miR-33 were 
enriched in FMRP associated RNP fraction vs non-transfected controls. The results are 




































  101 
3.7 FMRP can repress the translation of FLuc reporters for known target mRNAs 
that contain BoxB-like sequences in their 3’ UTRs.  
Since FMRP represses the translation of a reporter mRNA containing the BoxB 
motifs, we hypothesized that FMRP may be interacting with endogenous target mRNAs 
via similar sequences. Previous studies suggest that FMRP directly interacts with mRNAs 
encoding for the degenerin/sodium channel family protein, Ppk, GTPase activating protein, 
dRac1, microtubule associated protein Futsch, actin binding protein Chic, activity-
regulated cytoskeletal protein, Arc1, protein involved in mRNA localization, Tral, and 
itself , dFmr1 (Dictenberg et al., 2008; Lee, 2003; Monzo et al., 2006; Reeve et al., 2005; 
Schaeffer et al., 2001; Xu et al., 2004; Zhang et al., 2001).  
We used RNAfold to analyze the secondary structure of the 3’UTRs of the indicated 
mRNAs and observed stem loop sequences similar in structure to BoxB motifs (Figure 
18A). First, we determined if these mRNAs co-immunoprecipitated with FMRP in S2 cell 
lysates (Figure 18C). We found that dRac, dFmr1 and chic mRNAs were enriched in 
FMRP associated mRNP complexes. ppk is not expressed in S2 cells. These results suggest 
a direct association of FMRP with the indicated mRNA targets. Next, we determined 
whether untagged FMRP could repress the translation of FLuc-3’UTR reporter for all these 
candidate mRNAs. In each reporter, we removed the SV40 3’UTR sequence including the 
BoxB sequences and replaced with the 3’UTR of the above-mentioned genes. We observed 
that untagged FMRP effectively replaced translation of FLuc-ppk 3’UTR, FLuc-chic 
3’UTR and FLuc-Arc1 3’UTR in a dosage dependent manner (Figure 18D-E, p < 0.0001). 
However, FMRP did not repress the translation of the FLuc-dRac1 3’UTR or FLuc-Tral 
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3’UTR. (Figure 18E). These results suggest that FMRP mediated repression may not be 
limited to the BoxB-like stem-loop structures.  
We also determined the 3’UTRs of the candidate genes for the most well 
characterized FMRP-binding motif, G-quartets using QGRS mapper (Kikin et al., 2006). 
In our analysis, we found the 3’UTR of dRac with 2 and Arc1 with 6 predicted G-quartets 
while ppk, chic and Tral had none. Therefore, the analysis suggests that structural motifs 
may not be enough for FMRP to mediate repression and repression may be sequence 
specific. FMRP is predicted to bind to ACUK or WGGA sequence in the target mRNA for 
repression. It would be interesting to determine whether the repression is being mediated 
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Figure 18: Untethered FMRP can repress the translation of FLuc reporters for 
known target mRNAs that contain BoxB-like sequences in their 3’ UTRs.  
A) The secondary structure of the FLuc-1xBoxB structure was folded by RNAfold 
software. Stable structures were colored by base-pairing probabilities (ranging from red to 
green). Box B motifs denoted in red color were predicted to be stable structure. B) The 
3’UTR of ppk contained Box-B like motifs as predicted by RNAfold. C) FMRP containing 
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RNPs were pulled down from S2 cells and analyzed for associated mRNAs by Reverse-
transcription (RT-PCR). Chic, dRac and dFmr1 were enriched in FMRP-IP fraction 
compared to the IgG control. Ppk is not expressed in S2 cells. D) The entire 3’UTR region 
of ppk, chic and tral was cloned downstream of FLuc reporter. The SV40-3’UTR of the 
FLuc reporter was swapped by the entire 3’UTR of the indicated genes. These reporters 
were co-transfected with the RLuc, λN-HA (control), and with increasing concentration of 
untethered FMRP (0.125µg, 0.25µg and 0.50µg). Luciferase data shown here for the FLuc-
ppk 3’UTR (****; p < 0.0001). The errors are in + SEM. E) S2 cells were co-transfected 
with the FLuc-ppk 3’UTR, FLuc-chic 3’UTR, FLuc-tral 3’UTR reporters, RLuc, λN-HA 
(control) and 0.50µg of FMRP. Columns indicate the % of the control activity (****; p < 
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3.8   FMRP colocalizes to granules containing AGO1 and GW182 in S2 cells.   
Previous studies have demonstrated that FMRP localizes to P-bodies and stress 
granules along with translationally repressed mRNAs, miRNAs, AGO1, GW182 and 
several other RBPs, to mediate gene silencing (Parker and Sheth, 2007). The formation of 
these cytoplasmic granules is linked to the miRNA-mediated repression pathway (Eulalio 
et al., 2007c). Therefore, we wanted to determine if FMRP colocalizes with Dicer1, AGO1, 
and GW182 in cytoplasmic RNP granules in S2 cells.  
We performed immunostaining in S2 cells for FMRP, Dicer1, AGO1, and GW182 
(Figure 19A). Our results show a strong colocalization of FMRP with AGO1 (Mander’s 
coefficient 0.7+ 0.02) and GW182 (0.9+ 0.01) in S2 cells (Figure 19B). These results 
suggest that dFMRP and miRISC proteins are in close proximity in the cell and potentially 
interact with each other. On the other hand, we did not observe substantial colocalization 
of FMRP with Dicer1 (0.45+0.02) (Figure 19B). Interestingly, we observed a distinct 
perinuclear distribution of Dicer1 (Figure 19A). This distinct phenotype for Dicer1 has not 
been shown in other systems. This observation needs to be explored in future experiments 
to determine if this is significant for its function as a microRNA processor. 
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Figure 19: FMRP colocalizes to granules containing AGO1 and GW182 in S2 cells. 
A) S2 cells were stained with antibodies against FMRP, Dicer1, AGO1, and GW182. 
Images for FMRP (green), Dicer, AGO1 and GW182 (red) were taken at 100X objective. 
Cell nuclei were counterstained with DAPI (blue). Arrows point towards the regions with 
an overlap of green and red fluorescent signals. Scale bar: 5µm B) Degree of colocalization 
(Mander’s coefficient) was calculated for the overlap between green and red channels. N=6 
independent S2 cells were analyzed for the analysis. (****; p < 0.0001). The error bars are 
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3.9 FMRP is expressed in the same population of neurons as AGO1 and GW182 
within the cell bodies in the Drosophila larval CNS.  
Our data in S2 cells suggest FMRP to colocalize in granules with the miRISC 
components. Next, we wanted to determine if FMRP also colocalizes with the miRISC 
components in vivo. Previous studies suggest that FMRP can localize to neuronal transport 
granules in mammalian and Drosophila neurons (Cougot et al., 2008). These granules are 
enriched in translationally repressed mRNAs, along with several miRNAs, miRISC 
components and various RBPs. Moreover, dendritic P-bodies have also been suggested to 
contain FMRP, miRNAs, miRISC components with translationally repressed mRNAs 
(Cougot et al., 2008). The assembly of all the proteins involved in mRNA regulation in 
distinct granules is speculated to modulate translation in neurons (Barbee et al., 2006). 
Given the role of FMRP and miRNAs in translation regulation for proper neuronal 
morphology, we hypothesized FMRP would colocalize with the miRISC components and 
Dicer1 in neurons within the Drosophila larval CNS.  
Ventral ganglia of the Drosophila CNS contains descending motor neurons that 
project into the muscles carrying information to control flight, walking and other motor 
functions (Strausfeld, 2009). Therefore, we counterstained ventral ganglia to examine the 
intracellular localization of FMRP with Dicer1 and the miRISC components (Figure 20A). 
To examine the subcellular localization of FMRP and miRISC components in more detail, 
we imaged neuronal cell bodies of motor neurons along the midline (Figure 20B). We 
observed a strong overlap of pixels between FMRP, AGO1 (0.6+0.02) and GW182 
(0.8+0.01) within the soma of the cell bodies (Figure 20C). However, we do not have the 
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required resolution to determine if FMRP colocalizes with AGO1 and GW182.within 
neuronal granules in motor neurons. This question will require further analysis.  
In our analysis, FMRP did not show a as strong of an overlap with Dicer1 (0.5+0.05, 
Figure 20C). However, Dicer1 showed the similar perinuclear phenotype within cell bodies 
of the ventral ganglia as seen earlier in S2 cells (Figure 20B). Again, since there are no 
published studies to indicate that Dicer1 localizes to nuclear membranes, this could be a 















Figure 20: FMRP is expressed with AGO1 and GW182 in the same population of 
motor neurons within the Drosophila larval CNS.  
A) Ventral ganglion of the wandering third instar larvae stained with antibodies for FMRP 
(green), Dicer1, AGO1, and GW182 (all red). The panels are from a single optical section 
as acquired by confocal microscopy. The arrows in the merged panels indicate the overlap 
of FMRP fluorescent intensities between FMRP (green) and the indicated components of 
the miRNA pathway Scale bar: 50µM. B) Cell bodies within the ventral ganglion were 
imaged using 100X for FMRP (green) and the indicated miRISC components (red). Cell 
nuclei are counterstained for DAPI. The arrows in the merged panels indicate the overlap 
of FMRP fluorescent intensities between FMRP (green) and the indicated components of 
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the miRNA pathway (red). C) Degree of colocalization (Mander’s coefficient) was 
calculated for the overlap between green and red channels.  N=3 independent CNS images 
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3.10   dFmr1 interacts with GW182 to regulate synaptic growth.  
We used Drosophila larval NMJs as our model system to further characterize the 
phenotypic significance of the interaction between FMRP and miRISC components. The 
Drosophila larval NMJ is a well-defined and relatively simple model system to identify 
genetic interactions between genes by assessing the changes in synaptic structure and 
function (Budnik, 1996). It has been shown that FMRP interacts genetically with AGO1 to 
control NMJ growth (Jin et al., 2004b). Flies singly heterozygous for dAGO1 (ago1k00208/+) 
and dFmr1 (dFmr1∆113/+) have normal NMJ phenotype and a similar number of boutons 
compared to wild-type larvae. However, removal of a one copy of AGO1 in a 
phenotypically normal FMRP heterozygous background (an FMRP; AGO1 trans-
heterozygote) results in a highly significant overgrowth of the NMJ similar to that seen in 
a dFmr1 homozygous null mutant (Jin et al., 2004b). These results suggest that FMRP 
requires AGO1 to regulate proper synaptic development. Based on the published studies 
and our results in S2 cells, we speculated that FMRP might also genetically interact with 
GW182 to regulate NMJ development.  
To test the hypothesis, we examined whether dAGO1 (as a positive control) and 
gawky (fly GW182) could modulate the synaptic growth regulated by dFmr1 using the loss 
of function dFmr1 mutants (dFmr1∆113). We assessed the morphology of NMJs at muscle 
6/7 in abdominal segment 3 of wandering third instar larva (Figure 21A). We stained 
dissected NMJs with pre-synaptic marker anti-HRP and post-synaptic marker anti Dlg for 
characterizing synaptic morphology. First, we examined the NMJs from dFmr1 
heterozygotes (dFmr1∆113/+), AGO1 heterozygotes (ago1k00208/+) and gawky 
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heterozygotes (gw1/+). In our hands, dFmr1∆113 nulls did not survive to the third instar 
stage (data not shown). Counting the number of synaptic boutons for each of these 
genotypes assessed changes in NMJ development. We normalized the total number of 
boutons to the corresponding muscle surface area (MSA) to avoid any biases that might 
arise as the result of variations in the muscle size among different larvae (Figure 21B). 
We did not observe any significant increase in the number of synaptic boutons for 
AGO1 or dFmr1 heterozygotes relative to controls (Figure 21B). The gawky heterozygotes 
showed a small but significant increase in the number of boutons compared to w1118 
controls (25% increase, p < 0.05 Figure 21B). These results suggested that either loss of a 
single copy of gawky was sufficient to cause synaptic defects or could also stem from the 
combined effects of the balancer in the gawky heterozygous background.  
To address if AGO1 or GW182 act in the same pathway as FMRP, we generated 
trans-heterozygotes for dAGO1 (ago1k00208/+; dFmr1∆113/+) and GW182 (gw1/+; 
dFmr1∆113/+), respectively. Previous results have shown that dFmr1 causes synaptic 
overgrowth at the NMJ while dFmr1 heterozygotes appear to have normal NMJ (Jin et al., 
2004b). These results suggest that a single copy of FMRP can regulate proper synaptic 
development at the NMJ. If both the genes interact with dFmr1 in the same pathway, then 
reducing expression levels of these genes in dFmr1 heterozygous background should 
disrupt the function of FMRP and cause synaptic overgrowth.  
We observed a robust increase in boutons for gawky trans-heterozygotes compared 
to dFmr1 heterozygotes (80% increase, p<0.0005). The phenotype was stronger than 
gawky heterozygotes suggesting that the observed phenotype was due to the disruption of 
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gawky at the NMJ (Figure 21A-B). Taken together, the results suggest that FMRP interacts 
with GW182 in the same pathway to regulate synaptic growth. However, contrary to 
published results, the NMJs from AGO1 trans-heterozygotes background did not show any 
significant changes in the number of boutons (Figure 21A-B). It is possible that the allele 
for AGO1 used in our studies might have picked up a unique set of mutations or interactions 
with suppressors may have disrupted its function.   
Based on the size, shape glutamatergic type I boutons are classified into 1b (big) 
and 1s (small) boutons that are derived from two different motor neurons (Hoang and 
Chiba, 2001). We quantified the number of 1b and 1s boutons at the larval NMJ for the 
indicated genotypes (Figure 22A-B). The gawky trans-heterozygotes showed an even more 
pronounced change in the number of 1b boutons compared to mutant dFmr1 heterozygotes 
(75% increase, p<0.0005) (Figure 22A). Moreover, unlike 1b boutons, we did not observe 
any significant changes in the number of 1s boutons for AGO1 or gawky trans-
heterozygotes (Figure 22B). AGO1 heterozygotes did not show any significant changes in 
the number of 1b or 1s boutons at the NMJ (Figure 22A-B).  
dFmr1 nulls are also characterized by extensive neuronal branching at the NMJ 
(Zhang et al., 2001). Therefore, we quantified NMJs on the extent of synaptic branching 
and the number of branch-tips for the AGO1 and gawky trans-heterozygotes (Figure 22C-
D). We observed no significant changes in the number of branch points or tips in our 
analysis.  Taken together, our results indicate that FMRP requires GW182 to the proper 
synaptic structure during development at the Drosophila NMJ.  
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Figure 21: dFmr1 interacts genetically with gawky to regulate synaptic growth.  
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for AGO1, gawky 
and trans-heterozygotes for AGO1, gawky (generated in the dFmr1∆113 background) were 
analyzed for NMJ phenotype. The size of the NMJ (normalized to muscle surface area or 
 
  115 
MSA) was determined at muscle 6/7 in abdominal segment A3 for each genotype as 
indicated. The NMJs were stained against postsynaptic density marker Dlg (green). Scale 
bar: 50 µM. B) The total number of synaptic boutons/MSA were quantified for each 
genotype. Trans-heterozygotes of gawky had a robust increase in the number of boutons 
/MSA (normalized to control) compared to dFmr1∆113 heterozygotes. (*p< 0.05, **p < 
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Figure 22: Trans-heterozygotes of gawky display an increased number of 1b boutons. 
NMJs for the indicated genotypes were quantified for various parameters of NMJ 
morphology and compared to dFmr1 heterozygotes. A) Total number of 1b boutons/MSA 
were significantly higher for gawky trans-heterozygotes. B) No significant difference was 
observed for the normalized 1s boutons.  C) No significant difference was observed for the 
tips for the indicated genotypes. D) Branch-points were not affected in the indicated 
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3.11 dFmr1 and miRNA pathway components do not interact to control rates of larval 
locomotion. 
It was recently showed that an overgrowth of synaptic boutons at the larval NMJ 
correlates with locomotion dysfunction in dFmr1 heterozygotes (Kashima et al., 2017). 
Using a quantitative larval locomotion algorithm, known as “Larvatrack’’, the authors used 
dFmr1 heterozygotes (dFmr1∆50/+, and dFmr13/+) and found that synaptic overgrowth 
correlated with augmented crawling velocity. Taking a cue from their observations, we 
used Larvatrack to investigate if dFmr1 heterozygotes (dFmr1∆113/+) used in our NMJ 
analysis, exhibits increased velocity (Figure23 A-B). Based on our NMJ analysis, we 
speculated that in comparison to dFmr1 heterozygotes, we would observe a higher velocity 
for gawky heterozygotes and gawky trans-heterozygote larvae and no changes for AGO1 
heterozygotes or AGO1 trans-heterozygote larva. 
Although we did not observe synaptic overgrowth with dFmr1∆113 heterozygotes in 
our NMJ analysis, dFmr1 heterozygote larvae moved 30% faster than w1118 controls (Figure 
23B). These results suggest that changes in locomotion dysfunction does not correlate 
directly with changes in the number of synaptic boutons. Similar to the results observed in 
dFmr1 heterozygotes, we found that gawky heterozygotes were 22% faster than w1118 
controls while AGO1 heterozygotes were 12% faster than the controls. However, neither 
AGO1 nor gawky trans-heterozygotes displayed any significant alterations in velocity in 
comparison to the dFmr1 heterozygotes (Figure 23B). Contrary to previously reported 
observations our results suggest that there is no significant correlation between the 
observed synaptic overgrowth and aberrant velocity in Drosophila larva. It is also possible 
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that beyond a certain threshold, larvae cannot move faster, which could explain the lack of 
any significant changes in the velocity between and dFmr1 heterozygotes or trans-




  119 
 
Figure 23: dFmr1 and miRNA pathway components do not interact to control rates 
of larval locomotion. 
Larval locomotion was quantified using the “LarvaTrack” algorithm for indicated 
genotypes. A) Cumulative distance traveled in millimeters by the larvae over 60 seconds 
was plotted for comparison between w1118, dFmr1 heterozygotes, AGO1, gawky 
heterozygotes and for the trans-heterozygotes for AGO1 and gawky. No significant 
differences were observed between the trans-heterozygotes of the indicated genotypes and 
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dFmr1 heterozygotes. B) Quantitative histogram showing the velocity of the larvae for the 
indicated genotypes. No significant difference was observed between the indicated 
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3.12 The role of dFmr1 in regulating synaptic growth is independent of the 
deadenylase complex (CCR4 and NOT1), PABP or the decapping complex (Dcp1).  
We sought to determine the downstream mechanisms by which FMRP-GW182 
regulates synaptic morphology. Previous studies suggest that GW182 can act as the 
mediators of translation repression by interacting with the components of deadenylase 
machinery, including CCR4 and NOT1 and PABP to mediate deadenylation-dependent 
and independent mode of translation repression (Braun et al., 2013). Moreover, GW182 
also interacts with the decapping enzyme, Dcp1 to mediate gene silencing via the miRNAs 
(Rehwinkel et al., 2005). GW182 assembles with CCR4, NOT1, PABP, and Dcp1 into 
mRNP granules along with several miRNAs and associated mRNA targets in P-bodies 
(Decker and Parker, 2012). Therefore, we hypothesized that FMRP might interact with 
CCR4, NOT1 or PABP downstream of GW182 to mediate translation repression, which 
might play a role in proper synaptic development at the larval NMJ.   
3.13 FMRP is expressed with CCR4, CAF1, and NOT1 within the same cells in the 
larval CNS. 
 We immunostained larval ventral ganglia to investigate if FMRP and the 
deadenylase components co-localized to the same population of cells. In flies, CCR4 and 
NOT1 are the main enzymes responsible for the deadenylation of target mRNAs (Temme 
et al., 2004). CAF1 (fly ortholog of POP2) associates with CCR4 and possesses catalytic 
deadenylation ability (Temme et al., 2010). CAF1 can replace CCR4 as the main catalytic 
component of the deadenylase complex and the two proteins may exhibit some functional 
redundancy. We observed a diffused localization of FMRP and CCR4 in the CNSs (Figure 
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24A). Compared to CCR4, NOT1 and CAF1 appeared to be more punctate in appearance 
(Figure 24A). In our analysis, there was strong overlap between FMRP and CCR4 
(0.65+0.01) followed by NOT1 (0.6+0.01) and CAF1(0.5+0.01). However, we do not have 
sufficient optical resolution to conclude if FMRP colocalizes with deadenylase components 
at the larval NMJ. Imaging at higher resolution is required to determine the extent of 
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Figure 24: FMRP is expressed with CCR4, CAF1, and NOT1 within the same cells 
in the larval CNS. 
A) Ventral ganglion of the wandering third instar larvae stained with antibodies targeting 
FMRP (green), CCR4, NOT1, and CAF1 (red). The panels are from a single optical section 
as acquired by confocal microscopy. The arrows in the merged panels indicate the overlap 
of FMRP fluorescent intensities between FMRP (green) and the indicated deadenylase 
components. Scale bar: 50µM. Cell bodies within the ventral ganglion were imaged using 
100X for FMRP (green) and the indicated deadenylase components (red). The arrows in 
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the merged panels indicate the overlap of FMRP fluorescent intensities between FMRP 
(green), CCR4, NOT1, and CAF1(red). C) Degree of colocalization (Mander’s coefficient) 
was calculated for the overlap between green and red channels.  N=3 independent CNSs 
were analyzed for the analysis (****; p < 0.0001). The error bars are the mean + SEM.
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3.14 FMRP shows no genetic interaction with CCR4, NOT1, PABP or Dcp1 at the 
larval NMJ. 
Next, we used the larval NMJ as our in vivo model system to validate the 
interactions between FMRP and CCR4, NOT1, PABP or Dcp1. Based on the known 
interactions of GW182 in vitro, we hypothesized that CCR4, NOT1, PABP or Dcp1 may 
act downstream of FMRP and GW182 in the same genetic pathway to regulate synaptic 
development. To test this possibility, we asked if CCR4, NOT1, PABP or Dcp1 would 
show trans-heterozygous interactions with FMRP at the larval NMJ. We examined the 
NMJs from dFmr1 heterozygotes (dFmr1∆113/+), and heterozygotes for the candidate 
genes: TwinGS12209/+, Not1M107631/+, pAbpk10109 /+, and Dcp1442p/+. We assessed the 
changes at NMJ by counting the total number of synaptic boutons for each of these 
genotypes. Again, as the number of synaptic boutons can increase proportionally with 
MSA, we normalized synaptic bouton numbers against MSA for quantification. We did 
not observe any significant increase in the number of synaptic boutons for the heterozygous 
larvae of Twin, Not1, PABP or Dcp1 (Figure 26, 27). We observed a 5% increase in Twin 
Heterozygotes, increase, 0% increase in Not1 heterozygotes, 10% increase in pAbp 
heterozygotes and a 5% decrease in Dcp1 heterozygotes.  
 Next, we removed a single copy of the Twin, Not1, pAbp, and Dcp1 in the dFmr1 
heterozygous mutant background to generate trans-heterozygotes for the indicated genes. 
As described previously, an increase in the number of synaptic boutons in trans-
heterozygotes for these genes compared to controls would suggest genetic interactions 
within the FMRP pathway. In comparison to dFmr1 heterozygotes, Twin trans-
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heterozygotes (TwinGS12209/+; dFmr1∆113/+) displayed a 10% increase in synaptic boutons. 
Not1 trans-heterozygotes (Not1M107631/+; dFmr1∆113/+) exhibited a 15% increase over 
dFmr1 heterozygotes (Figure 26B). The trans-heterozygotes for pAbp (pAbpk10109 /+; 
dFmr1∆113/+) showed a 5% increase, and Dcp1 (Dcp1442p/+; dFmr1∆113/+) displayed a 5% 
decrease in the number of synaptic boutons over dFmr1 heterozygotes (Figure 27B). None 
of these results were statistically significant. These results suggest FMRP does not interact 
with CCR4, NOT1, PABP or DCP1 in the same pathway to controlling NMJ growth. It is 
possible that FMRP may regulate NMJ development via the miRISC through a non-
deadenylation dependent mechanism. Another possibility for the lack of any observed 
phenotype at the NMJ could be due to the redundancy between deadenylase enzymes and 
PABP in Drosophila. It would be interesting to test the genetic interactions between FMRP 
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Figure 25: dFmr1 shows no genetic interactions with Twin or Not1 at the larval NMJ. 
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for Twin, Not1 and 
trans-heterozygotes for Twin, Not1 (generated in the dFmr1∆113 background) were analyzed 
for NMJ phenotype. The size of the NMJ was determined at muscle 6/7 in abdominal 
segment A3 for each genotype as indicated. The NMJs were stained against postsynaptic 
density marker Dlg (green). Scale bar: 50 µM. B) Total number of synaptic boutons/MSA 
were quantified for each genotype. No significant difference was observed for the trans-
heterozygotes of Twin and Not1 in the number of boutons/MSA (normalized to control) 
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Figure 26: dFmr1 shows no genetic interactions with pAbp or Dcp1 at the larval 
NMJ. 
A) Larvae from w1118 controls, dFmr1∆113 heterozygotes, heterozygotes for pAbp or Dcp1, 
and trans-heterozygotes for pAbp or Dcp1 (generated in the dFmr1∆113 background) were 
analyzed for NMJ phenotype. The size of the NMJ was determined at muscle 6/7 in 
abdominal segment A3 for each genotype as indicated. The NMJs were stained against 
postsynaptic density marker Dlg (green). Scale bar: 50 µM. B) Total number of synaptic 
boutons/MSA were quantified for pAbp and Dcp1. No significant differences were 
observed between the indicated trans-heterozygotes and dFmr1∆113 heterozygotes. The 




3.15 FMRP does not interact with CCR4, NOT1, PABP or Dcp1 to control rates of 
larval locomotion. 
We used the larval crawling assay as a rapid and quantitative approach to screen 
components of the deadenylase complex including Twin (the fly ortholog of CCR4) and 
the scaffold protein Not1 as well as pAbp and the decapping enhancer Dcp1 for defects in 
locomotion. Based on the studies by Kashima et al. we speculated that trans-heterozygotes 
for these candidate genes might display a faster velocity than controls and might correlate 
with the synaptic overgrowth phenotype (Kashima et al., 2017).  
First, we examined the crawling velocity of the wild-type (w1118) and dFmr1 
heterozygote (dFmr1∆113p/+) larvae using “LarvaTrack” algorithm. We observed dFmr1 
heterozygotes to be 30% faster than the wild-type larvae (p< 0.01) (Figure 25). dFmr1 
heterozygotes display a normal NMJ phenotype, therefore, these results do not suggest a 
correlation between larval locomotion and synaptic overgrowth. Compared to wild-type 
larvae, Not1 heterozygotes (Not1M107631/+) displayed a higher velocity (p<0.01). However, 
heterozygotes of twin (TwinGS12209/+), pAbp (pAbpk10109 /+), or Dcp1 (Dcp1442p/+) did not 
exhibit a higher velocity than the wild-type larvae. These results suggest that compared to 
wild type larvae, Not1 heterozygotes are significantly more hyperactive than the Twin, 
pAbp, or Dcp1 heterozygous larvae (Figure 25).  
Next, we compared the locomotion between the dFmr1 heterozygous control larvae 
and animals that were trans-heterozygotes for the indicated genes. As with miRNA 
pathway components, none of the trans-heterozygotes displayed any significant increase in 
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velocity in comparison to the single heterozygotes genotypes (Figure 25). Together, our 
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Figure 27: dFmr1 does not interact with Twin, Not1, pAbp or Dcp1 to control rates of 
larval locomotion. 
Larval locomotion was quantified using “LarvaTrack” algorithm for the indicated 
genotypes. Average velocity for the larvae was plotted for comparison between w1118 and 
dFmr1 heterozygotes and the trans-heterozygotes for the indicated genotypes. No 
significant difference was observed between the indicated genotypes and the dFmr1 
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CHAPTER FOUR: DISCUSSION 
4.1 FMRP requires AGO1 and GW182 to mediate translation repression.  
 Previous studies suggest that FMRP associates with essential components of the 
miRNA pathway such as Dicer and AGO proteins, as well as with specific miRNAs 
(Cheever and Ceman, 2009; Edbauer et al., 2010; Jin et al., 2004b). FMRP associated miR-
125b and miR-132 have opposite effects on dendritic spine morphology in hippocampal 
neurons (Edbauer et al., 2010). Muddashetty et al. suggest that FMRP promotes the 
formation of an Ago2-miR-125a complex on PSD-95 mRNA and this translation inhibitory 
complex is regulated by the phosphorylation of FMRP. However, the mechanism by which 
the association of FMRP regulates translation via the miRNA pathway is not fully 
understood. Using an in vitro translation reporter assay in S2 cells, we provide the first 
evidence of a requirement for the downstream effector GW182 in FMRP mediated 
repression. We speculate that the interaction of FMRP with AGO1 and GW182 may 
facilitate miRNAs to bind to target mRNAs and repress their translation.  
The GW182 proteins are important miRISC effectors, and are recruited by AGO 
proteins to miRNA-targeted mRNAs (Fabian et al., 2012). FMRP could either interact 
directly with GW182 or interact with GW182 in an AGO-dependent manner. Our results 
suggest a weak interaction between FMRP and GW182 in co-IP assays, which could 
suggest an AGO-dependent interaction at play. However, we do not rule out the possibility 
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of our assay conditions playing a role in our observations. Additional experiments are 
required to further clarify the nature of these biochemical interactions.  
Why might FMRP interact with GW182?  GW182 binds to AGO proteins and act 
as a platform to recruit several proteins to the target mRNAs for gene silencing (Fabian 
and Sonenberg, 2012). Some studies suggest that GW182 can bind to PABP and thus 
interfere with mRNA circularization for target mRNA repression (Fabian and Sonenberg, 
2012). However, other studies in cell culture assays suggest that GW182 recruits CCR4-
NOT1 to mediate deadenylation independent or deadenylation dependent mode of 
translation repression (Fabian and Sonenberg, 2012). We speculate that FMRP could bind 
to multiple RBPs through GW182 to form an mRNP complex for translation regulation. A 
growing number of studies suggest that miRNAs and RISC components localize in P-
bodies, stress granules and neuronal granules (Buchan, 2014). Moreover, GW182 can act 
as a scaffold for P-body assembly as their depletion can cause dissolution of P-bodies 
(Eulalio et al., 2007a). Based on these observations, it is likely that FMRP through its 
interaction with GW182 could reside simultaneously in different types of mRNP granules, 
each regulating translation of specific targets in different ways.   
4.2 FMRP requires AGO1 and GW182 to control NMJ development. 
Previous studies by Jin et al. suggest genetic interactions between FMRP and 
AGO1 is crucial to regulate larval NMJ phenotypes (Jin et al., 2004b). We investigated 
genetic interactions between FMRP and both AGO1 and GW182 using Drosophila larval 
NMJs as our model system. We provide evidence for the first time that FMRP requires 
GW182 to regulate NMJ development. We observed a robust phenotype of synaptic 
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overgrowth at the larval NMJ for GW182 trans-heterozygotes. However, we could not 
detect any effect on the NMJs with AGO1 trans-heterozygotes. We speculate that either 
the AGO1 allele picked up suppressor mutations that may have disrupted its function. 
Nevertheless, our results suggest that FMRP requires components of miRNA pathway to 
control NMJ development. These interactions are crucial to control synaptic plasticity. 
How might the interaction control NMJ phenotype? One possibility may be that the 
interaction between FMRP and miRISC components may be involved in the transport and 
repression of specific transcripts within neuronal granules in motoneuron axons and that 
control NMJ development. Thus, disruption of the interaction between FMRP and miRISC 
components may be linked to defects in mRNP assembly or mRNA transport at the NMJ. 
However, future experiments are needed to explore the hypothesis in detail.  
We also investigated downstream components that might regulate NMJ 
development. However, none of the trans-heterozygotes for the candidate genes (Twin, 
Not1, pAbp or Dcp1) tested displayed a synaptic overgrowth phenotype. It may be possible 
that an alternate pathway might compensate for the function of Twin, Not1, PABP or Dcp1 
at the NMJ to control the NMJ phenotype. Therefore, the components by which FMRP 
through GW182 may regulate the NMJ phenotype still remains unclear. Future 
experiments will need to identify the downstream components of FMRP and GW182 
involved in mediating translation control within the same pathway.  
4.3 Cooperative interaction between FMRP and miRNAs regulate translation.  
 
Our results strongly suggest that FMRP binds to the BoxB stem loop sequence in 
the 3’UTR of the FLuc reporter, which is in close proximity to the binding site for miR-
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958. Both miR-958 and FMRP can cooperatively repress the translation of the FLuc 
reporter. Interestingly, depletion of FMRP from S2 cells resulted in attenuation of miR-
958-mediated repression. These results suggest that FMRP may play a role in recruiting 
miRNAs to nearby binding sites in target mRNAs. A similar cooperative regulation was 
reported for the PSD-95 mRNA by the association between FMRP and miR-125a for 
proper synaptic morphology and function (Muddashetty et al., 2011). 
We have identified putative miRNAs that might work in coordination with FMRP 
to repress translation of the FLuc-BoxB reporter. However, future experiments are required 
to verify the actual miRNAs involved in FMRP mediated repression in our assay. An 
obvious question is how might FMRP load miRNAs to the target mRNA? FMRP does not 
have a canonical miRNA-binding domain for interaction with miRNAs directly. Therefore, 
we speculate that either FMRP can interact with miRNAs via Dicer1 or through its 
interactions with AGO1 or GW182. To test this possibility, future experiments will be 
needed to gain mechanistic insights into this process.     
4.4 Role of the KH domains in FMRP mediated translation repression.  
Our results demonstrate that the KH domains of FMRP are involved in FMRP 
mediated translation repression (Figure 13B). We examined the effects of deleting RNA 
binding domains from FMRP on the translation of FLuc reporter and found that ∆KH1/2 
FMRP rescued the translation repression activity of tethered FMRP. Why might KH 
domains be involved in mediating this process? The KH domains of FMRP have been 
suggested to facilitate the direct assembly of miRNAs on some target mRNAs in vitro 
(Plante et al., 2006)). The authors suggested that FMRP could act as an acceptor of mature 
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miRNAs derived from Dicer processing of pre-miRNAs. Therefore, FMRP through its KH 
domains may cooperate with Dicer1 in miRNA assembly on target mRNAs for repression. 
It is possible that in our assays, deleting KH domains from FMRP comprised the ability of 
FMRP to form miRNA complex on target mRNAs. Additional experiments will be 
required to determine if KH domains are involved in direct interaction with Dicer1 for 
miRNA assembly on the FLuc-BoxB reporter.  
Another possibility by which KH domains can regulate FMRP mediated translation 
repression is through its ability to enhance the interaction between mRNA and miRNAs. 
KH domains of FMRP are known to enhance the formation of the kissing complex in vitro, 
where a target mRNA is bound to miRNAs in a specific secondary structure conformation 
(Bassell and Warren, 2008). While we have not directly investigated the secondary 
structure of the 3’ UTR of the FLuc mRNA when bound to FMRP, it is possible that FMRP 
mediates interaction between FLuc mRNA and miRNAs through its KH domain. This 
interaction may alter secondary structure and orient the FLuc mRNA in a favorable 
conformation for miRNA interaction. Further experiments are required to directly 
investigate this hypothesis. 
  A recent study suggests that FMRP can interact directly with ribosomes through its 
KH domains and the steric conflicts between KH domains and P-site tRNA can cause 
ribosomal stalling leading to translation repression (Chen et al., 2014). These results 
suggest a miRNA independent mode of translation repression for FMRP. Since ribosomes 
are stalled in the CDS region of target mRNAs, we do not consider ribosomal stalling as a 
potential mechanism for FMRP mediated repression for tethered experiments with the 
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FLuc-BoxB reporter. However, it is possible that the secondary structure of the mRNA 
may allow for FMRP (bound at the 3'UTR) to interact with ribosomes within the CDS. So, 
this mechanism cannot be ruled out completely for endogenous target mRNAs. 
4.5 Role of the KH domains in FMRP granule formation.  
A recent study by Gareau et al. suggest that FMRP granules assemble via its KH0 
domains (Gareau et al., 2013b). KH0 domains are involved in self-interaction of FMRP 
and may potentially direct multiple protein-protein interactions in RNP granules (Gareau 
et al., 2013b). KH0 domain of FMRP plays an important role in FMRP’s interaction with 
FXR1/2, CYFIP1 and FMRP interacting protein (FIP) (Hu et al., 2015). Moreover, lack of 
a GxxG motif in KH0 provides it the flexibility to interact with multiple mRNAs, including 
the ncRNA, BC1 (Hu et al., 2015). In consistent with the studies by Gareau et al. using live 
cell imaging, we observed that deleting KH0 domains from FMRP results in diffused 
localization of smaller FMRP granules in cells. These results suggest that FMRP requires 
the KH0 domain for granule assembly. Based on these studies, we speculate that FMRP 
through its KH0 domains may sequester translationally repressed mRNAs, miRNAs, and 
core miRISC components to granules. An increased local concentration of miRNAs and 
miRISC proteins may facilitate efficient translation repression of target mRNA. The 
observed dissociation of granules due to deletion of the KH0 domain might be due to the 
removal of the interactions between FMRP, target mRNA, miRISC components and other 
RBPs. Further, FRAP studies suggest that FMRP requires KH0 domains to shuttle from 
cytosol to granules. In an absence of shuttling activity, FMRP may not bind to specific 
proteins for granule formation and translation regulation. It would be interesting to 
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characterize how the KH0 domain chaperones transcripts and associated proteins to 
granules from free cytosolic fraction. Another explanation for the diffused localization of 
the KH0 deleted FMRP protein might be non-specific binding of this mutated FMRP to 
other proteins in absence of KH0 domain. KH0 domain is required for FMRP to form 
dimers. Therefore, an absence of self-dimerization of FMRP may lead to non-specific 
binding with other proteins, leading to loss of function phenotypes.  
In contrast to Gareau et al., we observed that ∆KH1/2-FMRP induced the formation 
of bigger FMRP granules in S2 cells. A possible explanation for the observed aberrant 
granules may be a loss of translation regulation by FMRP. Previous studies suggest that 
∆KH1/2-FMRP has compromised RNA and protein shuttling activity between the granule 
and the cytosol (Gareau et al., 2013b). Therefore, we speculate that ∆KH1/2-FMRP may 
be trapped with miRNAs or miRISC components in granules. It would be interesting to 
characterize whether aberrant granule formation contributes to FXS pathology. 
Unpublished data from Barbee lab suggests that disease-causing KH1 and two point 
mutants induce the formation of aberrant granules similar in morphology to ∆KH1/2-
FMRP. Further experiments are needed to investigate if difference in size and dynamics 
are due to mRNAs and miRISC proteins being trapped in these granules.  
4.6 RBPs can promote miRISC targeting at the 3’UTR of target mRNA. 
Sequences or structures in the 3'UTR of specific mRNAs may influence FMRP's 
role in the microRNA-mediated translation repression pathway. miRNAs mediate 
translation repression mainly by binding to seed regions within the 3'UTR. Various other 
RBPs can also interact with 3'UTRs in a sequence-specific manner. In both cases, this 
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interaction is necessary to modulate gene expression. An interplay between RBPs and 
miRNAs in the 3'UTR can either induce a structural switch in the mRNA which could 
facilitate miRISC assembly on the target mRNA. Conversely, RBP interaction with the 
3’UTR could occlude miRNAs from binding to their target mRNAs. 
As an example of RBP-mediated modulation of miRNA pathway, the 3'UTR of the 
p27 mRNA is regulated by miR-221, miR-222, and Pumilio (Kenny and Ceman, 2016). 
Pumilio is a ubiquitously expressed sequence-specific RBP. However, binding site for 
these miRNAs in the 3’UTR of p27 mRNA are inaccessible to miRISC for binding, 
because they are found within regions of complex secondary structure. There is evidence 
that Pumilio1 interacts with p27-3'UTR and induces a local change in mRNA structure. As 
a consequence of this structural change, the seed sequence is exposed, which allows for the 
interaction of miRISC components with the target mRNA. Another example of RBP-
mediated miRISC modulation is the role of dead end 1 (Dnd1) protein in inhibiting miRNA 
binding to target mRNAs. Dnd1 has been shown to compete with miRNAs to inhibit 
miRNAs from associating with their target sites (Kedde et al., 2007).  
Other RBPs have been demonstrated to have both an agonizing or antagonizing 
function in miRNA-mediated translation regulation. For example, the polypyrimidine tract 
binding protein (PTB) and human antigen R (HuR) can suppress or enhance miRNA 
binding in the 3'UTR of a subset of target mRNAs (Kenny and Ceman, 2016; Kim et al.). 
Therefore, we speculate that FMRP may serve a similar function in promoting miRNA 
binding to the 3’UTRs of some target mRNAs. FMRP may facilitate or inhibit miRNA 
mediated repression by modification of secondary structure in target mRNA, either by 
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making miRNA binding site accessible, or by masking miRNA binding sites. The factors 
that modulate secondary structure in the target mRNA require further investigation. 
4.7 Future directions  
Our data suggests that FMRP interacts with the components of the miRNA pathway 
to mediate translation repression. Based on our data, we propose a model where FMRP 
binds to 3’UTRs of target mRNAs and recruits the miRISC to a nearby miRNA binding 
site for translation repression (Figure 28). It would be interesting to perform a CLIP-Seq 
for FMRP to identify its mRNA targets in neuronal cell lines or in motor neurons and 
investigate whether these targets are co-regulated by miRNAs and FMRP.  Future 
experiments will also be required to identify other RBPs that may interact with FMRP and 
miRNAs for coupled control of mRNA translation in neurons.  
Our results also suggest a role of KH domains in FMRP translation in a mRNA 
independent way. It would be interesting to generate stable cell lines for ∆KH FMRP, pull 
down associated RBPs with FMRP, and compare these RBPs with the cell lines expressing 
wild-type FMRP to identify KH domain mediated FMRP-RBP interactions. The 
experiments will help identify if the absence of KH domains can lead to non-specific 
interactions of FMRP with other RBPs which leads to aberrant granules. Further, FMRP 
lacking KH domains and RGG domain should be investigated for their interactions with 
components of the miRNA pathway. We could also track the movement of miRISC 
components or other RBPs in FMRP granules in motor neurons using super-resolution 
microscopy to measure the dynamics of their interactions within FMRP granules.  
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Taken together, that work described in this thesis (and experiments that will 
logically follow) could help shed some light on the mechanisms by which FMRP regulates 
translation of target mRNAs with miRNAs, as well as identify key neuronal transcripts 
whose translation is affected by the loss of FMRP. An understanding of these processes 
will help in the development of therapeutic approaches to find a cure for FXS.  
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Figure 28: Proposed model of how FMRP interacts with the miRNA pathway to 
regulate translation.   
We propose that FMRP first recognizes structural elements in target mRNA and then 
recruits the miRISC components to mediate translation repression. FMRP potentially 
interacts with the miRISC complex through AGO1 which then recruits GW182 to mediate 
repression. GW182 could potentially interact with the components of the deadenylase 
complex (CCR4, NOT1) to mediate either deadenylation dependent or an independent 
mode of degradation. GW182 could also interact with other RBPs to mediate RNA 




















  145 
REFERENCES 
 
Ambros, V. (2011). MicroRNAs and developmental timing. Curr. Opin. Genet. Dev. 21, 
511–517. 
Ameres, S.L., and Zamore, P.D. (2013). Diversifying microRNA sequence and function. 
Nat. Rev. Mol. Cell Biol. 14, 475–488. 
Anderson, P., and Kedersha, N. (2006). RNA granules. J. Cell Biol. 172, 803–808. 
Anderson, B.R., Chopra, P., Suhl, J.A., Warren, S.T., and Bassell, G.J. (2016). 
Identification of consensus binding sites clarifies FMRP binding determinants. Nucleic 
Acids Res. 44, 6649–6659. 
Antar, L.N., Afroz, R., Dictenberg, J.B., Carroll, R.C., and Bassell, G.J. (2004). 
Metabotropic Glutamate Receptor Activation Regulates Fragile X Mental Retardation 
Protein and FMR1 mRNA Localization Differentially in Dendrites and at Synapses. J. 
Neurosci. 24, 2648–2655. 
Antar, L.N., Dictenberg, J.B., Plociniak, M., Afroz, R., and Bassell, G.J. (2005). 
Localization of FMRP-associated mRNA granules and requirement of microtubules for 
activity-dependent trafficking in hippocampal neurons. Genes, Brain Behav. 4, 350–359. 
Antar, L.N., Li, C., Zhang, H., Carroll, R.C., and Bassell, G.J. (2006). Local functions for 
FMRP in axon growth cone motility and activity-dependent regulation of filopodia and 
spine synapses. Mol. Cell. Neurosci. 32, 37–48. 
Antic, S., Wolfinger, M.T., Skucha, A., Hosiner, S., and Dorner, S. (2015). General and 
MicroRNA-Mediated mRNA Degradation Occurs on Ribosome Complexes in Drosophila 
Cells. Mol. Cell. Biol. 35, 2309–2320. 
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J.B., Nusbaum, J.D., Corcoran, D.L., 
Langlois, C., Munschauer, M., Dewell, S., Hafner, M., et al. (2012). FMRP targets distinct 
mRNA sequence elements to regulate protein expression. Nature 492, 382–386. 
Aschrafi, A., Cunningham, B. a, Edelman, G.M., and Vanderklish, P.W. (2005). The 
fragile X mental retardation protein and group I metabotropic glutamate receptors regulate 
levels of mRNA granules in brain. Proc. Natl. Acad. Sci. U. S. A. 102, 2180–2185. 
Ashley, C.T., Wilkinson, K.D., Reines, D., and Warren, S.T. (1993a). FMR1 protein: 
conserved RNP family domains and selective RNA binding. Science 262, 563–566. 
Ashley, C.T., Sutcliffe, J.S., Kunst, C.B., Leiner, H.A., Eichler, E.E., Nelson, D.L., and 
Warren, S.T. (1993b). Human and murine FMR-1: Alternative splicing and translational 
initiation downstream of the CGG-repeat. Nat. Genet. 4, 244–251. 
 
  146 
Baek, D., Villén, J., Shin, C., Camargo, F.D., Gygi, S.P., and Bartel, D.P. (2008). The 
impact of microRNAs on protein output. Nature 455, 64–71. 
Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., and Pasquinelli, A.E. 
(2005). Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 
122, 553–563. 
Bagni, C. (2008). On BC1 RNA and the fragile X mental retardation protein. Proc. Natl. 
Acad. Sci. U. S. A. 105, E19. 
Bagni, C., and Greenough, W.T. (2005). From mRNP trafficking to spine 
dysmorphogenesis: The roots of fragile X syndrome. Nat. Rev. Neurosci. 6, 376–387. 
Bagni, C., and Oostra, B.A. (2013). Fragile X syndrome: From protein function to therapy. 
Am. J. Med. Genet. Part A 161, 2809–2821. 
Banerjee, A., Ifrim, M.F., Valdez, A.N., Raj, N., and Bassell, G.J. (2018). Aberrant RNA 
Translation in Fragile X Syndrome: From FMRP Mechanisms to Emerging Therapeutic 
Strategies. Brain Res. 
Banko, J.L., Merhav, M., Stern, E., Sonenberg, N., Rosenblum, K., and Klann, E. (2007). 
Behavioral alterations in mice lacking the translation repressor 4E-BP2. Neurobiol. Learn. 
Mem. 87, 248–256. 
Barbee, S. a, Estes, P.S., Cziko, A.-M., Hillebrand, J., Luedeman, R. a, Coller, J.M., 
Johnson, N., Howlett, I.C., Geng, C., Ueda, R., et al. (2006). Staufen- and FMRP-
containing neuronal RNPs are structurally and functionally related to somatic P bodies. 
Neuron 52, 997–1009. 
Bartel, D.P. (2009). MicroRNAs: Target Recognition and Regulatory Functions. Cell 136, 
215–233. 
Bassell, G.J. (2011). Fragile balance: RNA editing tunes the synapse. Nat. Neurosci. 14, 
1492–1494. 
Bassell, G.J., and Warren, S.T. (2008). Fragile X syndrome: loss of local mRNA regulation 
alters synaptic development and function. Neuron 60, 201–214. 
Bear, M.F., Huber, K.M., and Warren, S.T. (2004). The mGluR theory of fragile X mental 
retardation. Trends Neurosci. 27, 370–377. 
Bechara, E.G., Didiot, M.C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., Castets, 
M., Pognonec, P., Khandjian, E.W., Moine, H., et al. (2009). A novel function for fragile 
X mental retardation protein in translational activation. PLoS Biol. 7. 
Behm-Ansmant, I., Rehwinkel, J., Doerks, T., Stark, A., Bork, P., and Izaurralde, E. (2006). 
 
  147 
mRNA degradation by miRNAs and GW182 requires both CCR4 : NOT deadenylase and 
DCP1 : DCP2 decapping complexes. Genes Dev. 20, 1885–1898 ST–MRNA degradation 
by miRNAs and GW1. 
Belmonte, M.K., and Bourgeron, T. (2006). Fragile X syndrome and autism at the 
intersection of genetic and neural networks. Nat. Neurosci. 9, 1221–1225. 
Bernstein, E., Caudy, A.A., Hammond, S.M., and Hannon, G.J. (2001). Role for a bidentate 
ribonuclease in the initiation step of RNA interference. Nature 409, 363–366. 
Berry-Kravis, E.M., Lindemann, L., Jønch, A.E., Apostol, G., Bear, M.F., Carpenter, R.L., 
Crawley, J.N., Curie, A., Des Portes, V., Hossain, F., et al. (2017). Drug development for 
neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat. Rev. Drug 
Discov. 
Bhakar, A.L., Dölen, G., and Bear, M.F. (2012). The Pathophysiology of Fragile X (and 
What It Teaches Us about Synapses). Annu. Rev. Neurosci. 35, 417–443. 
Bhattacharyya, S.N., Habermacher, R., Martine, U., Closs, E.I., and Filipowicz, W. (2006). 
Relief of microRNA-Mediated Translational Repression in Human Cells Subjected to 
Stress. Cell 125, 1111–1124. 
Bhogal, B., and Jongens, T.A. (2010). Fragile X syndrome and model organisms: 
identifying potential routes of therapeutic intervention. Dis. Model. Mech. 3, 693–700. 
Bienkowski, R.S., Banerjee, A., Rounds, J.C., Rha, J., Omotade, O.F., Gross, C., Morris, 
K.J., Leung, S.W., Pak, C.H., Jones, S.K., et al. (2017). The Conserved, Disease-
Associated RNA Binding Protein dNab2 Interacts with the Fragile X Protein Ortholog in 
Drosophila Neurons. Cell Rep. 20, 1372–1384. 
Blice-Baum, A.C., and Mihailescu, M.-R. (2014). Biophysical characterization of G-
quadruplex forming FMR1 mRNA and of its interactions with different fragile X mental 
retardation protein isoforms. RNA 20, 103–114. 
Bohnsack, M.T., Czaplinski, K., and Görlich, D. (2004). Exportin 5 is a RanGTP-
dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 
185–191. 
Bolduc, F. V., Bell, K., Cox, H., Broadie, K.S., and Tully, T. (2008). Excess protein 
synthesis in Drosophila Fragile X mutants impairs long-term memory. Nat. Neurosci. 11, 
1143–1145. 
Bolte, S., and Cordelieres, F.P. (2006). A guided tour into subcellular colocalisation 
analysis in light microscopy. J. Microsc. 224, 13–232. 
Bordeleau, M.E., Mori, A., Oberer, M., Lindqvist, L., Chard, L.S., Higa, T., Belsham, G.J., 
 
  148 
Wagner, G., Tanaka, J., and Pelletier, J. (2006). Functional characterization of IRESes by 
an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2, 213–220. 
De Boulle, K., Verkerk,  a J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy, B., Van den 
Bos, F., de Graaff, E., Oostra, B. a, and Willems, P.J. (1993). A point mutation in the FMR-
1 gene associated with fragile X mental retardation. Nat. Genet. 3, 31–35. 
Boyle, L., and Kaufmann, W.E. (2010). The behavioral phenotype of FMR1 mutations. 
Am. J. Med. Genet. Part C Semin. Med. Genet. 154, 469–476. 
Bramham, C.R., and Wells, D.G. (2007). Dendritic mRNA: Transport, translation and 
function. Nat. Rev. Neurosci. 8, 776–789. 
Braun, J.E., Huntzinger, E., Fauser, M., and Izaurralde, E. (2011). GW182 Proteins 
Directly Recruit Cytoplasmic Deadenylase Complexes to miRNA Targets. Mol. Cell 44, 
120–133. 
Braun, J.E., Huntzinger, E., and Izaurralde, E. (2013). Ten Years of Progress in GW/P 
Body Research. 768. 
Brennecke, J., Stark, A., Russell, R.B., and Cohen, S.M. (2005). Principles of microRNA-
target recognition. In PLoS Biology, pp. 0404–0418. 
Brown, V., Jin, P., Ceman, S., Darnell, J.C., O’Donnell, W.T., Tenenbaum, S.A., Jin, X., 
Feng, Y., Wilkinson, K.D., Keene, J.D., et al. (2001). Microarray identification of FMRP-
associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. 
Cell 107, 477–487. 
Buchan, J.R. (2014). mRNP granules : Assembly, function , and connections with disease. 
RNA Biol. 11, 1–12. 
Bushati, N., and Cohen, S.M. (2007). microRNA Functions microRNA (miRNA): ∼22-nt 
noncoding RNA that serves as a posttranscriptional regulator. Annu. Rev. Cell Dev. Biol 
23, 175–205. 
Caudy, A. a, Myers, M., Hannon, G.J., and Hammond, S.M. (2002). Fragile X-related 
protein and VIG associate with the RNA interference machinery. Genes Dev. 16, 2491–
2496. 
Ceman, S., Brown, V., and Warren, S.T. (1999). Isolation of an FMRP-associated 
messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-
related proteins as components of the complex. Mol. Cell. Biol. 19, 7925–7932. 
Ceman, S., O’Donnell, W.T., Reed, M., Patton, S., Pohl, J., and Warren, S.T. (2003). 
Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum. 
Mol. Genet. 12, 3295–3305. 
 
  149 
Chang, T.-C., and Mendell, J.T. (2007). microRNAs in Vertebrate Physiology and Human 
Disease. Annu. Rev. Genomics Hum. Genet. 8, 215–239. 
Cheever, A., and Ceman, S. (2009). Phosphorylation of FMRP inhibits association with 
Dicer. RNA 15, 362–366. 
Chekulaeva, M., Mathys, H., Zipprich, J.T., Attig, J., Colic, M., Parker, R., and Filipowicz, 
W. (2011). miRNA repression involves GW182-mediated recruitment of CCR4–NOT 
through conserved W-containing motifs. Nat. Struct. Mol. Biol. 18, 1218–1226. 
Chen, E., and Joseph, S. (2015). Fragile X mental retardation protein: A paradigm for 
translational control by RNA-binding proteins. Biochimie 114, 147–154. 
Chen, E., Sharma, M.R., Shi, X., Agrawal, R.K., and Joseph, S. (2014). Fragile X mental 
retardation protein regulates translation by binding directly to the ribosome. Mol. Cell 54, 
407–417. 
Chen, L., Yun, S.W., Seto, J., Liu, W., and Toth, M. (2003). The fragile X mental 
retardation protein binds and regulates a novel class of mRNAs containing u rich target 
sequences. Neuroscience 120, 1005–1017. 
Chendrimada, T.P., Gregory, R.I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, 
K., and Shiekhattar, R. (2005). TRBP recruits the Dicer complex to Ago2 for microRNA 
processing and gene silencing. Nature 436, 740–744. 
Chendrimada, T.P., Finn, K.J., Ji, X., Baillat, D., Gregory, R.I., Liebhaber, S.A., 
Pasquinelli, A.E., and Shiekhattar, R. (2007). MicroRNA silencing through RISC 
recruitment of eIF6. Nature 447, 823–828. 
Chu, C.Y., and Rana, T.M. (2006). Translation repression in human cells by MicroRNA-
induced gene silencing requires RCK/p54. PLoS Biol. 4, 1122–1136. 
Clarke, S.L., Davis, M.R., and Sunkar, R. (2012). MicroRNAs as Tools in 
Biopharmaceutical Production. 15–28. 
Coffee, B., Zhang, F., Warren, S.T., and Reines, D. (1999). Acetylated histones are 
associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22, 98–101. 
Coffee, B., Zhang, F., Ceman, S., Warren, S.T., and Reines, D. (2002). Histone 
Modifications Depict an Aberrantly Heterochromatinized FMR1 Gene in Fragile X 
Syndrome. Am. J. Hum. Genet. 71, 923–932. 
Coletta, A., Pinney, J.W., Sol??s, D.Y.W., Marsh, J., Pettifer, S.R., and Attwood, T.K. 
(2010). Low-complexity regions within protein sequences have position-dependent roles. 
BMC Syst. Biol. 4. 
 
  150 
Collins, S.C., Bray, S.M., Suhl, J.A., Cutler, D.J., Coffee, B., Zwick, M.E., and Warren, 
S.T. (2010). Identification of novel FMR1 variants by massively parallel sequencing in 
developmentally delayed males. Am. J. Med. Genet. Part A 152 A, 2512–2520. 
Costa-Mattioli, M., Sossin, W.S., Klann, E., and Sonenberg, N. (2009). Translational 
Control of Long-Lasting Synaptic Plasticity and Memory. Neuron 61, 10–26. 
Cougot, N., Bhattacharyya, S.N., Tapia-Arancibia, L., Bordonné, R., Filipowicz, W., 
Bertrand, E., and Rage, F. (2008). Dendrites of mammalian neurons contain specialized P-
body-like structures that respond to neuronal activation. J. Neurosci. 28, 13793–13804. 
Crawford, D.C., Acuña, J.M., and Sherman, S.L. (2001). FMR1 and the fragile X 
syndrome: human genome epidemiology review. Genet. Med. 3, 359–371. 
Cruz-Martín, A., Crespo, M., and Portera-Cailliau, C. (2012). Glutamate induces the 
elongation of early dendritic protrusions via mGluRs in wild type mice, but not in fragile 
X mice. PLoS One 7. 
Czech, B., Zhou, R., Erlich, Y., Brennecke, J., Binari, R., Villalta, C., Gordon, A., 
Perrimon, N., and Hannon, G.J. (2009). Hierarchical rules for Argonaute loading in 
Drosophila. Mol. Cell 36, 445–456. 
Darnell, J.C., and Klann, E. (2013). The Translation of Translational Control by FMRP: 
Therapeutic Targets for Fragile X Syndrome. Nat. Neurosci. 16, 1530–1536. 
Darnell, J.C., Jensen, K.B., Jin, P., Brown, V., Warren, S.T., and Darnell, R.B. (2001). 
Fragile X mental retardation protein targets G quartet mRNAs important for neuronal 
function. Cell 107, 489–499. 
Darnell, J.C., Fraser, C.E., Mostovetsky, O., Stefani, G., Jones, T.A., Eddy, S.R., and 
Darnell, R.B. (2005). Kissing complex RNAs mediate interaction between the Fragile-X 
mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 19, 903–
918. 
Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y.S., Mele, A., Fraser, C.E., Stone, 
E.F., Chen, C., Fak, J.J., Chi, S.W., et al. (2011). FMRP stalls ribosomal translocation on 
mRNAs linked to synaptic function and autism. Cell 146, 247–261. 
Davis, J.K., and Broadie, K. (2017). Multifarious Functions of the Fragile X Mental 
Retardation Protein. Trends Genet. 
Decker, C.J., and Parker, R. (2012). P-Bodies and Stress Granules: Possible Roles in the 
Control of Translation and mRNA Degradation. Cold Spring Harb. Perspect. Biol. 4, 
a012286–a012286. 
Denli, A.M., Tops, B.B.J., Plasterk, R.H.A., Ketting, R.F., and Hannon, G.J. (2004). 
 
  151 
Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231–235. 
DeRubeis, S., Pasciuto, E., Li, K.W., Fernández, E., DiMarino, D., Buzzi, A., Ostroff, L.E., 
Klann, E., Zwartkruis, F.J.T., Komiyama, N.H., et al. (2013). CYFIP1 coordinates mRNA 
translation and cytoskeleton remodeling to ensure proper dendritic Spine formation. 
Neuron 79, 1169–1182. 
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.P., and Mandel, J.L. (1993). The FMR-1 protein 
is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X 
premutation. Nat. Genet. 4, 335–340. 
Dictenberg, J.B., Swanger, S.A., Antar, L.N., Singer, R.H., and Bassell, G.J. (2008). A 
Direct Role for FMRP in Activity-Dependent Dendritic mRNA Transport Links 
Filopodial-Spine Morphogenesis to Fragile X Syndrome. Dev. Cell 14, 926–939. 
Didiot, M.C., Tian, Z., Schaeffer, C., Subramanian, M., Mandel, J.L., and Moine, H. 
(2008). The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic 
splicing enhancer. Nucleic Acids Res. 36, 4902–4912. 
Diederichs, S., and Haber, D.A. (2007). Dual role for argonautes in microRNA processing 
and posttranscriptional regulation of microRNA expression. Cell 131, 1097–1108. 
Ding, X.C., and Großhans, H. (2009). Repression of C. elegans microRNA targets at the 
initiation level of translation requires GW182 proteins. EMBO J. 28, 213–222. 
Dockendorff, T.C., Su, H.S., McBride, S.M.J., Yang, Z., Choi, C.H., Siwicki, K.K., Sehgal, 
A., and Jongens, T.A. (2002). Drosophila lacking dfmr1 activity show defects in circadian 
output and fail to maintain courtship interest. Neuron 34, 973–984. 
Doench, J.G., and Sharp, P.A. (2004). Specificity of microRNA target selection in 
translational repression. Genes Dev. 18, 504–511. 
Dolen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., and Bear, 
M.F. (2007). Correction of fragile X syndrome in mice. Neuron 56, 955–962. 
Dolzhanskaya, N., Sung, Y.J., Conti, J., Currie, J.R., and Denman, R.B. (2003). The fragile 
X mental retardation protein interacts with U-rich RNAs in a yeast three-hybrid system. 
Biochem. Biophys. Res. Commun. 305, 434–441. 
Drozd, M., Bardoni, B., and Capovilla, M. (2018). Modeling Fragile X Syndrome in 
Drosophila. Front. Mol. Neurosci. 11, 1–15. 
Du, T. (2005). microPrimer: the biogenesis and function of microRNA. Development 132, 
4645–4652. 
Eberhart, D.E., Malter, H.E., Feng, Y., and Warren, S.T. (1996). The fragile X mental 
 
  152 
retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear 
export signals. Hum. Mol. Genet. 5, 1083–1091. 
Edbauer, D., Neilson, J.R., Foster, K.A., Wang, C.F., Seeburg, D.P., Batterton, M.N., Tada, 
T., Dolan, B.M., Sharp, P.A., and Sheng, M. (2010). Regulation of Synaptic Structure and 
Function by FMRP-Associated MicroRNAs miR-125b and miR-132. Neuron 65, 373–384. 
Elkayam, E., Kuhn, C.D., Tocilj, A., Haase, A.D., Greene, E.M., Hannon, G.J., and Joshua-
Tor, L. (2012). The structure of human argonaute-2 in complex with miR-20a. Cell 150, 
100–110. 
Elvira, G., Wasiak, S., Blandford, V., Tong, X.-K., Serrano, A., Fan, X., del Rayo Sánchez-
Carbente, M., Servant, F., Bell, A.W., Boismenu, D., et al. (2006). Characterization of an 
RNA Granule from Developing Brain. Mol. Cell. Proteomics 5, 635–651. 
Eulalio, A., Behm-Ansmant, I., and Izaurralde, E. (2007a). P bodies: at the crossroads of 
post-transcriptional pathways. Nat. Rev. Mol. Cell Biol. 8, 9–22. 
Eulalio, A., Rehwinkel, J., Stricker, M., Huntzinger, E., Yang, S.F., Doerks, T., Dorner, S., 
Bork, P., Boutros, M., and Izaurralde, E. (2007b). Target-specific requirements for 
enhancers of decapping in miRNA-mediated gene silencing. Genes Dev. 21, 2558–2570. 
Eulalio, A., Behm-Ansmant, I., Schweizer, D., and Izaurralde, E. (2007c). P-body 
formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol. Cell. 
Biol. 27, 3970–3981. 
Eulalio, A., Huntzinger, E., and Izaurralde, E. (2008a). Getting to the root of miRNA-
mediated gene silencing. Cell 132, 9–14. 
Eulalio, A., Huntzinger, E., and Izaurralde, E. (2008b). GW182 interaction with Argonaute 
is essential for miRNA-mediated translational repression and mRNA decay. Nat. Struct. 
Mol. Biol. 15, 346–353. 
Eulalio, A., Tritschler, F., and Izaurralde, E. (2009). The GW182 protein family in animal 
cells: new insights into domains required for miRNA-mediated gene silencing. RNA 15, 
1433–1442. 
Fabian, M.R., and Sonenberg, N. (2012). The mechanics of miRNA-mediated gene 
silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 19, 586–593. 
Fabian, M.R., Mathonnet, G., Sundermeier, T., Mathys, H., Zipprich, J.T., Svitkin, Y. V, 
Rivas, F., Jinek, M., Wohlschlegel, J., Doudna, J. a, et al. (2009). Mammalian miRNA 
RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol. Cell 35, 
868–880. 
Fabian, M.R., Sonenberg, N., and Filipowicz, W. (2010). Regulation of mRNA translation 
 
  153 
and stability by microRNAs. Annu. Rev. Biochem. 79, 351–379. 
Fabian, M.R., Cieplak, M.K., Frank, F., Morita, M., Green, J., Srikumar, T., Nagar, B., 
Yamamoto, T., Raught, B., Duchaine, T.F., et al. (2012). miRNA-mediated deadenylation 
is orchestrated by GW182 through two conserved motifs that interact with CCR4–NOT. 
Nat. Struct. Mol. Biol. 19, 364–364. 
Fähling, M., Mrowka, R., Steege, A., Kirschner, K.M., Benko, E., Förstera, B., Persson, 
P.B., Thiele, B.J., Meier, J.C., and Scholz, H. (2009). Translational regulation of the human 
achaete-scute homologue-1 by fragile X mental retardation protein. J. Biol. Chem. 284, 
4255–4266. 
El Fatimy, R., Davidovic, L., Tremblay, S., Jaglin, X., Dury, A., Robert, C., De Koninck, 
P., Khandjian, E.W., Cajal, S.R. y, Abbott, L., et al. (2016). Tracking the Fragile X Mental 
Retardation Protein in a Highly Ordered Neuronal RiboNucleoParticles Population: A Link 
between Stalled Polyribosomes and RNA Granules. PLOS Genet. 12, e1006192. 
Feng, Y., Absher, D., Eberhart, D.E., Brown, V., Malter, H.E., and Warren, S.T. (1997). 
FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe 
fragile X syndrome abolishes this association. Mol. Cell 1, 109–118. 
Fernández, E., Rajan, N., and Bagni, C. (2013). The FMRP regulon: From targets to disease 
convergence. Front. Neurosci. 
Ferrari, F., Mercaldo, V., Piccoli, G., Sala, C., Cannata, S., Achsel, T., and Bagni, C. 
(2007). The fragile X mental retardation protein-RNP granules show an mGluR-dependent 
localization in the post-synaptic spines. Mol. Cell. Neurosci. 34, 343–354. 
Filipowicz, W., Bhattacharyya, S.N., and Sonenberg, N. (2008). Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 
102–114. 
Förstemann, K., Tomari, Y., Du, T., Vagin, V. V., Denli, A.M., Bratu, D.P., Klattenhoff, 
C., Theurkauf, W.E., and Zamore, P.D. (2005). Normal microRNA maturation and germ-
line stem cell maintenance requires loquacious, a double-stranded RNA-binding domain 
protein. PLoS Biol. 3, 1187–1201. 
Förstemann, K., Horwich, M.D., Wee, L., Tomari, Y., and Zamore, P.D. (2007). 
Drosophila microRNAs Are Sorted into Functionally Distinct Argonaute Complexes after 
Production by Dicer-1. Cell 130, 287–297. 
Fu, Y.H., Kuhl, D.P.A., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkert, 
A.J.M.H., Holden, J.J.A., Fenwick, R.G., Warren, S.T., et al. (1991). Variation of the CGG 
repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. 
Cell 67, 1047–1058. 
 
  154 
Fukao, A., Mishima, Y., Takizawa, N., Oka, S., Imataka, H., Pelletier, J., Sonenberg, N., 
Thoma, C., and Fujiwara, T. (2014). MicroRNAs Trigger Dissociation of eIF4AI and 
eIF4AII from Target mRNAs in Humans. Mol. Cell 56, 79–89. 
Fukaya, T., and Tomari, Y. (2011). PABP is not essential for microRNA-mediated 
translational repression and deadenylation in vitro. EMBO J. 30, 4998–5009. 
Fukaya, T., Iwakawa, H., and Tomari, Y. (2014). MicroRNAs Block Assembly of eIF4F 
Translation Initiation Complex in Drosophila. Mol. Cell 56, 67–78. 
Fukunaga, R., Han, B.W., Hung, J.H., Xu, J., Weng, Z., and Zamore, P.D. (2012). Dicer 
partner proteins tune the length of mature miRNAs in flies and mammals. Cell 151, 533–
546. 
Gabriela, M., Malena, T., Pascual, L., Maschi, D., and Luchelli, L. (2013). Synaptic control 
of local translation : the plot thickens with new characters. 
Gareau, C., Houssin, E., Martel, D., Coudert, L., Mellaoui, S., Huot, M.-E., Laprise, P., 
and Mazroui, R. (2013a). Characterization of fragile X mental retardation protein 
recruitment and dynamics in Drosophila stress granules. PLoS One 8, e55342. 
Gareau, C., Martel, D., Coudert, L., Mellaoui, S., and Mazroui, R. (2013b). 
Characterization of Fragile X Mental Retardation Protein granules formation and dynamics 
in Drosophila. Biol. Open 2, 68–81. 
Garzon, R., Calin, G.A., and Croce, C.M. (2009). MicroRNAs in Cancer. Annu Rev Med 
60, 167–179. 
Gibson, J.R., Bartley, A.F., Hays, S.A., and Huber, K.M. (2008). Imbalance of Neocortical 
Excitation and Inhibition and Altered UP States Reflect Network Hyperexcitability in the 
Mouse Model of Fragile X Syndrome. J. Neurophysiol. 100, 2615–2626. 
Gingras, A.C., Raught, B., Gygi, S.P., Niedzwiecka, A., Miron, M., Burley, S.K., 
Polakiewicz, R.D., Wyslouch-Cieszynska, A., Aebersold, R., and Sonenberg, N. (2001). 
Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852–
2864. 
Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., and 
Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs. 
Nature 432, 235–240. 
Gregory, R.I., Chendrimada, T.P., Cooch, N., and Shiekhattar, R. (2005). Human RISC 
couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631–640. 
Grimson, A., Farh, K.K.H., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. 
(2007). MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing. 
 
  155 
Mol. Cell 27, 91–105. 
Grishok, A., Pasquinelli, A.E., Conte, D., Li, N., Parrish, S., Ha, I., Baillie, D.L., Fire, A., 
Ruvkun, G., and Mello, C.C. (2001). Genes and mechanisms related to RNA interference 
regulate expression of the small temporal RNAs that control C. elegans developmental 
timing. Cell 106, 23–34. 
Gross, C., Berry-Kravis, E.M., and Bassell, G.J. (2012). Therapeutic strategies in fragile X 
syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37, 
178–195. 
Grossman, A.W., Aldridge, G.M., Weiler, I.J., and Greenough, W.T. (2006). Local protein 
synthesis and spine morphogenesis: Fragile X syndrome and beyond. J. Neurosci. 26, 
7151–7155. 
Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell 
Biol. 15, 509–524. 
Hagerman, R.J., and Hagerman, P.J. (2002). The fragile X premutation: Into the phenotypic 
fold. Curr. Opin. Genet. Dev. 12, 278–283. 
Hagerman, R., Lauterborn, J., Au, J., and Berry-Kravis, E. (2012). Fragile X syndrome and 
targeted treatment trials. Results Probl. Cell Differ. 54, 297–335. 
Han, J., Lee, Y., Yeom, K.H., Kim, Y.K., Jin, H., and Kim, V.N. (2004). The Drosha-
DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016–3027. 
Han, J., Lee, Y., Yeom, K.-H., Nam, J.-W., Heo, I., Rhee, J.-K., Sohn, S.Y., Cho, Y., 
Zhang, B.-T., and Kim, V.N. (2006). Molecular basis for the recognition of primary 
microRNAs by the Drosha-DGCR8 complex. Cell 125, 887–901. 
Harigaya, Y., and Parker, R. (2014). Fragile x mental retardation protein and the ribosome. 
Mol. Cell 54, 330–332. 
Hinds, H.L., Ashley, C.T., Sutcliffe, J.S., Nelson, D.L., Warren, S.T., Housman, D.E., and 
Schalling, M. (1993). Tissue specific expression of FMR-1 provides evidence for a 
functional role in fragile X syndrome [see comments] [published erratum appears in Nat 
Genet 1993 Nov;5(3):312]. Nat Genet 3, 36–43. 
Hoang, B., and Chiba, A. (2001). Single-cell analysis of Drosophila larval neuromuscular 
synapses. Dev. Biol. 229, 55–70. 
Hou, L., Antion, M.D., Hu, D., Spencer, C.M., Paylor, R., and Klann, E. (2006). Dynamic 
Translational and Proteasomal Regulation of Fragile X Mental Retardation Protein 
Controls mGluR-Dependent Long-Term Depression. Neuron 51, 441–454. 
 
  156 
Houseley, J., and Tollervey, D. (2009). The Many Pathways of RNA Degradation. Cell 
136, 763–776. 
Hu, W., Petzold, C., Coller, J., and Baker, K.E. (2010). Nonsense-mediated mRNA 
decapping occurs on polyribosomes in Saccharomyces cerevisiae. Nat. Struct. Mol. Biol. 
17, 244–247. 
Hu, Y., Chen, Z., Fu, Y., He, Q., Jiang, L., Zheng, J., Gao, Y., Mei, P., Chen, Z., and Ren, 
X. (2015). The amino-terminal structure of human fragile X mental retardation protein 
obtained using precipitant-immobilized imprinted polymers. Nat. Commun. 6. 
Humphreys, D.T., Westman, B.J., Martin, D.I.K., and Preiss, T. (2005). MicroRNAs 
control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) 
tail function. Proc. Natl. Acad. Sci. 102, 16961–16966. 
Huntzinger, E., and Izaurralde, E. (2011). Gene silencing by microRNAs: contributions of 
translational repression and mRNA decay. Nat. Rev. Genet. 12, 99–110. 
Huntzinger, E., Braun, J.E., Heimstädt, S., Zekri, L., and Izaurralde, E. (2010). Two 
PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing. 
EMBO J. 29, 4146–4160. 
Huntzinger, E., Kuzuoǧlu-Öztürk, D., Braun, J.E., Eulalio, A., Wohlbold, L., and 
Izaurralde, E. (2013). The interactions of GW182 proteins with PABP and deadenylases 
are required for both translational repression and degradation of miRNA targets. Nucleic 
Acids Res. 41, 978–994. 
Hurschler, B.A., Ding, X.C., and Großhans, H. (2010). Translational Control of 
Endogenous MicroRNA Target Genes in C . elegans. 21–41. 
Hutvágner, G., McLachlan, J., Pasquinelli, A.E., Bálint, É., Tuschl, T., and Zamore, P.D. 
(2001). A cellular function for the RNA-interference enzyme dicer in the maturation of the 
let-7 small temporal RNA. Science (80-. ). 293, 834–838. 
Iacoangeli, A., Rozhdestvensky, T.S., Dolzhanskaya, N., Tournier, B., Schutt, J., Brosius, 
J., Denman, R.B., Khandjian, E.W., Kindler, S., and Tiedge, H. (2008a). On BC1 RNA 
and the fragile X mental retardation protein. Proc. Natl. Acad. Sci. 105, 734–739. 
Iacoangeli, A., Rozhdestvensky, T.S., Dolzhanskaya, N., Tournier, B., Schütt, J., Brosius, 
J., Denman, R.B., Khandjian, E.W., Kindler, S., and Tiedge, H. (2008b). Reply to Bagni: 
On BC1 RNA and the fragile X mental retardation protein. Proc. Natl. Acad. Sci. U. S. A. 
105, E29. 
Inoue, S.B., Shimoda, M., Nishinokubi, I., Siomi, M.C., Okamura, M., Nakamura, A., 
Kobayashi, S., Ishida, N., and Siomi, H. (2002). A role for the Drosophila fragile X-related 
gene in circadian output. Curr. Biol. 12, 1331–1335. 
 
  157 
Ipsaro, J.J., and Joshua-Tor, L. (2015). From guide to target: Molecular insights into 
eukaryotic RNA-interference machinery. Nat. Struct. Mol. Biol. 22, 20–28. 
Irwin, S.A., Patel, B., Idupulapati, M., Harris, J.B., Crisostomo, R.A., Larsen, B.P., Kooy, 
F., Willems, P.J., Cras, P., Kozlowski, P.B., et al. (2001). Abnormal dendritic spine 
characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A 
quantitative examination. Am. J. Med. Genet. 98, 161–167. 
Ishizuka, A., Siomi, M.C., Siomi, H., and M.C., S. (2002). A Drosophila fragile X protein 
interacts with components of RNAi and ribosomal proteins. Genes Dev. 16, 2497–2508. 
Iwakawa, H., and Tomari, Y. (2015). The Functions of MicroRNAs : mRNA Decay and 
Translational Repression. Trends Cell Biol. 25, 651–665. 
Iwasaki, S., Kobayashi, M., Yoda, M., Sakaguchi, Y., Katsuma, S., Suzuki, T., and Tomari, 
Y. (2010). Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of 
small RNA duplexes. Mol. Cell 39, 292–299. 
Jackson, R.J., Hellen, C.U.T., and Pestova, T. V. (2010). The mechanism of eukaryotic 
translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 11, 113–
127. 
Jin, P., Alisch, R.S., and Warren, S.T. (2004a). RNA and microRNAs in fragile X mental 
retardation. Nat. Cell Biol. 6, 1048–1053. 
Jin, P., Zarnescu, D.C., Ceman, S., Nakamoto, M., Mowrey, J., Jongens, T. a, Nelson, D.L., 
Moses, K., and Warren, S.T. (2004b). Biochemical and genetic interaction between the 
fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 7, 113–
117. 
Jinek, M., Fabian, M.R., Coyle, S.M., Sonenberg, N., and Doudna, J. a (2010). Structural 
insights into the human GW182-PABC interaction in microRNA-mediated deadenylation. 
Nat. Struct. Mol. Biol. 17, 238–240. 
Joachimi, A., Benz, A., and Hartig, J.S. (2009). A comparison of DNA and RNA 
quadruplex structures and stabilities. Bioorganic Med. Chem. 17, 6811–6815. 
Kanai, Y., Dohmae, N., and Hirokawa, N. (2004). Kinesin transports RNA: Isolation and 
characterization of an RNA-transporting granule. Neuron 43, 513–525. 
Kao, D.-I., Aldridge, G.M., Weiler, I.J., and Greenough, W.T. (2010). Altered mRNA 
transport, docking, and protein translation in neurons lacking fragile X mental retardation 
protein. Proc. Natl. Acad. Sci. 107, 15601–15606. 
Kashima, R., Redmond, P.L., Ghatpande, P., Roy, S., Kornberg, T.B., Hanke, T., Knapp, 
S., Lagna, G., and Hata, A. (2017). Hyperactive locomotion in a Drosophila model is a 
 
  158 
functional readout for the synaptic abnormalities underlying fragile X syndrome. 8133, 1–
12. 
Kawamata, T., and Tomari, Y. (2010). Making RISC. Trends Biochem. Sci. 35, 368–376. 
Kawamata, T., Seitz, H., and Tomari, Y. (2009). Structural determinants of miRNAs for 
RISC loading and slicer-independent unwinding. Nat. Struct. Mol. Biol. 16, 953–960. 
Kedde, M., Strasser, M.J., Boldajipour, B., Vrielink, J.A.F.O., Slanchev, K., le Sage, C., 
Nagel, R., Voorhoeve, P.M., van Duijse, J., ??rom, U.A., et al. (2007). RNA-Binding 
Protein Dnd1 Inhibits MicroRNA Access to Target mRNA. Cell 131, 1273–1286. 
Kedersha, N., and Anderson, P. (2007). Mammalian Stress Granules and Processing 
Bodies. Methods Enzymol. 431, 61–81. 
Kenny, P., and Ceman, S. (2016). RNA Secondary Structure Modulates FMRP ’ s Bi-
Functional Role in the MicroRNA Pathway. 10, 1–13. 
Kenny, P.J., Zhou, H., Kosik, K.S., Ceman, S., Kim, M., Skariah, G., Khetani, R.S., 
Drnevich, J., and Arcila, M.L. (2014). MOV10 and FMRP Regulate AGO2 Association 
with MicroRNA Recognition Elements MOV10 and FMRP Regulate AGO2 Association 
with MicroRNA Recognition Elements. CellReports 1–13. 
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site 
accessibility in microRNA target recognition. Nat. Genet. 39, 1278–1284. 
Keryer-Bibens, C., Barreau, C., and Osborne, H.B. (2008). Tethering of proteins to RNAs 
by bacteriophage proteins. Biol. Cell 100, 125–138. 
Ketting, R.F., Fischer, S.E.J., Bernstein, E., Sijen, T., Hannon, G.J., and Plasterk, R.H.A. 
(2001). Dicer functions in RNA interference and in synthesis of small RNA involved in 
developmental timing in C. elegans. Genes Dev. 15, 2654–2659. 
Khandjian, E.W. (1999). Biology of the fragile X mental retardation protein, an RNA-
binding protein. Biochem. Cell Biol. 77, 331–342. 
Khayachi, A., Gwizdek, C., Poupon, G., Alcor, D., Chafai, M., Cassé, F., Maurin, T., 
Prieto, M., Folci, A., De Graeve, F., et al. (2018). Sumoylation regulates FMRP-mediated 
dendritic spine elimination and maturation. Nat. Commun. 9, 757. 
Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and miRNAs 
exhibit strand bias. Cell 115, 209–216. 
Kiebler, M.A., and Bassell, G.J. (2006). Neuronal RNA Granules: Movers and Makers. 
Neuron 51, 685–690. 
 
  159 
Kikin, O., D’Antonio, L., and Bagga, P.S. (2006). QGRS Mapper: A web-based server for 
predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res. 34. 
Kim, V.N. (2004). MicroRNA precursors in motion: Exportin-5 mediates their nuclear 
export. Trends Cell Biol. 14, 156–159. 
Kim, V.N. (2005). MicroRNA biogenesis: Coordinated cropping and dicing. Nat. Rev. 
Mol. Cell Biol. 6, 376–385. 
Kim, H.H., Kuwano, Y., Srikantan, S., Lee, E.K., Martindale, J.L., and Gorospe, M. HuR 
recruits let-7 / RISC to repress c-Myc expression. 1743–1748. 
Kim, V.N., Han, J., and Siomi, M.C. (2009). Biogenesis of small RNAs in animals. Nat. 
Rev. Mol. Cell Biol. 10, 126–139. 
Kiriakidou, M., Tan, G.S., Lamprinaki, S., De Planell-Saguer, M., Nelson, P.T., and 
Mourelatos, Z. (2007). An mRNA m7G Cap Binding-like Motif within Human Ago2 
Represses Translation. Cell 129, 1141–1151. 
Kirkpatrick, L.L., McIlwain, K.A., and Nelson, D.L. (2001). Comparative genomic 
sequence analysis of the FXR gene family: FMR1, FXR1, and FXR2. Genomics 78, 169–
177. 
Klann, E., and Richter, J.D. (2007). Translational Control of Synaptic Plasticity and 
Learning and Memory. In Translational Control in Biology and Medicine, pp. 489–510. 
Knight, S.W., and Bass, B.L. (2001). A role for the RNase III enzyme DCR-1 in RNA 
interference and germ line development in Caenorhabditis elegans. Science (80-. ). 293, 
2269–2271. 
Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610. 
Krueger, D.D., and Bear, M.F. (2011). Toward Fulfilling the Promise of Molecular 
Medicine in Fragile X Syndrome. Annu. Rev. Med. 62, 411–429. 
Laggerbauer, B., Ostareck, D., Keidel, E.M., Ostareck-Lederer,  a, and Fischer, U. (2001). 
Evidence that fragile X mental retardation protein is a negative regulator of translation. 
Hum. Mol. Genet. 10, 329–338. 
Landthaler, M., Yalcin, A., and Tuschl, T. (2004). The human DiGeorge syndrome critical 
region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr. 
Biol. 14, 2162–2167. 
Lee, A. (2003). Control of dendritic development by the Drosophila fragile X-related gene 
involves the small GTPase Rac1. Development 130, 5543–5552. 
 
  160 
Lee, H.Y., and Doudna, J.A. (2012). TRBP alters human precursor microRNA processing 
in vitro. RNA 18, 2012–2019. 
Lee, H.Y., Zhou, K., Smith, A.M., Noland, C.L., and Doudna, J.A. (2013). Differential 
roles of human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic 
Acids Res. 41, 6568–6576. 
Lee, Y., Jeon, K., Lee, J.T., Kim, S., and Kim, V.N. (2002). MicroRNA maturation: 
Stepwise processing and subcellular localization. EMBO J. 21, 4663–4670. 
Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S.H., and Kim, V.N. (2004a). 
MicroRNA genes are transcribed by RNA polymerase II. Eur. Mol. Biol. Organ. J. 23, 
4051–4060. 
Lee, Y.S., Nakahara, K., Pham, J.W., Kim, K., He, Z., Sontheimer, E.J., and Carthew, R.W. 
(2004b). Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing 
pathways. Cell 117, 69–81. 
Li, X., and Jin, P. (2009). Macro role(s) of microRNAs in fragile X syndrome? 
Neuromolecular Med. 11, 200–207. 
Li, Y., Lin, L., and Jin, P. (2008). The microRNA pathway and fragile X mental retardation 
protein. Biochim Biophys Acta 1779, 702–705. 
Li, Y., Tang, W., Zhang, L., and Zhang, C. (2014). FMRP regulates miR196a-mediated 
repression of HOXB8 via interaction with the AGO2 MID domain. Mol. Biosyst. 10, 1757–
1764. 
Li, Z., Zhang, Y., Ku, L., Wilkinson, K.D., Warren, S.T., and Feng, Y. (2001). The fragile 
X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids 
Res. 29, 2276–2283. 
Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, 
D.P., Linsley, P.S., and Johnson, J.M. (2005). Microarray analysis shows that some 
microRNAs downregulate large numbers of target mRNAs. Nature 433, 769–773. 
Lin, A.C., and Holt, C.E. (2008). Function and regulation of local axonal translation. Curr. 
Opin. Neurobiol. 18, 60–68. 
Lin, M. Der, Fan, S.J., Hsu, W.S., and Chou, T. Bin (2006). Drosophila Decapping Protein 
1, dDcp1, Is a Component of the oskar mRNP Complex and Directs Its Posterior 
Localization in the Oocyte. Dev. Cell 10, 601–613. 
Lindsay, A.J., and Mccaffrey, M.W. (2014). Myosin Va is required for the transport of 
fragile X mental retardation protein (FMRP) granules. Biol. Cell 106, 57–71. 
 
  161 
Liu-Yesucevitz, L., Bassell, G.J., Gitler, A.D., Hart, A.C., Klann, E., Richter, J.D., Warren, 
S.T., and Wolozin, B. (2011). Local RNA translation at the synapse and in disease. J. 
Neurosci. 31, 16086–16093. 
Liu, J., Valencia-Sanchez, M.A., Hannon, G.J., and Parker, R. (2005). MicroRNA-
dependent localization of targeted mRNAs to mammalian P-bodies. Nat. Cell Biol. 7, 719–
723. 
Livak, K., and Schmittgen, T. (2001). Analysis of relative gene expression data using real-
time quantitative PCR and the 2(T)(-Delta Delta C) method. METHODS 25, 402–408. 
Loffreda, A., Rigamonti, A., Barabino, S.M.L., and Lenzken, S.C. (2015). RNA-Binding 
Proteins in the Regulation of miRNA Activity: A Focus on Neuronal Functions. 
Biomolecules 5, 2363–2387. 
Loomis, E.W., Eid, J.S., Peluso, P., Yin, J., Hickey, L., Rank, D., McCalmon, S., 
Hagerman, R.J., Tassone, F., and Hagerman, P.J. (2013). Sequencing the unsequenceable: 
Expanded CGG-repeat alleles of the fragile X gene. Genome Res. 23, 121–128. 
Lund, E., Güttinger, S., Calado, A., Dahlberg, J.E., and Kutay, U. (2004). Nuclear Export 
of MicroRNA Precursors. Science (80-. ). 303, 95–98. 
Lytle, J.R., Yario, T.A., and Steitz, J.A. (2007). Target mRNAs are repressed as efficiently 
by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc. Natl. Acad. Sci. 104, 
9667–9672. 
Ma, J.B., Ye, K., and Patel, D.J. (2004). Structural basis for overhang-specific small 
interfering RNA recognition by the PAZ domain. Nature 429, 318–322. 
Macrae, I.J., Zhou, K., Li, F., Repic, A., Brooks, A.N., Cande, W.Z., Adams, P.D., and 
Doudna, J.A. (2006). Structural basis for double-stranded RNA processing by Dicer. 
Science 311, 195–198. 
MacRae, I.J., Zhou, K., and Doudna, J.A. (2007). Structural determinants of RNA 
recognition and cleavage by Dicer. Nat. Struct. Mol. Biol. 14, 934–940. 
MacRae, I.J., Ma, E., Zhou, M., Robinson, C. V., and Doudna, J.A. (2008). In vitro 
reconstitution of the human RISC-loading complex. Proc. Natl. Acad. Sci. 105, 512–517. 
Maniataki, E., and Mourelatos, Z. (2005). A human, ATP-independent, RISC assembly 
machine fueled by pre-miRNA. Genes Dev. 19, 2979–2990. 
Marcotrigiano, J., Gingras, A.C., Sonenberg, N., and Burley, S.K. (1999). Cap-dependent 
translation initiation in eukaryotes is regulated by a molecular mimic of elF4G. Mol. Cell 
3, 707–716. 
 
  162 
Maroney, P.A., Yu, Y., Fisher, J., and Nilsen, T.W. (2006). Evidence that microRNAs are 
associated with translating messenger RNAs in human cells. Nat. Struct. Mol. Biol. 13, 
1102–1107. 
Martin, K.C., and Zukin, R.S. (2006). RNA Trafficking and Local Protein Synthesis in 
Dendrites: An Overview. J. Neurosci. 26, 7131–7134. 
Mathonnet, G., Fabian, M.R., Svitkin, Y. V., Parsyan, A., Huck, L., Murata, T., Biffo, S., 
Merrick, W.C., Darzynkiewicz, E., Pillai, R.S., et al. (2007). MicroRNA inhibition of 
translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (80-. ). 
317, 1764–1767. 
Mazroui, R. (2002). Trapping of messenger RNA by Fragile X Mental Retardation protein 
into cytoplasmic granules induces translation repression. Hum. Mol. Genet. 11, 3007–
3017. 
McNeill, E., and Van Vactor, D. (2012). MicroRNAs shape the neuronal landscape. 
Neuron 75, 363–379. 
Meijer, H.A., Kong, Y.W., Lu, W.T., Wilczynska, A., Spriggs, R. V., Robinson, S.W., 
Godfrey, J.D., Willis, A.E., and Bushell, M. (2013). Translational repression and eIF4A2 
activity are critical for microRNA-mediated gene regulation. Science (80-. ). 340, 82–85. 
Menon, L., and Mihailescu, M.R. (2007). Interactions of the G quartet forming semaphorin 
3F RNA with the RGG box domain of the fragile X protein family. Nucleic Acids Res. 35, 
5379–5392. 
Menon, L., Mader, S.A., and Mihailescu, M.-R. (2008). Fragile X mental retardation 
protein interactions with the microtubule associated protein 1B RNA. Rna 14, 1644–1655. 
Meyer, S., Temme, C., and Wahle, E. (2004). Messenger RNA turnover in eukaryotes: 
Pathways and enzymes. Crit. Rev. Biochem. Mol. Biol. 39, 197–216. 
Mientjes, E.J., Nieuwenhuizen, I., Kirkpatrick, L., Zu, T., Hoogeveen-Westerveld, M., 
Severijnen, L., Rifé, M., Willemsen, R., Nelson, D.L., and Oostra, B.A. (2006). The 
generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. 
Neurobiol. Dis. 21, 549–555. 
Mishima, Y., Fukao, A., Kishimoto, T., Sakamoto, H., Fujiwara, T., and Inoue, K. (2012). 
Translational inhibition by deadenylation-independent mechanisms is central to 
microRNA-mediated silencing in zebrafish. Proc. Natl. Acad. Sci. 109, 1104–1109. 
Mitchell, S.F., and Parker, R. (2014). Principles and properties of eukaryotic mRNPs. Mol. 
Cell 54, 547–558. 
Miyashiro, K.Y., Beckel-Mitchener, A., Purk, T.P., Becker, K.G., Barret, T., Liu, L., 
 
  163 
Carbonetto, S., Weiler, I.J., Greenough, W.T., and Eberwine, J. (2003). RNA cargoes 
associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 
37, 417–431. 
Monzo, K., Papoulas, O., Cantin, G.T., Wang, Y., Yates, J.R., and Sisson, J.C. (2006). 
Fragile X mental retardation protein controls trailer hitch expression and cleavage furrow 
formation in Drosophila embryos. Proc. Natl. Acad. Sci. U. S. A. 103, 18160–18165. 
Morales, J., Hiesinger, P.R., Schroeder, A.J., Kume, K., Verstreken, P., Jackson, F.R., 
Nelson, D.L., and Hassan, B.A. (2002). Drosophila fragile X protein, DFXR, regulates 
neuronal morphology and function in the brain. Neuron 34, 961–972. 
Muddashetty, R.S., Kelic, S., Gross, C., Xu, M., and Bassell, G.J. (2007). Dysregulated 
Metabotropic Glutamate Receptor-Dependent Translation of AMPA Receptor and 
Postsynaptic Density-95 mRNAs at Synapses in a Mouse Model of Fragile X Syndrome. 
J. Neurosci. 27, 5338–5348. 
Muddashetty, R.S., Nalavadi, V.C., Gross, C., Yao, X., Xing, L., Laur, O., Warren, S.T., 
and Bassell, G.J. (2011). Reversible Inhibition of PSD-95 mRNA Translation by miR-
125a, FMRP Phosphorylation, and mGluR Signaling. Mol. Cell 42, 673–688. 
Myrick, L.K., Nakamoto-Kinoshita, M., Lindor, N.M., Kirmani, S., Cheng, X., and 
Warren, S.T. (2014). Fragile X syndrome due to a missense mutation. Eur. J. Hum. Genet. 
22, 1185–1189. 
Myrick, L.K., Deng, P.-Y., Hashimoto, H., Oh, Y.M., Cho, Y., Poidevin, M.J., Suhl, J.A., 
Visootsak, J., Cavalli, V., Jin, P., et al. (2015a). Independent role for presynaptic FMRP 
revealed by an FMR1 missense mutation associated with intellectual disability and 
seizures. Proc. Natl. Acad. Sci. 112, 949–956. 
Myrick, L.K., Hashimoto, H., Cheng, X., and Warren, S.T. (2015b). Human FMRP 
contains an integral tandem Agenet (Tudor) and KH motif in the amino terminal domain. 
Hum. Mol. Genet. 24, 1733–1740. 
Nakanishi, K., Weinberg, D.E., Bartel, D.P., and Patel, D.J. (2012). Structure of yeast 
Argonaute with guide RNA. Nature 486, 368–374. 
Nalavadi, V.C., Muddashetty, R.S., Gross, C., and Bassell, G.J. (2012). 
Dephosphorylation-Induced Ubiquitination and Degradation of FMRP in Dendrites: A 
Role in Immediate Early mGluR-Stimulated Translation. J. Neurosci. 32, 2582–2587. 
Napoli, I., Mercaldo, V., Boyl, P.P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., 
Mohr, E., Massimi, M., Falconi, M., et al. (2008). The fragile X syndrome protein represses 
activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134, 1042–1054. 
Narayanan, U., Nalavadi, V., Nakamoto, M., Pallas, D.C., Ceman, S., Bassell, G.J., and 
 
  164 
Warren, S.T. (2007). FMRP Phosphorylation Reveals an Immediate-Early Signaling 
Pathway Triggered by Group I mGluR and Mediated by PP2A. J. Neurosci. 27, 14349–
14357. 
Nesler, K.R., Sand, R.I., Symmes, B.A., Pradhan, S.J., Boin, N.G., Laun, A.E., and Barbee, 
S.A. (2013). The miRNA Pathway Controls Rapid Changes in Activity-Dependent 
Synaptic Structure at the Drosophila melanogaster Neuromuscular Junction. PLoS One 8. 
Niere, F., Wilkerson, J.R., and Huber, K.M. (2012). Evidence for a Fragile X Mental 
Retardation Protein-Mediated Translational Switch in Metabotropic Glutamate Receptor-
Triggered Arc Translation and Long-Term Depression. J. Neurosci. 32, 5924–5936. 
Nimchinsky, E. a, Oberlander,  a M., and Svoboda, K. (2001). Abnormal development of 
dendritic spines in FMR1 knock-out mice. J. Neurosci. 21, 5139–5146. 
Nishimura, T., Padamsi, Z., Fakim, H., Milette, S., Dunham, W.H., Gingras, A.C., and 
Fabian, M.R. (2015). The eIF4E-Binding Protein 4E-T Is a Component of the mRNA 
Decay Machinery that Bridges the 5’ and 3’ Termini of Target mRNAs. Cell Rep. 11, 
1425–1436. 
Nottrott, S., Simard, M.J., and Richter, J.D. (2006). Human let-7a miRNA blocks protein 
production on actively translating polyribosomes. Nat. Struct. Mol. Biol. 13, 1108–1114. 
O’Donnell, W.T., and Warren, S.T. (2002). A decade of molecular studies of fragile x 
syndrome. Annu Rev Neurosci 25, 315–338. 
Okamura, K., Ishizuka, A., Siomi, H., and Siomi, M.C. (2004). Distinct roles for Argonaute 
proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 18, 1655–1666. 
Olsen, P.H., and Ambros, V. (1999). The lin-4 regulatory RNA controls developmental 
timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation 
of translation. Dev. Biol. 216, 671–680. 
Otero, Y.Y.D.D., De Diego Otero, Y., Severijnen, L. a, van Cappellen, G., Schrier, M., 
Oostra, B., and Willemsen, R. (2002). Transport of fragile X mental retardation protein via 
granules in neurites of PC12 cells. Mol. Cell. Biol. Cell. Biol. 22, 8332–8341. 
Ozdilek, B.A., Thompson, V.F., Ahmed, N.S., White, C.I., Batey, R.T., and Schwartz, J.C. 
(2017). Intrinsically disordered RGG/RG domains mediate degenerate specificity in RNA 
binding. Nucleic Acids Res. 45, 7984–7996. 
Parker, R., and Sheth, U. (2007). P bodies and the control of mRNA translation and 
degradation. Mol. Cell 25, 635–646. 
Parker, R., and Song, H. (2004). The enzymes and control of eukaryotic mRNA turnover. 
Nat. Struct. Mol. Biol. 11, 121–127. 
 
  165 
Pasquinelli, A.E. (2012). MicroRNAs and their targets: Recognition, regulation and an 
emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–282. 
Penagarikano, O., Mulle, J.G., and Warren, S.T. (2007). The pathophysiology of fragile x 
syndrome. Annu. Rev. Genomics Hum. Genet. 8, 109–129. 
Petersen, C.P., Bordeleau, M.E., Pelletier, J., and Sharp, P.A. (2006). Short RNAs repress 
translation after initiation in mammalian cells. Mol. Cell 21, 533–542. 
Peterson, S.M., Thompson, J.A., Ufkin, M.L., Sathyanarayana, P., Liaw, L., and Congdon, 
C.B. (2014). Common features of microRNA target prediction tools. Front. Genet. 5, 1–
10. 
Pfaff, J., and Meister, G. (2013). Argonaute and GW182 proteins: an effective alliance in 
gene silencing. Biochem. Soc. Trans. 41. 
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S.T., Oostra, B.A., Caskey, C.T., and Nelson, 
D.L. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 
817–822. 
Pillai, R.S. (2012). Inhibition of Translational Initiation by Let-7 MicroRNA in Human 
Cells. Science (80-. ). 1573, 1573–1576. 
Pillai, R.S., Artus, C.G., and Filipowicz, W. (2004). Tethering of human Ago proteins to 
mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 10, 1518–1525. 
Pillai, R.S., Bhattacharyya, S.N., Artus, C.G., Zoller, T., Cougot, N., Basyuk, E., Bertrand, 
E., and Filipowicz, W. (2005). Molecular biology: Inhibition of translational initiation by 
let-7 microRNA in human cells. Science (80-. ). 309, 1573–1576. 
Plante, I., Davidovic, L., Ouellet, D.L., Gobeil, L.A., Tremblay, S., Khandjian, E.W., and 
Provost, P. (2006). Dicer-derived microRNAs are utilized by the fragile X mental 
retardation protein for assembly on target RNAs. J. Biomed. Biotechnol. 2006, 1–12. 
Ray, D., Kazan, H., Cook, K.B., Weirauch, M.T., Najafabadi, H.S., Li, X., Gueroussov, S., 
Albu, M., Zheng, H., Yang, A., et al. (2013). A compendium of RNA-binding motifs for 
decoding gene regulation. Nature 499, 172–177. 
Reeve, S.P., Bassetto, L., Genova, G.K., Kleyner, Y., Leyssen, M., Jackson, F.R., and 
Hassan, B.A. (2005). The Drosophila fragile X mental retardation protein controls actin 
dynamics by directly regulating profilin in the brain. Curr. Biol. 15, 1156–1163. 
Rehwinkel, J., Behm-Ansmant, I., Gatfield, D., and Izaurralde, E. (2005). A crucial role 
for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing. 
RNA 11, 1640–1647. 
 
  166 
Ricci, E.P., Limousin, T., Soto-Rifo, R., Rubilar, P.S., Decimo, D., and Ohlmann, T. 
(2013). MiRNA repression of translation in vitro takes place during 43S ribosomal 
scanning. Nucleic Acids Res. 41, 586–598. 
Richter, J.D., and Sonenberg, N. (2005). Regulation of cap-dependent translation by eIF4E 
inhibitory proteins. Nature 433, 477–480. 
Richter, J.D., Bassell, G.J., and Klann, E. (2015). Dysregulation and restoration of 
translational homeostasis in fragile X syndrome. Nat. Rev. Neurosci. 16, 595–605. 
Ronesi, J.A., and Huber, K.M. (2008). Metabotropic glutamate receptors and fragile x 
mental retardation protein: Partners in translational regulation at the synapse. Sci. Signal. 
1. 
Russell, D.W., and Spremulli, L.L. (1978). Identification of a wheat germ ribosome 
dissociation factor distinct from initiation factor eIF-3. J. Biol. Chem. 253, 6647–6649. 
Saito, K., Ishizuka, A., Siomi, H., and Siomi, M.C. (2005). Processing of pre-microRNAs 
by the Dicer-1-Loquacious complex in drosophila cells. PLoS Biol. 3, 1202–1212. 
Saito, K., Ishizu, H., Komai, M., Kotani, H., Kawamura, Y., Nishida, K.M., Siomi, H., and 
Siomi, M.C. (2010). Roles for the Yb body components Armitage and Yb in primary 
piRNA biogenesis in Drosophila. Genes Dev. 24, 2493–2498. 
Santoro, M.R., Bray, S.M., and Warren, S.T. Molecular Mechanisms of Fragile X 
Syndrome : A Twenty-Year Perspective. 
Santos, A.R., Kanellopoulos, A.K., and Bagni, C. (2014). Learning and behavioral deficits 
associated with the absence of the fragile X mental retardation protein: what a fly and 
mouse model can teach us. Learn. Mem. 21, 543–555. 
Saugstad, J.A. (2010). MicroRNAs as effectors of brain function with roles in ischemia 
and injury, neuroprotection, and neurodegeneration. J. Cereb. Blood Flow Metab. 30, 
1564–1576. 
Schaeffer, C., Bardoni, B., Mandel, J.L., Ehresmann, B., Ehresmann, C., and Moine, H. 
(2001). The fragile X mental retardation protein binds specifically to its mRNA via a purine 
quartet motif. EMBO J. 20, 4803–4813. 
Schaeffer, C., Beaulande, M., Ehresmann, C., Ehresmann, B., and Moine, H. (2003). The 
RNA binding protein FMRP: new connections and missing links. Biol. Cell 95, 221–228. 
Schenck, A., Bardoni, B., Moro, A., Bagni, C., and Mandel, J.-L. (2001). A highly 
conserved protein family interacting with the fragile X mental retardation protein (FMRP) 
and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. 
Proc. Natl. Acad. Sci. 98, 8844–8849. 
 
  167 
Schirle, N.T., and MacRae, I.J. (2012). The crystal structure of human Argonaute2. Science 
336, 1037–1040. 
Schneider, M.D., Najand, N., Chaker, S., Pare, J.M., Haskins, J., Hughes, S.C., Hobman, 
T.C., Locke, J., and Simmonds, A.J. (2006). Gawky is a component of cytoplasmic mRNA 
processing bodies required for early Drosophila development. J. Cell Biol. 174, 349–358. 
Schwarz, D.S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003). 
Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208. 
Seggerson, K., Tang, L., and Moss, E.G. (2002). Two genetic circuits repress the 
Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. Dev. Biol. 
243, 215–225. 
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., and Rajewsky, N. 
(2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58–
63. 
Shenoy, A., and Blelloch, R.H. (2014). Regulation of microRNA function in somatic stem 
cell proliferation and differentiation. Nat. Rev. Mol. Cell Biol. 15, 565–576. 
Siomi, H., and Dreyfuss, G. (1997). RNA-binding proteins as regulators of gene 
expression. Curr. Opin. Genet. Dev. 7, 345–353. 
Siomi, H., Siomi, M.C., Nussbaum, R.L., and Dreyfuss, G. (1993). The protein product of 
the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74, 291–
298. 
Siomi, H., Choi, M., Siomi, M.C., Nussbaum, R.L., and Dreyfuss, G. (1994). Essential role 
for KH domains in RNA binding: Impaired RNA binding by a mutation in the KH domain 
of FMR1 that causes fragile X syndrome. Cell 77, 33–39. 
Siomi, M.C., Siomi, H., Sauer, W.H., Srinivasan, S., Nussbaum, R.L., and Dreyfuss, G. 
(1995). FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J. 
14, 2401–2408. 
Siomi, M.C., Zhang, Y., Siomi, H., and Dreyfuss, G. (1996). Specific sequences in the 
fragile X syndrome protein FMR1 and the FXR proteins mediate their binding to 60S 
ribosomal subunits and the interactions among them. Mol. Cell. Biol. 16, 3825–3832. 
Sittler,  a, Devys, D., Weber, C., and Mandel, J.L. (1996). Alternative splicing of exon 14 
determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. Hum. Mol. Genet. 
5, 95–102. 
Song, J.J., Liu, J., Tolia, N.H., Schneiderman, J., Smith, S.K., Martienssen, R.A., Hannon, 
G.J., and Joshua-Tor, L. (2003). The crystal structure of the Argonaute2 PAZ domain 
 
  168 
reveals an RNA binding motif in RNAi effector complexes. Nat. Struct. Biol. 10, 1026–
1032. 
Stefani, G. (2004). Fragile X Mental Retardation Protein Is Associated with Translating 
Polyribosomes in Neuronal Cells. J. Neurosci. 24, 7272–7276. 
Sterne, G.R., Kim, J.H., and Ye, B. (2015). Dysregulated Dscam levels act through 
Abelson tyrosine kinase to enlarge presynaptic arbors. Elife 4. 
Steward, O., and Schuman, E.M. (2003). Compartmentalized synthesis and degradation of 
proteins in neurons. Neuron 40, 347–359. 
Strausfeld, N.J. (2009). Brain and Optic Lobes. In Encyclopedia of Insects, pp. 121–130. 
Sudhakaran, I.P., Hillebrand, J., Dervan, A., Das, S., Holohan, E.E., Hülsmeier, J., Sarov, 
M., Parker, R., VijayRaghavan, K., and Ramaswami, M. (2014). FMRP and Ataxin-2 
function together in long-term olfactory habituation and neuronal translational control. 
Proc. Natl. Acad. Sci. U. S. A. 111, E99–E108. 
Suhl, J.A., Chopra, P., Anderson, B.R., Bassell, G.J., and Warren, S.T. (2014a). HMG 
Advance Access published May 29, 2014 1. 1–41. 
Suhl, J.A., Chopra, P., Anderson, B.R., Bassell, G.J., and Warren, S.T. (2014b). Analysis 
of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-
quadruplex structures formed via clustered WGGA sequences. Hum. Mol. Genet. 23, 
5479–5491. 
Suhl, J.A., Muddashetty, R.S., Anderson, B.R., Ifrim, M.F., Visootsak, J., Bassell, G.J., 
and Warren, S.T. (2015). A 3′ untranslated region variant in FMR1 eliminates neuronal 
activity-dependent translation of FMRP by disrupting binding of the RNA-binding protein 
HuR. Proc. Natl. Acad. Sci. 112, E6553–E6561. 
Sutcliffe, J.S., Nelson, D.L., Zhang, F., Pieretti, M., Caskey, C.T., Saxe, D., and Warren, 
S.T. (1992). DNA methylation represses FMR-1 transcription in fragile x syndrome. Hum. 
Mol. Genet. 1, 397–400. 
Tat, T.T., Maroney, P.A., Chamnongpol, S., Coller, J., and Nilsen, T.W. (2016). 
Cotranslational microRNA mediated messenger RNA destabilization. Elife 5, 1–18. 
Teixeira, D., Sheth, U., Valencia-Sanchez, M.A., Brengues, M., and Parker, R. (2005). 
Processing bodies require RNA for assembly and contain nontranslating mRNAs. RNA 11, 
371–382. 
Temme, C., Zaessinger, S., Meyer, S., Simonelig, M., and Wahle, E. (2004). A complex 
containing the CCR4 and CAF1 proteins is involved in mRNA deadenylation in 
Drosophila. EMBO J. 23, 2862–2871. 
 
  169 
Temme, C., Zhang, L., Kremmer, E., Ihling, C., Chartier, A., Sinz, A., Simonelig, M., and 
Wahle, E. (2010). Subunits of the Drosophila CCR4-NOT complex and their roles in 
mRNA deadenylation. RNA 16, 1356–1370. 
The Fragile X Consortium (1994). Fmr1 knockout mice: a model to study fragile X mental 
retardation. Cell 78, 23–33. 
Todd, P.K., Mack, K.J., and Malter, J.S. (2003). The fragile X mental retardation protein 
is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. 
Proc. Natl. Acad. Sci. U. S. A. 100, 14374–14378. 
Todd, P.K., Oh, S., Krans, A., He, F., Sellier, C., Frazer, M., Renoux, A.J., Chen, K. chun, 
Scaglione, K.M., Basrur, V., et al. (2013). CGG repeat-associated translation mediates 
neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78, 440–455. 
Tomari, Y., Du, T., and Zamore, P.D. (2007). Sorting of Drosophila Small Silencing 
RNAs. Cell 130, 299–308. 
Trabucchi, M., Briata, P., Garcia-Mayoral, M., Haase, A.D., Filipowicz, W., Ramos, A., 
Gherzi, R., and Rosenfeld, M.G. (2009). The RNA-binding protein KSRP promotes the 
biogenesis of a subset of microRNAs. Nature 459, 1010–1014. 
Udagawa, T., Farny, N.G., Jakovcevski, M., Kaphzan, H., Alarcon, J.M., Anilkumar, S., 
Ivshina, M., Hurt, J.A., Nagaoka, K., Nalavadi, V.C., et al. (2013). Genetic and acute 
CPEB1 depletion ameliorate fragile X pathophysiology. Nat. Med. 19, 1473–1477. 
Verkerk, A.J., De Graaff, E., De Boulle, K., Eichler, E.E., Konecki, D.S., Reyniers, E., 
Manca, A., Poustka, A., Willems, P.J., Nelson, D.L., et al. (1993). Alternative splicing in 
the fragile X gene FMR1. Hum Mol Genet 2, 399–404. 
Vermeulen, A., Behlen, L., Reynolds, A., Wolfson, A., Marshall, W.S., Karpilow, J., and 
Khvorova, A. (2005). The contributions of dsRNA structure to Dicer specificity and 
efficiency. RNA 11, 674–682. 
Waghray, S., Williams, C., Coon, J.J., and Wickens, M. (2015). Xenopus CAF1 requires 
NOT1-mediated interaction with 4E-T to repress translation in vivo. RNA 21, 1335–1345. 
Wahle, E., and Winkler, G.S. (2013). RNA decay machines: Deadenylation by the Ccr4-
Not and Pan2-Pan3 complexes. Biochim. Biophys. Acta - Gene Regul. Mech. 1829, 561–
570. 
Wakiyama, M., Takimoto, K., Ohara, O., and Yokoyama, S. (2007). Let-7 microRNA-
mediated mRNA deadenylation and translational repression in a mammalian cell-free 
system. Genes Dev. 21, 1857–1862. 
Wan, L., Dockendorff, T.C., Jongens, T.A., and Dreyfuss, G. (2000). Characterization of 
 
  170 
dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. 
Mol. Cell. Biol. 20, 8536–8547. 
Wang, H., Ku, L., Osterhout, D.J., Li, W., Ahmadian, A., Liang, Z., and Feng, Y. (2004). 
Developmentally-programmed FMRP expression in oligodendrocytes: A potential role of 
FMRP in regulating translation in oligodendroglia progenitors. Hum. Mol. Genet. 13, 79–
89. 
Wang, H., Iacoangeli, A., Lin, D., Williams, K., Denman, R.B., Hellen, C.U.T., and 
Tiedge, H. (2005). Dendritic BC1 RNA in translational control mechanisms. J. Cell Biol. 
171, 811–821. 
Weiler, I.J., Irwin, S. a, Klintsova,  a Y., Spencer, C.M., Brazelton,  a D., Miyashiro, K., 
Comery, T. a, Patel, B., Eberwine, J., and Greenough, W.T. (1997). Fragile X mental 
retardation protein is translated near synapses in response to neurotransmitter activation. 
Proc. Natl. Acad. Sci. U. S. A. 94, 5395–5400. 
Weisz, E.D., Monyak, R.E., and Jongens, T.A. (2015). Deciphering discord: How 
Drosophila research has enhanced our understanding of the importance of FMRP in 
different spatial and temporal contexts. Exp. Neurol. 274, 14–24. 
Westmark, C.J., and Malter, J.S. (2007). FMRP mediates mGluR5-dependent translation 
of amyloid precursor protein. PLoS Biol. 5, 0629–0639. 
Wilczynska, A., and Bushell, M. (2014). The complexity of miRNA-mediated repression. 
22, 22–33. 
Williamson, J.R., Raghuraman, M.K., and Cech, T.R. (1989). Monovalent cation-induced 
structure of telomeric DNA: The G-quartet model. Cell 59, 871–880. 
Wu, L., and Belasco, J.G. (2008). Review Let Me Count the Ways : Mechanisms of Gene 
Regulation by miRNAs and siRNAs. 1–7. 
Wu, L., Fan, J., and Belasco, J.G. (2006). MicroRNAs direct rapid deadenylation of 
mRNA. 2006. 
Xing, L., and Bassell, G.J. (2013). MRNA localization: An orchestration of assembly, 
traffic and synthesis. Traffic 14, 2–14. 
Xu, K., Bogert, B.A., Li, W., Su, K., Lee, A., and Gao, F.B. (2004). The fragile X-related 
gene affects the crawling behavior of Drosophila larvae by regulating the mRNA level of 
the DEG/ENaC protein Pickpocket1. Curr. Biol. 14, 1025–1034. 
Yamashita, A., Chang, T.C., Yamashita, Y., Zhu, W., Zhong, Z., Chen, C.Y.A., and Shyu, 
A. Bin (2005). Concerted action of poly(A) nucleases and decapping enzyme in 
mammalian mRNA turnover. Nat. Struct. Mol. Biol. 12, 1054–1063. 
 
  171 
Yoda, M., Kawamata, T., Paroo, Z., Ye, X., Iwasaki, S., Liu, Q., and Tomari, Y. (2010). 
ATP-dependent human RISC assembly pathways. Nat. Struct. Mol. Biol. 17, 17–24. 
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Penta, A. Di, Reis, S., Oostra, B., Bagni, 
C., Biologia, D., Vergata, T., et al. (2003). The Fragile X Syndrome Protein FMRP 
Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses. 
112, 317–327. 
Zalfa, F., Adinolfi, S., Napoli, lsken, E., Urlaub, H., Achsel, T., Pastore, A., and Bagni, C. 
(2005). Fragile X mental retardation protein (FMRP) binds specifically to the brain 
cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. J. Biol. Chem. 280, 
33403–33410. 
Zalfa, F., Eleuteri, B., Dickson, K.S., Mercaldo, V., Rubeis, D., Penta, A., Tabolacci, E., 
Chiurazzi, P., Grant, S.G.N., Bagni, C., et al. (2010). A new function for the Fragile X 
mental retardation protein in the regulation of PSD-95 mRNA stability. Nat. Neurosci. 10, 
578–587. 
Zekri, L., Huntzinger, E., Heimstädt, S., and Izaurralde, E. (2009). The silencing domain 
of GW182 interacts with PABPC1 to promote translational repression and degradation of 
microRNA targets and is required for target release. Mol. Cell. Biol. 29, 6220–6231. 
Zhang, H., Kolb, F.A., Brondani, V., Billy, E., and Filipowicz, W. (2002). Human Dicer 
preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J. 
21, 5875–5885. 
Zhang, H., Kolb, F.A., Jaskiewicz, L., Westhof, E., and Filipowicz, W. (2004). Single 
processing center models for human Dicer and bacterial RNase III. Cell 118, 57–68. 
Zhang, M., Wang, Q., and Huang, Y. (2007). Fragile X mental retardation protein FMRP 
and the RNA export factor NXF2 associate with and destabilize Nxf1 mRNA in neuronal 
cells. Proc. Natl. Acad. Sci. U. S. A. 104, 10057–10062. 
Zhang, P., Abdelmohsen, K., Liu, Y., Tominaga-Yamanaka, K., Yoon, J.-H., Ioannis, G., 
Martindale, J.L., Zhang, Y., Becker, K.G., Yang, I.H., et al. (2015). Novel RNA- and 
FMRP-binding protein TRF2-S regulates axonal mRNA transport and presynaptic 
plasticity. Nat. Commun. 6, 8888. 
Zhang, Y., O’Connor, J.P., Siomi, M.C., Srinivasan, S., Dutra, A., Nussbaum, R.L., and 
Dreyfuss, G. (1995). The fragile X mental retardation syndrome protein interacts with 
novel homologs FXR1 and FXR2. EMBO J. 14, 5358–5366. 
Zhang, Y.Q., Bailey, A.M., Matthies, H.J.G., Renden, R.B., Smith, M.A., Speese, S.D., 
Rubin, G.M., and Broadie, K. (2001). Drosophila fragile x-related gene regulates the 
MAP1B homolog Futsch to control synaptic structure and function. Cell 107, 591–603. 
 
  172 
Zukin, R.S. (2009). Signals, synapses, and synthesis: how new proteins control plasticity. 









  173 
APPENDIX: LIST OF ABBREVIATIONS 
1. AGO protein - Argonaute protein 
2. APP - Amyloid Precursor Protein 
3. ApppN - An unmethylated cap analog 
4. ARC- Activity-regulated cytoskeleton- associated protein 
5. BC1 - Brain Cytoplasmic RNA1 
6. CaMKII - Calcium/Calmodulin-Dependent Protein Kinase II 
7. CDS - Coding Sequence  
8. CYFIP1- Cytoplasmic FMRP Interacting Protein 
9. Dlg- Discs large 
10. Dnd1- Dead end 1  
11. 4E-BP- eIF4E-binding proteins 
12. FMRP - Fragile X mental retardation protein 
13. FXPOI- Fragile X-related primary ovarian insufficiency 
14. FXTAS - Fragile X tremor ataxia syndrome 
15. GW - Glycine-Tryptophan 
16. HITS-CLIP - High-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation 
17. HRP-Horseradish peroxidase  
18. HuR- Human antigen R  
19. IRES - Internal Ribosome entry site 
20. KH domains - Ribonucleoprotein K homology domains 
21. LCD - Low complexity domain 
22. MNK - MAP kinase-interacting serine/threonine- protein 
23. mGluR 5 - Metabotropic glutamate receptor 5 
24. MAP1B - Microtubule associated protein 
25. NES - Nuclear export signal 
26. NLS - Nuclear localization signal 
27. MSA-Muscle surface area 
28. NR2A-  N-methyl-D- aspartate receptor subunit 
29. NXF - Nuclear export factor 
30. PABP - Poly-A binding protein 
31. PACT- Protein activator of the interferon induced protein kinase  
32. PAIP2 - Polyadenylate-binding protein-interacting protein 2  
33. P-bodies - Processing bodies 
34. PSD 95 - Post synaptic protein 95 
35. Rac1- Ras-related C3 botulinum toxin substrate 1 
36. RBP - RNA binding protein 
37. RBD- RNA binding domain  
38. RGG box - Arginine Glycine Glycine box  
39. RISC - RNA induced silencing complex 
40. RNP - Ribonucleoprotein complex 
41. SIX3- Sine oculis homeobox homolog transcription factor 
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42. SMN-Survival of motor neuron  
43. Sod1 - Superoxide Dismutase 
44. SoSLIP - Sod1 mRNA Stem Loops Interacting with FMRP 
45. TNRC - Trinucleotide repeat-containing protein 
46. TRAP- Translating Ribosome Affinity Purification 
47. TRBP- TAR RNA binding protein  
48. UTR - Untranslated Region 
49. ZC3H14-Zinc-finger CysCysCysHis [CCCH]-type 14  
 
 
 
 
 
 
 
 
